Transcript Allegato_B_bando_II_fascia_art 24_c 6_L 240_ago14_filled_8def

ALLEGATO B
UNIVERSITÀ DEGLI STUDI DI MILANO
Procedura di valutazione per la chiamata a professore II fascia da ricoprire ai sensi dell’art. 24, comma
6, della Legge n. 240/2010 per il settore concorsuale 06/D4, (settore scientifico-disciplinare MED/12 GASTROENTEROLOGIA) presso il Dipartimento di FISIOPATOLOGIA MEDICO-CHIRURGICA E
DEI TRAPIANTI, Codice concorso 2910.
CURRICULUM VITAE
(Agosto 2014)
Nome e Cognome:
Pietro Lampertico
Nascita:
13/7/1961 Sierre (Svizzera)
Cittadinanza:
Italiana
Residenza:
Milano
Indirizzo:
Foro Buonaparte 63
Stato civile
coniugato, 2 figli
Indirizzo del luogo di lavoro:
UO di Gastroenterologia ed Epatologia
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Università degli Studi di Milano
Via Francesco Sforza 35
20122 Milano
Tel: 0255035432
Fax: 0250320410
e-mail: [email protected]
1
CORSO DEGLI STUDI
1980
Maturita' Classica al Liceo Cesare Beccaria, Via Linneo 5, Milano.
1986
Laurea in Medicina e Chirurgia, presso Universita' degli Studi di Milano, con
votazione 110/110 e lode e tesi dal titolo “La fibrosi epatica nell’epatopatia alcolica:
correlazione tra valutazione biochimica e istologia”. Relatore Prof N. Dioguardi
1987
Iscrizione all’Albo Professionale dei Medici e dei Chirurghi di Milano
1988
Borsa di Ricerca Annuale Associazione Copev “Beatrice Vitiello”, presso Scuola di
Specializzazione in Malattie del Fegato e del Ricambio, Università degli Studi di
Milano, direttore Prof. N. Dioguardi
1988-1990 Post–Doc research fellowship, Dipartimento di Patologia Sperimentale, Tulane
University, New Orleans, Louisiana, USA.
1990
Specializzazione in Malattie del Fegato e del Ricambio presso Istituto di Medicina
Interna, Universita' degli Studi di Milano con voti 70/70 e lode e tesi dal titolo” Gli
effetti di un analogo purinico, la 2’-deossiguanosina ciclica (CDG), sulla produzione
del virus dell’epatite B (HBV) in vitro. Relatore Prof. N. Dioguardi.
1994-1995 Borsa di Ricerca Annuale dell’Ospedale Maggiore di Milano con progetto dal titolo:
“Studio dell’attivazione del sistema complementare e delle citochine nelle patologie
infiammatorie degenerative del connettivo”, presso la Clinica Medica II, sotto la
supervisione del Prof A. Agostoni.
1995
Specializzazione in Medicina Interna presso l’Istituto di Medicina Interna, Universita'
degli Studi di Milano con votazione 70/70 e tesi dal titolo: “Il ruolo dei mutanti precore del virus dell’epatite B (HBV) nella storia naturale dell’epatite cronica HBeAg
positiva”. Relatore Prof A. Agostoni.
1998-2000 Dottorato di Ricerca in Metodologia Clinica (XII ciclo), presso il Dipartimento di
Medicina Interna, Universita' degli Studi di Milano con tesi dal titolo: “La storia
naturale dell’infezione da HCV nel trapianto di rene: studio prospettico di una coorte di
443 pazienti seguiti per 10 anni”. Relatore Prof A. Agostoni.
2
2001
Borsa di Ricerca Annuale dell’Ospedale Maggiore di Milano sul tema “Fisiopatologia
dell’emorragia da varici esofago-gastriche nel cirrotico: valutazione del ruolo
dell’endotossinemia
nell’induzione
di
iperfibrinolisi
e
nell’aggravamento
dell’ipertensione portale”, svolta presso la Patologia Medica VII, sotto la supervisione
del Dr M. Primignani.
2001-2002 Assegno di Ricerca Biennale della Università degli Studi di Milano sul progetto: “Il
ruolo della proliferazione cellulare, dell’estressione dei recettori per gli estrogeni,
dell’espressione della beta-catenina e dell’alfafetoproteina nella diagnosi precoce e
nello sviluppo del cacinoma primitivo del fegato” svolto presso il dipartimento di
Medicina Interna, sotto la supervisione del Prof. M. Colombo.
2003-2004 Assegno di Ricerca Biennale della Università degli Studi di Milano sul progetto:
“Espressione dei fattori pro-angiogenetici e anti-angiogenetici nel tessuto tumorale e
nel circostante tessuto non tumorale e correlazione con la proliferazione cellulare e
l’espressione dei recettori degli estrogeni” svolto presso il Dipartimento di Medicina
Interna sotto la supervisione dal Prof M. Colombo.
2006
Ricercatore Universitario MED/12 Università degli Studi di Milano, UO
Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico.
2006
Dirigente Medico di I livello, UO di Gastroenterologia I, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico.
2009
Ricercatore Universitario Confermato MED/12, Università degli Studi di Milano, UO
Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico.
2012-13
Idoneo alle procedure di Abilitazione Scientifica Nazionale a Professore Associato e
Professore Ordinario di Gastroenterologia, settore concorsuale 06/D4, settore
scientifico-disciplinare MED/12 – GASTROENTEROLOGIA.
3
ATTIVITA’ DIDATTICA E SCIENTIFICA
Attività didattica
Dal 1992 al 1996 ha svolto il ruolo di Tutore nel Corso Integrato di Metodologia Clinica e
Semeiotica Medica.
Dal 1996 al 2000 ha svolto lezioni frontali, seminari ed esercitazioni nel Corso di Metodologia
Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano.
Dal 2000 ad oggi ha svolto le stesse attività didattiche come da periodo precedente anche nel Corso
di Semeiotica e Sistematica II, Facoltà Facoltà di Medicina e Chirurgia, Università degli Studi di
Milano.
Dal 2006 ad oggi, è assegnato in qualità di Ricercatore Universitario Med 12 al corpo docente del
Corso di Semeiotica e Sistematica II, Facoltà Facoltà di Medicina e Chirurgia, Università degli
Studi di Milano. In questo Corso è impegnato in attività didattiche frontali, seminari ed esercitazioni
oltre che membro della commissione degli esami di profitto.
Dal 2010 ad oggi è è assegnato in qualità di Ricercatore Universitario Med 12 al corpo docente per
le attivitaà professionalizzanti del Corso di Clinica Medica V anno, Facoltà Facoltà di Medicina e
Chirurgia, Università degli Studi di Milano.
Dal 2014 è docente del Corso di Laurea in Igiene Dentale, Scienze Cliniche, II anno,
Gastroenterologia
Ha svolto attività didattica nei corsi delle Scuole di Specializzazione in Malattie del Fegato e del
Ricambio (1992,2003), Gastroenterologia (2000,2003,2005,2007,2008-2014), Medicina Interna
(2004,2008-2012), Geriatria (2005,2012), Nefrologia (2006,2011,2013), Ematologia (2004,2005)
ed Endocrinologia (2013) dell’Università degli Studi di Milano, Malattie infettive dell’Universiata
degli Studi di Pavia (2014).
Ha ricevuto l’incarico dell’insegnamento di Gastroenterologia (40 ore) – Scuola di Specializzazione
in Gastroenterologia ed Endoscopia Digestiva II per l’anno accademico 2006/2007, come da
delibera del Consiglio della Facoltà di Medicina e Chirurgia, Università degli Studi di Milano
approvato dal Senato Accademico del 13/3/2007.
Ha ricevuto l’incarico dell’insegnamento di Gastroenterologia (10 ore) – Scuola di Specializzazione
in Gastroenterologia ed Endoscopia Digestiva, Università degli Studi di Milano per l’anno
accademico 2009/2010, approvato dal Consiglio di Facoltà di Medicina e Chirurgia nella seduta del
28/09/2009 con la possibilità di valersi del titolo di Professore Aggregato per tutta la durata del
corso.
4
Attività scientifica
Dal 1985 ha svolto l’attività scientifica presso i laboratori di ricerca della Clinica Medica III,
Università degli studi di Milano.
Dal 1998 al 1990, in qualità di post-Doc Fellow ha svolto studi sulla patogenesi della epatite virale,
sviluppato modelli in vitro per testare farmaci anti-HBV e metodiche molecolari in PCR per
determinare le sequenze virali nel siero e nel tessuto di pazienti con infezione da HBV e HCV
presso i laboratori del Department of Experimental Pathology, Tulane University, New Orleans,
USA, sotto la direzione del Prof. Michael Gerber.
Dal 1990 ha svolto l’attività scientifica presso i laboratori di ricerca della Clinica Medica III, della
V Divisione di Medicina Generale, del Dipartimento di Medicina Interna, Patologia Medica VII e
della UO di Gastroenterologia I.
È responsabile della Sezione HBV del laboratorio di Biologia Molecolare ed Immunologia, presso
la UO di Gastroenterologia ed Epatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, diretta dal Prof. M. Colombo.
I principali temi di ricerca sono stati:
Componenti della matrice extracellulare e patogenesi della fibrosi epatica nelle epatopatie croniche
e sviluppo di test radioimmunologici per il dosaggio del collagene, laminina e fibronectina (19851986).
Storia naturale, patogenesi e trattamento dell’epatite virale, sviluppo di tecniche di biologia
molecolare applicate allo studio della cirrosi e epatica e del carcinoma primitivo del fegato (19871996).
Nuovi trattamenti antivirali in pazienti con epatite cronica/cirrosi HBV-correlata (1990-2008).
Farmacoresistenza ad antivirali anti-HBV: tecniche di biologia molecolare ed impatto clinico
(1996-2008).
Efficienza e sicurezza della terapia con analoghi di terza generazione in pazienti con HBV (20072014). Prevenzione delle complicanze, quali HCC, scompenso epatico e ipertensione portale, e
miglioramento delle sopravvivneza nei pazienti trattati a lungo-termine con NUC (2009-2014).
Sviluppo di score prognostici per definire il rischio di sviluppo di HCC in pazienti tratatti a lungo
termine con NUC (2013-2014). Farmacogenomica e linee guida nel trattamento di pazienti con
epatite cronica B trattati con interferone (2009-2014). Studio delle funzioni immunitarie cellulari e
umorali nei pazienti con epatite B non trattati e trattati con interferone o analoghi (2009-2014).
Marcatori non invasivi di fibrosi epatica in HBV (2009-2014). Storia naturale e trattamento
dell’infezione da HBV in pazienti in emodialisi o sottoposti a trapianto renale (2008-2014).
5
Profilassi e trattamento antivirale dei pazienti sottoposti a chemioterapia per patologie oncoematologiche (2009-2014). Studio del metabolismo osseo e della funzione glomerulare e tubulare
renale in pazienti non trattati e trattati con analoghi per HBV (2009-2014).
Ha coordinato e partecipato a progetti nazionali ed internazionali di studio sulle malattie del fegato,
in particolare sulle epatiti virali. Membro del Gruppo di Studio Italiano Lamivudina, gruppo di
Studio Italiano Adefovir, del Gruppo di Studio Terapia Epatite B in pazienti immunocompromessi.
Dal 2007 coordina lo “Studio Multicentrico Italiano Entecavir in pazienti NUC naïve arruolati in
pratica clinica” e dal 2009 lo “Studio Multicentrico Europeo Tenofovir in pazienti NUC naïve
arruolati in pratica clinica”.
Ha partecipato a numerosi studi clinici internazinonali di phase II, III e IV nel campo delle epatiti
virali (GS-01-550, Gilead Sciences, Phase 3, NCT00042393, 2002-2006; ML18253, Hoffman La
Roche, Phase 3, NCT01095835, 2005-2010; CLDT600A2406, Novartis, Phase 3, NCT00412750,
2007-2009; ML28470, Hoffmann-La Roche, Phase 3, NCT01697501, 2012-2013; ML28262,
Hoffmann-La Roche, Phase 2, NCT01706575, 2012-ongoing; GS-US-320-0108, Gilead Sciences,
Phase
3,
NCT01940341,
2013-ongoing;
GS-US-320-0110,
Gilead
Sciences,
Phase
3,
NCT01940471, 2013-ongoing).
Membro del comitato editoriale delle Linee Guida sul Trattamento dell’Epatite Cronica B,
pubblicate nel 2004 e nel 2008 e 2011, delle Linee Guida sulla Profilassi dell’Epatite Cronica B in
Pazienti Immunocompromessi, pubblicate nel 2007, entrambe della Associazione Italiana Studio
Fegato (AISF). Membro del comitato editoriale delle Linee Guida sul trattamento dell’epatite B,
pubblicate nel 2009 ed aggiornate nel 2012 per la European Association for the Study of the Liver
(EASL), pubblicate su Journal of Hepatology. Condidato al board internazionale isituito nel 2013
per la revisione delle linee guida americane su HBV (AASLD).
Membro dello Steering Committee dei seguenti studi: Studio internazionale multicentrico GIANTB: Genetic Study of Peinterferon in Chronic Hepatitis B (2012); Studio internazionale multicentrico
LIFA: Liver Fibrosis Assessment (LiFA) Study Group (2012)
Negli anni ha sviluppato numerose collaborazioni scientifiche con gruppi di lavoro nazionali ed
internazionali, tra le quali le più consolidate sono con l’Università del Michigan di Ann Harbor, A.
Lok (USA); Università del Texas, B Perrillo (USA); Università Royal Free Hospital, A. Burroughs
6
(Inghilterrra); Università College London Medical School, G. Dusheiko (Inghilterrra); Università
Erasmus MS Medical Center Rotterdam, HLA Janssen (Olanda); Liver Unit, IFI Institute for
Interdisciplinary Medicine, Asklepios Klinik St. Georg Hamburg, J. Petersen (Germania);
Università Wolfgang Goethe-Universität Frankfurt am Main, S. Zeuzem (Germania); Università di
Hannover, M. Manns (Germania); Università di Parigi, P. Marcellin (Francia); Centre de Recherche
en Cancerologie de Lyion, INSERM U1052, F. Zoulim (Francia); Università di Parigi, S. Pol
(Francia); Liver Unit Hospital General Universitari Vall d´Hebron, R. Esteban e M Buti (Spagna);
Università di Ankara, C. Yurdaydin (Turchia); Università di Atene, G. Papatheodoridis e S.
Hadziyannis (Grecia); Università di Bangkok, T. Piratvisuth (Tailandia); Università di Singapore,
SG Lim (Singapore); Università di Hong Kong, Henry LY Chan (Cina); Università di Pechino, J Jia
(Cina); Universita di Taiwan, YF Liaw e JH Kao (Taiwan); Università di Melbourne, S. Locarnini
(Australia).
Socio dell’American Association for the Study of Liver disease (AASLD), della European
Association for the Study of the Liver (EASL), dell’Associazione Italiana Studio Fegato (AISF) e
della Società Italiana di Gastroenterologia (SIGE). É stato membro del Comitato Coordinatore
AISF (2005-2008) ed è membro del Consiglio di Amministrazione della Fondazione Italiana
Ricerca in Epatologia, FIRE (2009-2012).
Membro del Board Editoriale delle seguenti riviste: Gut, Journal of Hepatology, APT, Current
Hepatitis B Reports, The Open Hepatology Journal, Liver International
Svolge attività di revisore per le seguenti riviste scientifiche internazionali: Gastroenterology, Gut,
Hepatology, Journal of Hepatology, Antiviral Therapy, American Journal of Gastroenterology,
Journal of Viral Hepatitis, Digestive and Liver Disease, European Journal of Gastroenterology and
Hepatology, Expert Review, Expert Review in Clinical Pharmacology, Liver International, Clinical
Gastroenterology and Hepatology, Antiviral Research, Expert Opinion Pharmacotherapy.
L’attività scientifica è certificata da numerosi abstracts di lavori presentati a congressi nazionali e
internazionali, articoli pubblicati su riviste nazionali e internazionali, capitoli di libri e atti di
congressi nazionali e internazionali. Ha pubblicato oltre 100 tra articoli, review e capitoli di libri,
oltre 270 Abstracts su riviste nazionali ed internazionali. È stato invitato come relatore ad oltre 400
convegni nazionali ed internazionali.
7
Indici bibliometrici
Al Novembre 2012 (domanda Idoneità per ASN): Impact Factor Totale: 480 (corretto 280), H-index
28, Numero Totale Citazioni 3515, Pubblicazioni 94, Pubblicazioni negli ultimi 10 anni 74, Hcindex 22, Numero Citazioni normalizzate per età accademica 135.
Ad Agosto 2014 (fonte Google Scholar): Numero citazioni totali 4291 (2671 dal 2009), Indice H
totoale 29 (23 dal 2009), i10-index totale 72 (57 dal 2009).
Ad Agosto 2014 (fonte Web of Science): Results found 325, Sum of the Times Cited 3288, Sum of
Times Cited without self-citations 3160, Citing Articles 2710, Citing Articles without self-citations
2658, Average Citations per Item 10.12, h-index 28.
Negli ultimi 5 anni ha partecipato a questi progetti scientifici che sono stati finanziati:
Ricerca Corrente 2009: Titolo del progetto: “Ruolo della viremia minima residua HBV nello
sviluppo delle complicanze della cirrosi epatica in pazienti trattati con farmaci anti-virali” (durata
tutto il 2009)
Ricerca Corrente 2010: Titolo del progetto: “Valutazione del rischio di osteopenia/osteoporosi nei
pazienti con epatite cronica B in trattamento con antivirali orali” (durata tutto il 2010)
Ricerca Corrente 2011: Titolo del progetto: “Analisi istomorfometrica della fibrosi residua in
pazienti con cirrosi HCV e HBV-correlata e risposta virologica a terapia specifica” (durata tutto il
2011)
Ricerca Corrente 2012: Titolo del progetto: “Sequenziamento diretto della regione NS3 Proteasi di
HCV in pazienti con epatite cronica C genotipo 1“ (durata tutto il 2012)
BANDO CARIPLO 2011 “RICERCA SCIENTIFICA IN AMBITO BIOMEDICO”
Project Title: "Immune and epigenetic mechanisms in the control of viral transcription/replication in
chronic HBV patients antiviral treatments: an integrated approach to the new biomarkers
identification and rational clinical decisions”. Durata: luglio 2012 – giugno 2014
Proponent: Dipartimento di Scienze Mediche, PI: Prof. Massimo Colombo
Team Members: Dr. Pietro Lampertico Dott.ssa Floriana Facchetti Dott.ssa Roberta Soffredini
Other Partners (name, surname and institution):
- Partner 1. Raffaele De Francesco. Istituto Nazionale Genetica Molecolare (INGM, Milano, Italy),
- Partner 2. Massimo Levrero, Dipartimento di Medicina Interna e Specialita’ Mediche (DMISM),
Sapienza University – Rome (Uniroma 1)
- Partner 3. Carlo Ferrari, Laboratory of Viral Immunopathology at the Azienda OspedalieroUniversitaria of Parma (AO-UniPr)
8
ATTIVITA’ CLINICA ASSISTENZIALE
Dal 1985 al 1986, ha svolto attività di Medico Interno c/o il reparto Degenza della Clinica Medica
III, IRCCS Ospedale Maggiore Policlinico, Milano.
Dal 1990 ad oggi ha costantemente svolto attività clinico-assistenziale presso l’Ambulatorio di
Epatologia della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
Negli ultimi anni ha svolto anche attività clinica presso il Reparto Degenza, UO di
Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano
Nel 2008 è stato Medico Responsabile del Reparto Degenza, UO di Gastroenterologia I,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
Dal 1990 ad oggi è consulente epatologo della divisione di Nefrologia e Dialisi, Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, Milano.
Dal 1990 al 2006, è stato consulente epatologo del Centro Cardiologico, Fondazione Monzino,
Università degli Studi di Milano.
Dal 2006 ad oggi è consulente Epatologo per tutti i reparti della Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milano.
9
ARTICOLI ORIGINALI
1.
Annoni G, Donato MF, Cantaluppi MC, Lampertico P, Cargnel A, Vigano' P, Hahan EG,
Colombo M. Serum procollagen type III levels in patient with acute viral hepatitis. La
Ricerca in Clinica e Laboratorio 1988;18(1):37-44
2.
Mojana E, Tommasini MA, Annoni G, Sangiovanni A, Lampertico P. Valutazione del
metodo LAPIA per la determinazione dell'AFP sierica e della FBN nell'ascite. The Ligand
Quaterly 1988;7:62-64
3.
Annoni G, Khlat B, Lampertico P, Dell'Oca M, Dioguardi FS. Metadoxine (Metadoxil) in
alcoholic liver disease. Its therapeutic role. Clinical Trials Journal 1988;25(5):333-341
4.
Annoni G, Colombo M, Cantaluppi MC, Khlat B, Lampertico P, Rojkind M. Serum type III
procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol
abusers. Hepatology 1989;9(5):693-697
5.
Salerno F, Restelli B, Incerti PL, Annoni G, Capozza L, Badalamenti S, Lampertico P,
Mojana E, Moser P, Tommasini M. Utility of ascitic fluid analysis in patients with
malignancy-related ascites. Scand J Gastroenterol 1990;25(3):251-256
6.
Lampertico P, Malter JS, Colombo M, Gerber MA. Detection of Hepatitis B Virus DNA in
formalin-fixed, paraffin-embedded liver tissue by Polymerase Chain Reaction. Am J Pathol
1990;137(2):253-258
7.
Annoni G, Lampertico P, Colombo M. Marcatori sierici della matrice extracellulare
nell'epatite alcolica. Argomenti di Gastroenterologia Clinica 1990;3:209-216
8.
Lampertico P, Malter JS, Geber MA. Development and application of an in vitro model for
screening of anti-Hepatitis B Virus therapeutics. Hepatology 1991;13(3):422-426
9.
Romeo R, Rumi MG, Lampertico P, De Filippi F, Annoni G, Colombo M. Il ruolo del virus
dell'epatite C nell'epatite cronica degli alcolisti. Argomenti di Gastroenterologia Clinica
1991;4:285–291
10.
Shieh YSC, Shim KS, Lampertico P, Balart LA, Jeffers LJ, Thung SN, Regenstein F, Reddy
KR, Farr G, Shiff ER, Gerber MA. Detection of Hepatitis C virus sequences in liver tissue by
the Polymerase Chain Reaction. Laboratory Investigation 1991;65(4):408–411
11.
Manzin A, Paolucci S, Lampertico P, Menzo S, Rumi MG, Colombo M, Clementi M. Direct
detection of HBV preC mutants in heterogeneous viral population by a modified DNA
sequencing method. Res Virol 1993;144(4):303-306
12.
Gramegna M, Lampertico P, Lobbiani A, Colucci G. Detection of the hepatitis B major precore mutation by the amplification refractory mutation system technique. Res Virol
1993;144(4):307-309
13.
Colombo M, Lampertico P, Rumi MG. A multicentre randomised controlled trial of
recombinant interferon alf–2b in patients with acute non–A, non–B/type C hepatitis after
transfusion. Gut 1993;34:2(Suppl):S141
10
14.
Lampertico P, Rumi MG, Romeo R, Craxì A, Soffredini R, Biassoni D, Colombo M. A
multicenter randomized controlled trial of recombinant interferon alpha 2b in patients with
acute transfusion–associated hepatitis C. Hepatology 1994;19(1):19-22
15.
Lampertico P, Rumi MG, De Filippi F, Romeo F, Soffredini R, Biassoni D, Colombo M.
IFN ricombinante nell'epatite acuta non-A, non-B post-trasfusionale. Argomenti di
Gastroenterologia Clinica 1994;7:111-115
16.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Del Ninno E, Colombo M.
Hepatitis B virus pre-core mutants in HBeAg carriers with chronic hepatitis B treated with
interferon. J Viral Hepatitis 1995;2(5):251-256.
17.
Soffredini R, Rumi MG, Lampertico P, Aroldi A, Tarantino A, Ponticelli C, Colombo M.
Increased detection of antibody to hepatitis C virus in renal transplant patients by third
generation assays. Am J Kid Dis 1996;28(3):437-440
18.
Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Clementi M,
Colombo M. A randomized controlled trial of 24-month course of interferon alfa 2b in
patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen
in serum. Hepatology 1997;26(6):1621-1625
19.
Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, Colucci G. Clinical
evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA
PCR assay. J Virol Meth 1998;74(2):155-165
20.
Aroldi A, Lampertico P, Elli A, Lunghi G, Tarantino A, Montagnino G, Colombo M,
Ponticelli C. Long-term evolution of anti-HCV positive renal transplant recipients.
Transplant Proc 1998;30(5):2076-2078
21.
Aroldi A, Elli A, Tarantino A, Lampertico P, Lunghi G, Maccario M, Quaglini S, Ponticelli
C. Worse outcome in younger adult renal graft recipients with HCV infection:. An 8-year
prospective study. Transpl Int 2000;13(Suppl 1):S90-1
22.
Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR,
Colombo M. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell
proliferative activity. Hepatology 2001;34(3):523-528
23.
De Filippi F, Lampertico P, Soffredini R, Rumi MG, Lunghi G, Aroldi A, Tarantino A,
Ponticelli C, Colombo M. High prevalence, low pathogenicity of hepatitis G virus in kidney
transplant recipients. Dig Liver Dis 2001;33(6):477-479
24.
Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Morabito M, Colombo M.
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month
interferon therapy. Hepatology 2003;37(4):756-763
25.
Iavarone M, Lampertico P, Seletti C, Donato MF, Ronchi G, Del Ninno E, Colombo M. The
clinical and pathogenetic significance of estrogen receptor beta expression in chronic liver
diseases and liver cancer. Cancer 2003;98(3):529-34
26.
Lampertico P, Colombo M. Interferon Therapy in Hepatitis B e Antigen-Negative Chronic
Hepatitis B – Reply. Hepatology 2003;38(3):780
11
27.
Iavarone M, Lampertico P, Ronchi G, Del Ninno E, Zanella A, Colombo M. A prospective
study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of
hepatocellular carcinoma. J Viral Hepat 2003;10(6):423-426
28.
Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, Colucci G,
Rizzetto M. Epidemilogical and clinical burden of chronic hepatitis B virus/hepatitis C virus
infection. A multicenter Italian study*. J Hepatol 2003;39(6):1036-41
29.
Beckebaum S, Malago M, Dirsch O, Cicinnati VR, Trppler M, Lampertico P, Brolsch CE,
Gerken G, Lama N, Treichel U. Efficacy of combined lamivudine and adefovir dipivoxil
treatment for severe HBV graft reinfection after living donor liver transplantation. Clin
Tranplant 2003;17(6):554-559
30.
Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL,
Samuel D, Zeuzem S, Lilly L, Rendina M,Villeneuve J-P, Lama N, James C, Wulfsohn MS,
Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL, on behalf of
The Adefovir Dipivoxil Study 435 International Investigators Group. Adefovir Dipivoxil
Therapy for Lamivudine-Resistant Hepatitis B in Pre– and Post–Liver Transplantation
Patients. Hepatology 2003;38(6):1419-1427
31.
Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G,
Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F. Assessing
tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates
viability of circulating endothelial cells. Cancer Res 2004;64:4373-4377
32.
Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio P, Rizzetto M,
Craxì A for the Italian Association for the Study of the Liver (AISF) Lamivudine Study
Group. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological
response to lamivudine. Hepatology 2004;40:883-891
33.
Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Hepatitis C virus
infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment
Pharmacol Ther 2005;21:623-32
34.
Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, Pulvirenti A,
Franchello A, Colombo M, Salizzoni M, Rizzetto M. Prophylaxis of hepatitis B virus
recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver
Transpl 2005;11:532-538
35.
Aroldi A, Lampertico P, Montagnino G, Lunghi G, Passerini P, Villa M, Campise M,
Cesana BM, Ponticelli C. Natural history of hepatitis C virus infection in adult renal graft
recipients. Transplant Proc 2005;37(2):940-1.
36.
Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, Lunghi G,
Tarantino A, Cesana BM, Messa P, Ponticelli C. Natural history of hepatitis B and C in renal
allograft recipients. Transplantation 2005;79(9):1132-6
37.
Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P. Longterm lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis.
Antivir Ther 2005;10:709-713
12
38.
Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G and Colombo M. Adefovir
rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to
lamivudine. Hepatology 2005;42:1414-1419
39.
Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, Tono
N, and Associazione Italiana Studio Fegato (AISF) Cooperative Group*. Longitudinal
evaluation reveals a complex spectrum of virological profiles in hepatitis B virus / hepatitis C
virus coinfected patients. Hepatology 2006;43(1):100-107
40.
Cortelezzi A, Viganò M, Zilioli VR, Fantini NN, Pasquinia MC, Lambertenghi Deliliers G,
Colombo M, Lampertico P. Adefovir added to lamivudine for hepatitis B recurrent infection
in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with campath-1H. J
Clin Virol 2006;35:467-469
41.
Lampertico P. Entecavir versus lamivudine for HBeAg positive and negative chronic
hepatitis B. J Hepatol 2006;45:457-460
42.
Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Bertolini F,
Primignani M, Sangiovanni A, Colombo M. Increased expression of endothelial growth
factor in small hepatocellular carcinoma. J Viral Hepat 2007;14(2):133–139
43.
Eugene Schiff, Ching-Lung Lai, Stephanos Hadziyannis, Peter Neuhaus, Norah Terrault,
Massimo Colombo, Hans Tillmann, Didier Samuel, Stefan Zeuzem, Jean-Pierre Villeneuve,
Sarah Arterburn, Katyna Borroto-Esoda, Carol Brosgart, and Steven Chuck, for the Adefovir
Dipivoxil Study 435 International Investigators Group. Adefovir dipivoxil for wait-listed
and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term
results. Liver Transpl 2007;13(3):349-60
44.
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A,
Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini
MK. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK
cell-mediated liver damage. J Exp Med 2007;204(3):667-80
45.
Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B,
Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconim R, Mangia A, Puoti
M, Raimondo G, Smedile A, for the Italian Association for the Study of the Liver (A.I.S.F.).
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis
2007;39:397–408
46.
Viganò M, Lampertico P, Rumi MG, Folli C, Maggioni L, Morabito A, Del Ninno E,
Cicardi M, Colombo M. Natural history and clinical impact of cryoglobulins in chronic
hepatitis C: 10-year prospective study of 343 patients. Gastroenterology 2007;133:835-842
47.
Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to
adefovir combined with lamivudine: a 3 year study of 145 lamivudine resistant hepatitis B
patients. Gastroenterology 2007;133:1445-1451
48.
Mangia A. Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, Farci P,
Lampertico P, Marzano A, Niro G, Pisani G, Prati D, Puoti M, Raimondo G, Santantonio T,
Smedile A, Lauria F, for the Italian Association for the Study of the Liver (A.I.S.F.). The use
of molecular assays in the management of viral hepatitis. Dig Liver Dis 2008;40(6):395-404
13
49.
Viganò M, Lampertico P, Colombo M. Acute hepatitis following assumption of a herbal
remedy. Eur J Gastroenterol Hepatol 2008;20(4):364-5
50.
Gatta A, Giannini C, Lampertico P, Pontisso P, Quarta S, Zignego AL, Atzeni F, SarziPuttini P. Hepatotropic viruses: new insights in pathogenesis and treatment. Clin Exp
Rheumatol 2008;26:S33-8
51.
Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P. Hepatitis B virus infection in the
dialysis population: current perspectives. Int J Artif Organs 2008;31(5):386-94
52.
Viganò M, Lampertico P, Facchetti F, Lunghi G, Colombo M. Failure of adefovir 20 mg to
improve suboptimal response in lamivudine resistant hepatitis B patients treated with
adefovir 10 mg and lamivudine. J Viral Hepat 2008;15:992-924
53.
Lampertico P, Colombo M. HBeAg-negative chronic hepatitis B: why do I treat my patients
with nucleos(t)ide analogues. Liver Int 2009;29(Suppl 1):130-132
54.
EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol
2009;50:227-242
55.
Lampertico P. Partial virological response to nucleos(t)ide analogues for naive patients with
chronic hepatitis B: from guidelines to field practice. J Hepatol 2009;50:644-647
56.
Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses
2009;1(3):484-509
57.
Viganò M, Aghemo A, Iavarone M, Rumi MG, Agnelli F, Lampertico P, Donato MF,
Colombo M. The course of inactive hepatitis B in hepatitis C co-infected patients treated with
interferon and ribavirin. Antivir Ther 2009;14(6):789-796
58.
Viganò M, Massironi S, Lampertico P, Iavarone M, Paggi S, Pozzi R, Conte D and
Colombo M. Transient elastography assessment of the liver stiffness dynamics during acute
hepatitis B. Eur J Gasteroenterol Hepatol 2010;22(2):180-184
59.
Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular
carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic
review. J Hepatol 2010;53(2):348-56
60.
Viganò M., Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F,
Scalamogna M, Deliliers GL, Colombo M. Risk of hepatitis B surface antigen seroreversion
after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011;46(1):125-131.
61.
Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M,
Lampertico P, Colombo M. Etiology-related determinants of liver stiffness values in chronic
viral hepatitis B or C. J Hepatol 2011;54(4):621-8
62.
Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther
2011;11(3):285-300
63.
Lampertico P, Viganò M, Colombo M. Treatment of HBeAg-negative chronic hepatitis B
with pegylated interferon. Liver Int 2011;31(Suppl 1):90-4
14
64.
Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, Filice G, Levrero M,
Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto M,
Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti
M, Santantonio T, Smedile A. Treatment of chronic hepatitis B: update of the
recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011;43(4):259-65
65.
Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent
hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol
Gastroenterol 2011;35(6-7):455-64
66.
Lampertico P, Viganò M, Facchetti F, Invernizzi F, Aroldi A, Lunghi G, Messa PG,
Colombo M. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft
recipients with chronic hepatitis B. Nephrol Dial Transplant 2011;26(6):2037-41
67.
Lampertico P, Viganò M., Colombo M. Current management of HBV antiviral drug
resistance. Current Hepatitis Reports 2011;10(2):120-127
68.
Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection.
Expert Opin Drug Saf 2011;10(5):809-18
69.
D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'era A, Lampertico P, Donato
MF, De Nicola S, Prati GM, de Franchis R, Colombo M. The course of esophageal varices in
patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther
2011;16(5):677-84
70.
M. Viganò, S. Paggi, P. Lampertico, M. Fraquelli, S. Massironi, G. Ronchi, C. Rigamonti,
D. Conte and M. Colombo. Dual cut-off transient elastography to assess liver fibrosis in
chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther 2011;34
(3):353–362
71.
Viganò M, Paggi S, Lampertico P. Application of transient elastography in chronic hepatitis
B: Authors'reply. Aliment Pharmacol Ther 2011;34(7):818-819.
72.
Fabrizi F, Viganò M, Banfi G, Martin P, Messa P, Lampertico P. HBV-related liver disease
in renal insufficiency: Successful antiviral therapy with entecavir. Int J Artif Organs
2011;34(10):1031-1035.
73.
Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim
F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P. Entecavir
plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an
international multicenter cohort study. J Hepatol 2012;56(3):520-6
74.
Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients
with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther
2012;12(2):193-207
75.
Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG,
Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P.
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative
patients treated with peginterferon alfa-2a. J Hepatol 2012;56(5):1006-11
15
76.
Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D,
Lampertico P, Viganò M, Colombo M, Loggi E, Missale G, Ferrari C.Peginterferon-α does
not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative
chronic hepatitis. J Hepatol 2012;56(6):1239-46
77.
Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A,
Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA
suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on
lamivudine therapy for over 5 years. J Hepatol 2012;56(6):1254-8
78.
Viganò M, Lampertico P. Clinical implications of HBsAg quantification in patients with
chronic hepatitis B. Saudi J Gastroenterol 2012;18(2):81-6.
79.
Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R,
Abrignani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related
HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B.
Hepatology 2013;57(3):890-6. doi: 10.1002/hep.25749. Epub 2012 Dec 20
80.
Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in
'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012;19(6):377-86.
doi: 10.1111/j.1365-2893.2012.01602.x. Epub 2012 Mar 28
81.
Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut
2012;61 (Suppl 1):i18-24
82.
Lampertico P, Galmozzi E, Colombo M. Studies of IL28B genotype and response to
peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology
2013;57(3):1283-4. doi: 10.1002/hep.25882. Epub 2013 Feb 15
83.
Aghemo A, Lampertico P, Colombo M. Assessing Long-Term Treatment Efficacy in
Chronic Hepatitis B and C: Between Evidence and Common Sense. J Hepatol
2012;57(6):1326-35. doi: 10.1016/j.jhep.2012.06.025. Epub 2012 Jun 28. Review.
84.
Lampertico P, Viganò M., Colombo M. Partial Response to Entecavir and Tenofovir in
Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. Curr Hepatitis
Rep 2012;11(2):90-94
85.
Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci
M, Gaeta GB, Brancaccio G, Colombo M, Missale1 G, Ferrari C. Restored Function of HBVSpecific T Cells after Long-Term Effective Therapy with Nucleos(t)ide Analogues.
Gastroenterology 2012;143(4):963-973
86.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna
S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo
M on behalf of the PegBeLiver Study Group. A randomized study comparing 48 and 96
weeks peginterferon alfa-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut
2013;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.
87.
Abhishek Das, Gidon Ellis, Celeste Pallant, A. Ross Lopes, Pooja Khanna, Dimitra Peppa,
Antony Chen, Paul Blair, Geoffrey Dusheiko, Upkar Gill, Patrick T Kennedy, Maurizia
16
Brunetto, Pietro Lampertico, Claudia Mauri and Mala K. Maini. IL-10 producing regulatory
B cells in the pathogenesis of chronic HBV infection. J Immunology 2012;189(8):3925-35.
88.
Burra P, Germani G, Adam R, Karam V, Marzano A, Lampertico P, Salizzoni M, Filipponi
F, Klempnauer JL, Castaing D, Kilic M, Carlis LD, Neuhaus P, Yilmaz S, Paul A, Pinna AD,
Burroughs AK, Russo FP. Liver transplantation for HBV-related cirrhosis in Europe: a ELTR
study on evolution and outcomes. J Hepatol 2013;58(2):287-96.doi: 10.1016/j.jhep.2012.10.
016. Epub 2012 Oct 23
89.
Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P. Allelic inhibition of
displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA
polymorphisms. J Virol Methods 2013;187(2):271-3. doi: 10.1016/j.jviromet.2012.11. 026.
Epub 2012 Nov 29
90.
Lampertico P, Viganò M, Colombo M. Why do I treat HBeAg-negative chronic hepatitis B
patients with pegylated interferon? Liver Int 2013;33(Suppl 1):157-63. doi: 10.1111/liv.
12064
91.
Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. The use
of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of
response to treatment in chronic hepatitis B patients. BMJ Open 2013;24;3(1). pii: e001309.
doi: 10.1136/bmjopen-2012-001309.
92.
Viganò M, Valenti L, Lampertico P, Facchetti F, Motta BM, D'Ambrosio R, Romagnoli S,
Dongiovanni P, Donati B, Fargion S, Colombo M. Patatin-like phospholipase domaincontaining 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology
2013;58(4):1245-52. doi: 10.1002/hep.26445. Epub 2013 Aug 6
93.
Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M. PegIFN-α2a for the
treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther
2013;11(5):459-74. doi: 10.1586/eri.13.37. Review
94.
Viganò M, Mangia G, Lampertico P. Results of treatment of chronic hepatitis B with
pegylated interferon. Clin Liver Dis 2013;17(3):425-43. doi: 10.1016/j.cld.2013. 05.004.
Epub 2013 Jul 3. Review
95.
Aghemo A, Lampertico P. Absolute and relative contraindications to pegylated-interferon or
ribavirin in the US general patient population with chronic hepatitis C. Aliment Pharmacol
Ther 2013;38(5):553-4. doi: 10.1111/apt.12406. Commentary
96.
Lampertico P, Colombo M. Nucleos(t)ide analogs-based chemoprevention of liver cancer in
hepatitis B patients: effective, yet in search of optimization. Gastroenterology
2013;145(5):1155-6. doi: 10.1053/j.gastro.2013.09.018. Epub 2013 Sep 19.
97.
Lampertico P. Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the
block with a long way to go. Gut 2014;63(6):869-70. doi: 10.1136/gutjnl-2013-305859. Epub
2013 Oct 25. Commentary
98.
Viganò M, Mangia G, Lampertico P. HBeAg-negative chronic hepatitis B: why do I treat
my patients with nucleos(t)ide analogues? Liver Int 2014;34(Suppl 1):120-6. doi: 10.1111
/liv.12401
17
99.
Galmozzi E, Viganò M, Lampertico P. Systematic review with meta-analysis: do interferon
lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?
Aliment Pharmacol Ther 2014;39(6):569-78. doi: 10.1111/apt.12631. Epub 2014 Jan 26
100. Galmozzi E, Lampertico P. Does the IFNL4 gene discovery really provide a causal role for
the IL28B haplotype blocks? Aliment Pharmacol Ther 2014;39(5):548-9. doi: 10.1111/apt.
12615. Letter
101. Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M,
Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline
viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic
hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. doi:
10.1186/2046-4053-3-21
102. Galmozzi E, Viganò M, Lampertico P. Do interferon lambda 3 polymorphisms predict the
outcome of interferon therapy in hepatitis B infection? Aliment Pharmacol Ther
2014;39(10):1251-2. doi: 10.1111/apt.12736. Letter, Authors' reply.
103. Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M,
Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient
elastography in the identification of liver fibrosis in patients with chronic hepatitis B
infection. J Viral Hepat 2014;21(6):430-8. doi: 10.1111/jvh.12161. Epub 2013 Aug 15.
104. Lampertico P. Discontinuation of nucleoside analogues in hepatitis B virus infection.
Gastroenterol Hepatol (NY) 2013;9(10):656-8
105. D'Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S, Cheroni
C, Clark PJ, Ronchi G, Lampertico P, Colombo M. Int J Mol Sci 2014;15(5):7213-24. doi:
10.3390/ijms15057213
106. Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved
hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther
2014;14(7):1019-31. doi: 10.1517/14712598.2014.912273
107. Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or
continue? Gut 2014;0:1–2. doi:10.1136/gutjnl-2014-307596. Commentary
18
CAPITOLI DI LIBRI
1.
Cantaluppi MC, Annoni G, Lampertico P, Dioguardi N, Colombo M. Serum collagen
peptides as markers of chronic hepatic damage. Occupational & Environmental Chemical
Hazards. Ed: Foa, Ellis Horvood, Chirchester, 178—181, 1987.
2.
Annoni G, Lampertico P, Donato MF, Khlat B, Colombo M. Serum markers for
extracellular matrix components in the diagnosis of alcoholic hepatitis. Elsevier Science
Publishers BV. Chronic liver damage. Ed: M.U. Dianzani and P. Gentilini. Chapter 19, 171—
180, 1990.
3.
Lampertico P, Rumi MG, Romeo R, Craxi' A, Soffredini R, Biassoni D, Colombo M. Studio
multicentrico randomizzato controllato del trattamento con IFN alfa 2b in pazienti con epatite
acuta post-trasfusionale non-A, non-B. L'interferone nelle epatiti croniche virali. Eds.
Piccinino F, Sagnelli E, Felaco FM, Giusti G. CNR Progetto Finalizzato Prevenzione e
Controllo dei Fattori di Malattia. 1995, 213-220.
4.
Colombo M, Lampertico P, Rumi MG. Treatment of viral hepatitis. Falk symposium 90.
Update on hepatobiliary diseases 1996. Ed: SK Lam, G Paumgartner, B Wang. Chapter 4, 2737,1997
5.
Colombo M, Lampertico P. Natural history of chronic hepatitis B and HCC. Zuckerman and
Thomas: Viral hepatitis, II edition. Eds. Churchill Livingstone 1997
6.
Colombo M, Lampertico P. Treatment of hepatocellular carcinoma. Therapy of liver
disease: the pathophysiological basis of therapy, Arroyo V, Bosh J, Bruguera M, Rodes J
(Eds), Masson S.A. Barcelona, Madrid, Paris, Milano, Asuncion, Bogota', Buenos Aires,
Caracas, Lima, Lisboa, Mexico, Montevideo, Rio de Janeiro, San Juan de Puerto Rico,
Santiago de Chile, 1997:497-503.
7.
De Filippi F, Lampertico P, Soffredini R, Rumi M, Lunghi G, Aroldi A, Tarantino A,
Ponticelli C, Colombo M. High prevalence, low pathogenicity of hepatitis G virus in kidney
transplant recipients. First Research Project on Viral Hepatitis: Etiopathogenesis and
diagnosis (1997-1999) progress report, Rapicetta M (Ed), Rapporti ISTISAN, Roma, 2000:
167-173
8.
Lampertico P. Quantitative determination of HBV-DNA in patients with chronic hepatitis B
undergoing antiviral treatment. Clinical and diagnostic relevance of HBV-DNA. (EsaDia).
Pag 10-13, 2001
9.
Colombo M, Lampertico P. Natural history of chronic hepatitis B and Hepatocellular
Carcinoma. Editors: H. Thomas, A Zuckermann, S. Lemon: Viral hepatitis, III edition. Eds.
Blackwell Publishing, Oxford, 2004
10.
Lampertico P. Lamivudine for chronic hepatitis B. Editors: M Buti and R Esteban: Hepatitis
B. Eds. Permanyer Publications, Barcelona, 2005
11.
Colombo M, Lampertico P. Neoplasie del fegato. Manuale di Gastroenterologia,
UNIGASTRO (ed), EGI, Roma, 2007;362-369
19
ATTI DI CONGRESSI NAZIONALI E INTERNAZIONALI
1.
Colombo M, Annoni G, Lampertico P, Cantaluppi C, Dioguardi N. Il ruolo della
fibrillogenesi nell'epatite cronica virale. Atti della XXXI settimana medica degli ospedali:
moderni aspetti in patologia epatica e pancreatica., pag. 157-173, 1986.
2.
Lampertico P, Colucci G, Piva A, Soffredini R, De Filippi F, Rumi MG, Colombo M.
Replicazione criptica del virus dell'epatitie B (HBV) in pazienti con carcinoma
epatocellulare. Atti del 11° Simposio Epatite e AIDS, International Meeting on Viral and
Human Retroviruses, Ed: Antonio Delfino. pag 322–325, 1991.
3.
Lampertico P, Rumi MG, Romeo R, Donato MF, Elevata prevalenza di infezione virale C in
pazienti con epatopatia alcolica. I test di II generazione per la ricerca dell'anti–HCV in clinica
in laboratorio. Alessandro Moroni. Ed: Wiching Milano, pag 19–20, 1992.
4.
Lampertico P, Rumi MG, Colombo M. Gruppo Italiano per lo Studio della Terapia
dell'Epatite Virale. Studio randomizzato multicentrico controllato del trattamento con IFN
a
alfa 2b nell'epatite acuta post–trasfusionale. Atti della 5 Settimana Italiana delle Malattie
Digestive. L Barbara, R Corinaldesi, M Miglioli, E Pisi, E Roda. Ed: Monduzzi, pag 487–
490, 1992.
5.
Lunghi G, Lampertico P, Orlandi A, Viganò M, Mascheroni E, Galli C, Colombo M,
Pagano A. Comparison of different methods for the quantitative determination of HBV-DNA
in chronic hepatitis B patients. Proceedings of the VII International Conference on
Current Trends in Chronic Evolving Viral Hepatitis, 23-25 Settembre 2001, Firenze, 39
6.
Colombo M and Lampertico P. Cirrhosis by hepatitis B virus. Proceedings of the
International workshop “What’s there again in gastroenterology?”. Ed. M Carrara, L.
Trevisani, G Verdianelli, pag 99-101, 2001.
7.
Lampertico P, Iavarone M, Del Ninno E, Colombo M. Alpha-fetoprotein messanger RNA in
blood of patients with cirrhosis. Proceedings of the 10th International Symposium on Viral
Hepatitis and Liver Disease. Ed: Harold S. Margolis, Miriam J Alter, T. Jake Liang, Jules L.
Dienstag. 2002 International Medical Press, pag 428-431.
8.
Lampertico P. Treatment of the HBeAg-negative chronic hepatitis B with interferon”
Proceedings of the Workshop: Chronic viral hepatitis: the general practitioner and the
specialist. Pag 27-30, 2002.
9.
Lampertico P. Adefovir Dipivoxil and new antiviral agents in the treatment of chronic
Hepatitis B. Eds: EDIMES. Italian Journal of Infectious Diseases 2003;9:S37-S39
20
ABSTRACTS
1.
Annoni G, Donato MF, Cantaluppi MC, Lampertico P, Nardelli P, Colombo M. Livelli
sierici di peptide aminoterminale del procollagene III (sPIIIP) nell'evoluzione dell'epatite
virale acuta (EAV). XII Giornate di Gastroenterologia Medico-Chirurgica. Ente ospedaliero
San Carlo Borromeo. Milano, 16-18 gennaio, 1986.
2.
Lampertico P, Petrovic LM, Malter JS, Banerjee R, Price M, Gerber MA. Effect of cyclic 2'deoxyguanosine on the production of hepatitis B virus in vitro. Hepatitis B Viruses, Cold
Spring Harbor Laboratory Meeting, 79, 1989.
3.
Lampertico P, Petrovic LM, Malter JS, Banerjee R, Price M, Gerber MA. Effect of cyclic 2'deoxyguanosine on the production of hepatitis B virus in vitro. Annual Meeting AASLD.
Hepatology 1989;11: 258
4.
Lampertico P, Malter JS, Colombo M, Gerber MA. Detection of Hepatitis B Virus DNA in
formalin-fixed, paraffin-embedded liver tissue by Polymerase Chain Reaction. 1990
International Symposium on Viral Hepatitis and Liver Disease, Houston, 4–8 Aprile, 1990.
5.
Annoni G, Rumi MG, Lampertico P, Colombo M. Prevalence of Hepatitis C Virus (HCV)
antibodies in alcoholics abusers and its association with the severity of liver disease. Annual
Meeting AISF. Italian Journal of Gastroenterology 1990;22 (3):153
6.
Rumi MG, Romeo R, Aroldi A, Paparella M, Lampertico P, Colombo M. Hepatitis C virus
and chronic liver disease in renal allograft recipients. Annual Meeting AISF. Italian Journal
of Gastroenterology 1990;22(3):261
7.
Lampertico P, Malter JS, Colombo M, Gerber MA. Detection of Hepatitis B Virus DNA in
formalin—fixed, paraffin—embedded liver tissue by Polymerase Chain Reaction. Annual
Meeting AISF. Italian Journal of Gastroenterology 1990; 22(3):190
8.
Rumi MG, Annoni G, Donato MF, Lampertico P, Romeo R, Colombo M. Hepatitis C virus
(HCV) infection and liver disease in alcoholics. Annual Meeting SIGE. Italian Journal of
Gastroenterology 1990;22(4):262
9.
Rumi MG, Romeo R, Aroldi A, Paparella M, Lampertico P, Colombo M. Hepatitis C virus
and chronic liver disease in renal allograft recipients. Annual Meeting SIGE. Italian Journal
of Gastroenterology 1990; 22(4):261
10.
Lampertico P, Malter JS, Colombo M, Gerber MA. Detection of Hepatitis B Virus DNA in
formalin—fixed, paraffin—embedded liver tissue by Polymerase Chain Reaction. Annual
Meeting EASL. J Hepatol 1990; 11(Suppl. 2): S37 #146
11.
Annoni G, Rumi MG, Donato MF, Lampertico P, Colombo M. Hepatitis C virus (HCV)
antibodies in alcoholics. Annual Meeting EASL. J Hepatol 1990;11(Suppl. 2):S2 #7
12.
Rumi MG, Annoni G, Donato MF, Lampertico P, Romeo R, Colombo M. Hepatitis C
(HCV) infection and liver disease in alcoholics. Annual Meeting AASLD. Hepatology 1990;
12: 971, #536
21
13.
Rumi M.G, Annoni G, Donato MF, Lampertico P, Romeo R, Colombo M. Hepatitis C
(HCV) infection and chronic hepatitis in alcoholics. 2nd International Symposium on HCV.
Abstract Book , 1990.
14.
Lampertico P, Colucci G, Piva A, Rumi, M.G, Colombo M. Cryptic hepatitis B virus
replication in patients with hepatocellular Carcinoma (HCC). Molecular Biology of Hepatits
B Viruses Abstract Book, pag.104,1991.
15.
Lampertico P, Colucci G, Piva A, Rumi, MG, Colombo M. Replicazione criptica del virus
dell'epatite B (HBV) in pazienti con carcinoma epatocellulare (CE). 11° Simposio Epatite e
AIDS, Abstracts Book, pag 110, 1991.
16.
Lampertico P, Colombo M, Rumi MG, Annoni G, Romeo R, Donato MF, Del Ninno E.
Epatite cronica da virus C (HCV) in pazienti alcolisti. 11° Simposio Epatite e AIDS,
Abstracts Book, pag 125, 1991.
17.
Lampertico P, Colombo M, Rumi MG, Annoni G, Romeo R, Donato MF, Del Ninno E.
Hepatits C virus (HCV)–related chronic hepatitis in italian alcoholic patients. Annual
Meeting AASLD. Hepatology 1991; 14(4): A211
18.
Lampertico P., Colucci G., Piva A., Rumi, M.G., Colombo M. Cryptic hepatitis B virus
replication in patients with hepatocellular carcinoma (HCC). Annual Meeting AASLD.
Hepatology 1991:14(4),A177
19.
Lampertico P, Rumi MG, Colombo M. A randomized, multicenter, controlled trial of
recombinant interferon alpha 2b in patients with acute posttransfusion non–A, non–B
hepatitis. 5th International Symposium on Viral Hepatitis, Abstract Book, pag 111, 1992.
20.
Lampertico P., Colucci G., Piva A., Rumi, M.G., Colombo M. Cryptic hepatitis B virus
replication in patients with hepatocellular Carcinoma (HCC). 5th International Symposium
on Viral Hepatitis, Abstract Book, pag 111, 1992.
21.
Lampertico P, Rumi MG, Colombo M. Studio multicentrico, randomizzato controllato del
trattamento con IFN alfa 2b nell'epatitie acuta post–trasfusionale. 2° Simposio Internazionale
sulla Terapia delle Malattie Epatiche, Abstract Book, pag 73, 1992.
22.
Lampertico P, Rumi MG, Colombo M. Studio multicentrico, randomizzato controllato del
trattamento con IFN alfa 2b nell'epatitie acuta post–trasfusionale. Corso di Aggiornamento
sull'Epatite C, Abstract Book, pag 57, 1992.
23.
Lampertico P, Rumi MG, Colombo M. A randomized, multicenter, controlled trial of
recombinant interferon alpha 2b in patients with acute posttransfusion non–A, non–B
hepatitis (PTH). Annual Meeting AGA. Gastroenterology 1992; 102(4): A838
24.
Lampertico P, Rumi MG, Colombo M. Studio randomizzato, multicentrico, controllato del
a
trattamento con IFN alfa 2b nell'epatitie acuta post–trasfusionale. 5 Settimana Italiana delle
Malattie Digestive, Abstract Book, pag 71, 1992.
22
25.
Lampertico P, Rumi MG, Colombo M. Treatment of acute post–transfusion non–A, non–B
hepatitis (PTH) with recombinant interferon alpha 2b: a randomized, multicenter, controlled
trial in italian patients. Annual Meeting AISF, The Italian Journal of Gastroenterology 1992;
24(5):283
26.
Lampertico P, Rumi MG, Colombo M. A multicenter RCT of interferon alpha 2b in patients
with acute posttransfusion non–A, non–B hepatitis (PTH). 1° Annual Meeting on Hepatitis C
Virus and Related Viruses, Abstract Book, pag 152, 1992.
27.
Rumi MG, Lampertico P, Soffredini R, Romeo R, Craxì A, Colombo M. Serum HCV–RNA
during acute hepatitis C: the effect of interferon therapy. Annual Meeting on Molecular
Biology of Hepatitis B Viruses, Abstract Book, pag 196, 1992.
28.
Lampertico P, Rumi MG, Colombo M. A multicenter RCT of interferon alpha 2b in patients
with acute posttransfusion non–A, non–B hepatitis (PTH). Annual Meeting EASL. J Hepatol
1992;16:S48
29.
Rumi MG, Lampertico P, Soffredini R, Romeo R, Craxì A, Colombo M. Serum HCV–RNA
in patients with acute hepatitis C treated with recombinant interferon alfa. Annual Meeting
AASLD. Hepatology 1992; 16(4):A72
30.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Detection of
HBV pre–core mutants before and after interferon treatment in patients with chronic hepatitis
B. Annual Meeting AASLD. Hepatology 1992;16(4): A209
31.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. HBV pre–core
mutants in interferon–treated HBeAg positive patients with chronic hepatitis. International
symposium on viral hepatitis and liver disease (The 8th triennal congress), Abstract book,
pag.122, #84, 1993.
32.
Lampertico P, Aroldi A, Rumi MG, Paparella M, Tarantino A, Ponticelli C, Colombo M.
Relationship between HCV infection and chronic hepatitis in renal allograft recipients.
International symposium on viral hepatitis and liver disease (The 8th triennal congress),
Abstract book, pag.232, #585, 1993.
33.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Paparella M, Tarantino A, Ponticelli C,
Colombo M. HCV infection and chronic hepatitis in renal transplant patients. 4th
international symposium on HCV. Abstract book, pag. 93, #107, 1993.
34.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. HBV pre–core
mutants in interferon–treated HBeAg positive patients with chronic hepatitis. 94th Annual
Meeting AGA. Gastroenterology 1993;104(4),A934
35.
Rumi MG, Lampertico P, Soffredini R, Romeo R, Craxì A, Colombo M. Serum HCV–RNA
in patients with acute hepatitis C treated with recombinant interferon alfa. 94th Annual
Meeting AGA Gastroenterology 1993; 104(4): A981
36.
Lampertico P, Aroldi A, Rumi MG, Paparella M, Tarantino A, Ponticelli C, Colombo M.
Relationship between HCV infection and chronic hepatitis in renal allograft recipients. 94th
Annual Meeting AGA, Abstract Book, A21,82,1993.
23
37.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Paparella M, Tarantino A, Ponticelli C,
Colombo M. HCV infection and chronic liver disease in renal transplant patients.
International Meeting on biology, immunopathology and clinic of hepatitis viruses. Abstract
book, pag,. 128, 1993.
38.
Gramegna M, Lampertico P, Lobbiani A, Colucci G. Detection of the hepatitis B virus
(HBV) major pre–core mutation by the amplification refractory mutation system (ARMS)
technique. International Meeting on biology, immunopathology and clinic of hepatitis
viruses. Abstract book, pag,. 90, 1993.
39.
Lampertico P, Rumi MG, Romeo R, Colombo M. Treatment of patients with acute
transfusion–associated non–A, non–B hepatitis. International Meeting on biology,
immunopathology and clinic of hepatitis viruses. Abstract book, pag,. 81, 1993.
40.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Changes of
HBV pre–core sequences in HBeAg positive patients with chronic hepatitis treated with
interferon. International Meeting on biology, immunopathology and clinic of hepatitis
viruses. Abstract book, pag,. 41, 1993.
41.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Changes of
HBV genomic population in HBeAg positive patients with chronic hepatitis treated with
interferon. Annual Meeting AISF. Italian Journal of Gastroenterology 1993;25 (4):222
42.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Paparella M, Tarantino A, Ponticelli C,
Colombo M. HCV infection and chronic liver disease in renal transplant patients. Annual
Meeting AISF. Italian Journal of Gastroenterology 1993:25(4):222
43.
Manzin A, Lampertico P, Paolucci S, Rumi MG, Colombo M, Clementi M. Take over of
HBV pre–core mutants over the wild–type strains associated with sustained response to
alpha–interferon in HBeAg positive patients with chronic hepatitis. Annual Meeting on
Molecular Biology of Hepatitis B Viruses, Abstract Book, pag 161, 1993.
44.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Paparella M, Tarantino A, Ponticelli P,
Colombo M. HCV infection and chronic liver disease in renal transplant patients. Annual
Meeting EASL. J Hepatol 1993; 18 (Suppl. 1): S137,#T–236
45.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Changes of
serum HBV genomic population in HBeAg positive patients with chronic hepatitis treated
with interferon. Annual Meeting EASL. J Hepatol 1993;18(Suppl.1): S137,#T–237
46.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Emergence and
takeover of pre-core mutants are associated to anti-HBe seroconversion and hepatitis
remission in HBeAg chronic hepatitis B. Annual Meeting AASLD. Hepatology 1993; 18(4):
#232
47.
Soffredini R, Rumi MG, Lampertico P, Aroldi A, Tarantino A, Polito AJ, Di Nello R, Quan
S, Colombo M. Increased sensitivity and specificity of third generation assays for HCV in
transplanted patients. Annual Meeting AASLD. Hepatology 1993;18(4):#801
48.
Lampertico P, Manzin A, Rumi MG, Paolucci S, Clementi M, Colombo M. Emergence and
takeover of pre-core mutants are associated to anti-HBe seroconversion and hepatitis
24
remission in HBeAg chronic hepatitis B. Annual Autumn Meeting AISF. Italian Journal of
Gastroenterology 1993;8:457
49.
Soffredini R, Rumi MG, Lampertico P, Aroldi A, Tarantino A, Polito AJ, Di Nello R, Quan
S, Nelles MJ, Lee S, Colombo M. Increased sensitivity and specificity of third generation
assays for HCV in transplanted patients. Annual Autumn Meeting AISF. Italian Journal of
Gastroenterology 1993; 8:467
50.
Soffredini R, Rumi MG, Lampertico P, Romeo R, Aroldi A, Tarantino A, Colombo M.
Aumentata sensibilita' e specificita' dei test anti-HCV di terza generazione in pazienti
sottoposti a trapianto di rene. Third course on hepatitis C: early diagnosis and prevention.
Abstract book, pag 51, 1994
51.
Lampertico P, Gramegna M, Manzin A, Clementi M, Rumi MG, Colombo M. Development
of a new PCR-based technique to detect pre-core HBV mutants: the amplification refractory
mutation system (ARMS). 95th Annual meeting AGA. Gastroenterology 1994;106 (4):A924
52.
Soffredini R, Rumi MG, Lampertico P, Romeo R, Aroldi A, Tarantino A, Colombo M.
Increased sensitivity and specificity of third generation assays for HCV in renal transplanted
patients. 2nd International Meeting on Hepatitis C and Related Viruses. Abstract Book, pag
250, 1994
53.
Soffredini R, Rumi MG, Lampertico P, Romeo R, Aroldi A, Tarantino A, Colombo M.
Increased sensitivity and specificity of third generation assays for HCV in renal transplanted
patients. 29th Annual meeting EASL. J Hepatol 1994; 21 (Suppl 1):S67
54.
Lampertico P, Gramegna M, Mundo A, Rumi MG, Del Ninno E, Colucci G, Colombo M.
Quantitative and qualitative dynamic analysis of HBV-DNA by amplification refractory
mutation system (ARMS) in anti-HBe positive patients treated with interferon. Annual
meeting on Molecular Biology of Hepatitis B viruses. Abstract Book,pag 170,1994
55.
Lampertico P, Gramegna M, Manzin A, Clementi M, Rumi MG, Colombo M. Development
of a new PCR-based technique to detect pre-core HBV mutants: the amplification refractory
mutation system (ARMS). 10th World Congress of Gastroenterology. Abstract book II, 955P,
1994.
56.
Lampertico P, Gramegna M, Mundo A, Rumi MG, Del Ninno E, Colucci G, Colombo M.
Quantitative and qualitative dynamic analysis of HBV-DNA by amplification refractory
mutation system (ARMS) in anti-HBe positive patients treated with interferon. Annual
meeting of AASLD. Hepatology 1994; 20(4): 308A, #845
57.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Tarantino A, Ponticelli C, Colombo M.
The natural history of hepatitis C in renal allograft recipients: a 5-year prospective study in
443 patients. 4th International Conference Current Trends in Chronically-Evolving Viral
Hepatitis. Abstract Book, pag 111, #P69,1995
58.
Lampertico P, Aroldi A, Rumi MG, Soffredini R, Tarantino A, Ponticelli C, Colombo M.
The natural history of hepatitis C in renal allograft recipients: a 5-year prospective study in
443 patients. 96th Annual meeting of the AGA. Gastroenterology 1995, 108 (4):A1106
25
59.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, Del Ninno E, Clementi,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. Annual Spring Meeting of the
AISF. The Italian Journal of Gastroenterology 1995;27(4):217
60.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, Del Ninno E, Clementi,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. Annual Meeting on Molecular
Biology of Hepatitis B Viruses. Abstract Book,pag 140,1995
61.
Lampertico P, Aroldi A, Lunghi G, Archenti A, Rumi MG, Soffredini R, Tarantino A,
Ponticelli C, Colombo M. The natural history of hepatitis C in renal allograft recipients: a 5year prospective study in 443 patients. 30th Annual Meeting of the EASL. J Hepatol 1995;23
(suppl 1): 174
62.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, Del Ninno E, Clementi,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. 30th Annual Meeting of the
EASL. J Hepatol 1995; 23 (suppl 1): 174
63.
Rumi MG, Del Ninno E, Romeo R, Parravicini ML, Lampertico P, Soffredini R, Colombo
M. Long-term course of IFN alpha 2b treatment in chronic hepatitis delta. 5th International
Symposium on Hepatitis Delta Virus and Liver Disease. Abstract Book, D46,1995
64.
Lampertico P, Aroldi A, Lunghi G, Archenti A, Rumi MG, Soffredini R, Tarantino A,
Ponticelli C, Colombo M. The natural history of hepatitis C in renal allograft recipients: a 5year prospective study in 443 patients. 5th International Symposium on Hepatitis C Virus and
Related Viruses. Abstract Book,C46,1995
65.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, Del Ninno E, Clementi,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. III Simposio Internazionale. La
terapia delle malattie epatiche. Abstracts book,pag.11,1995
66.
Lunghi G, Cardone R, Archenti A, Aroldi A, Lampertico P, Rabacchi F, Ognissanti M,
Pagano M. Elevata prevalenza del genotipo 4 di HCV in una popolazione di trapiantati renali.
III Simposio Internazionale. La terapia delle malattie epatiche. Abstracts book,pag.155,1995
67.
Rumi MG, Del Ninno E, Romeo R, Parravicini ML, Lampertico P, Soffredini R, Colombo
M. Long-term course of IFN 2b treatment in chronic hepatitis delta. Annual Meeting of
AASLD. Hepatology 1995;22(4):306
68.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, del Ninno E, Clementi M,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha-2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. Annual Meeting of AASLD.
Hepatology 1995; 22 (4): 874
69.
Lampertico P, Rumi MG, Donato MF, Lunghi G, Manzin A, Del Ninno E, Clementi M,
Colombo M. Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe
positive chronic hepatitis B: a randomized controlled trial. IASL Biennial Scientific meeting.
Cape Town, South Africa 18-24 February 1996. Abstract Book, 153P.
26
70.
Rumi MG, Del Ninno E, Romeo R, Parravicini ML, Lampertico P, Soffredini R, Colombo
M. Long-term course of IFN 2b treatment in chronic hepatitis Delta. IASL Biennial Scientific
meeting. Cape Town, South Africa 18-24 February 1996. Abstract Book, 226P.
71.
Lunghi G, Archenti A, Cardone R, Ognissanti M, Mazzucchi F, Lampertico P, Aroldi A,
Pagano A. Genotype 4 of hepatitis c virus and kidney transplantation in north Italy. IX
Triennial International Symposium on viral hepatitis and liver disease. Rome, Italy. April 2125 1996. Abstract Book B271.
72.
Donato MF, Agnelli F, Ronchi G, Balestrieri M, Lampertico P, Tarantino A, Ponticelli C,
Colombo M. Increased expression of hepatitis C virus related liver antigens (HCV-Ag) in
kidney transplanted patients. Annual meeting of AASLD. Hepatology 1996; 24(4): 375A,
#994,
73.
Lampertico P, Romeo R, Hess G, Lunghi G, Aroldi A, Tarantino A, Ponticelli C, Colombo
M. High prevalence, low pathogenecity of hepatitis G virus (HGV) in kidney transplant
recipients. Annual meeting of AASLD. Hepatology 1996;24(4):417A,#1163
74.
Lampertico P, Romeo R, Hess G, Lunghi G, Aroldi A, Tarantino A, Ponticelli C, Colombo
M. High prevalence, low pathogenecity of hepatitis G virus (HGV) in kidney transplant
recipients. National Congress of Digestive Diseases. The Italian Journal of Gastroenterology
1996; 28 (2): 150
75.
Lampertico P, De Filippi F, Romeo R, Hess G, Lunghi G, Aroldi A, Tarantino A, Ponticelli
C, Colombo M. High prevalence, low pathogenecity of hepatitis G virus (HGV) in kidney
transplant recipients. 4th International Meeting on Hepatitis C virus and Related Viruses.
Abstract Book. pag 242, 1997.
76.
Donato MF, Agnelli F, Ronchi G, Balestrieri M, Lampertico P, Tarantino A, Ponticelli C,
Colombo M. Increased expression of hepatitis C virus related liver antigens (HCV-Ag) in
kidney transplanted patients. 4th International Meeting on Hepatitis C virus and Related
Viruses. Abstract Book. pag 124, 1997
77.
Lampertico P, De Filippi F, Romeo R, Hess G, Lunghi G, Aroldi A, Tarantino A, Ponticelli
C, Colombo M. High prevalence, low pathogenecity of hepatitis G virus (HGV) in kidney
transplant recipients. 32nd Annual meeting of EASL. J Hepatol 1997;26 (suppl 1): 189
78.
Gerken G, Gomes J, Lampertico P, Rothaar T, Colucci G. Clinical evaluation of a
competitive PCR assay for the quantification of HBV viremia. 48th Annual Meeting of
AASLD. Hepatology 1997;26(4): suppl 2, 318A, #758
79.
Lampertico P, Aroldi A, Lunghi G, Rumi MG, Donato MF, Soffredini R, Tarantino A,
Morabito A, Ponticelli C, Colombo M. The natural history of hepatitis C in renal allograft
recipients: an 8-year prospective study of 443 patients. 4° Simposio Internazionale. La terapia
delle Malattie Epatiche 1998. Abstract Book, #07, pag 91, 1998
80.
Lampertico P, Aroldi A, Lunghi G, Rumi MG, Donato MF, Soffredini R, Tarantino A,
Morabito A, Ponticelli C, Colombo M. The natural history of hepatitis C in renal allograft
recipients: a 8-year prospective study of 443 patients. 49th Annual Meeting of AASLD.
Hepatology 1998; 28 (4): Suppl 2, #2, 163A
27
81.
Donato MF, Arosio E, Balestrieri M, Lampertico P, Fasani P, Morabito A, Ronchi G, Del
Ninno E, Colombo M. Increased risk of hepatocellular carcinoma (HCC) in cirrhotic patietns
with high proliferating cellular nuclear antigen index (PCNA-I). 49th Annual Meeting of
AASLD. Hepatology 1998; 28 (4): Suppl 2, #700, 337A
82.
Lampertico P, Aroldi A, Lunghi G, Rumi MG, Donato MF, Soffredini R, Tarantino A,
Morabito A, Ponticelli C, Colombo M. La storia naturale dell’epatite C nei trapiantati renali:
studio prospettico di 8 anni in 443 pazienti. XCIX Congresso Nazionale della Società Italiana
di Medicina Interna. Bari 10-14 Novembre 1998. Abstract Book, ???, pag ??, 1998
83.
Lampertico P, Aroldi A, Lunghi G, Rumi MG, Donato MF, Soffredini R, Tarantino A,
Morabito A, Ponticelli C, Colombo M. The natural history of hepatitis C in renal allograft
recipients: a 8-year prospective study of 443 patients. Annual Meeting of SIGE. Italian
Journal of Hepatology and Gastroenterology 1998; 30 (Suppl.2): A87, #9
84.
Donato MF, Arosio E, Balestrieri M, Lampertico P, Fasani P, Morabito A, Ronchi G, Del
Ninno E, Colombo M. Increased risk of hepatocellular carcinoma (HCC) in cirrhotic patienTs
with high proliferating cellular nuclear antigen index (PCNA-I). Annual Meeting of SIGE.
Italian Journal of Hepatology and Gastroenterology 1998; 30(Suppl.2): A103, #51
85.
Lampertico P, Lunghi G, Bazzaco S, Iavarone M, Soffredini R, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Il monitoraggio dell’HBV-DNA sierico mediante PCR quantitativa
predice lo sviluppo di mutanti YMDD in pazienti con epatite cronica HBV-correlata trattati
con lamivudina. 100° Congresso Nazionale della Società Italiana di Medicina Interna.
Abstract Book, #367, pag 463, 1999.
86.
Lampertico P, Bazzaco S, Iavarone M, Del Ninno E, Colombo M. Studio prospettico della
determinazione dell’RNA dell’alfafetoproteina (AFP) nel sangue periferico di pazienti
cirrotici nella diagnosi precoce di carcinoma epatocellulare (CE). 100° Congresso Nazionale
della Società Italiana di Medicina Interna. Abstract Book, #368, pag 464, 1999.
87.
Donato MF, Lampertico P, Arosio E, Del Ninno E, Ronchi G, Morabito A, Fasani P,
Colombo M. Riduzione della proliferazione epatocellulare in pazienti con epatite cronica B
trattati con interferone. 100° Congresso Nazionale della Società Italiana di Medicina Interna.
Abstract Book, #356, pag 452, 1999.
88.
Donato MF, Lampertico P, Arosio E, Del Ninno E, Ronchi G, Morabito A, Fasani P,
Colombo M. Reduction of liver cell proliferation in patients with anti-HBe chronic hepatitis
B treated with interferon (IFN). 50° Annual Meeting of AASLD. Hepatology 1999; 30 (4):
suppl 2, #740,.
89.
Lampertico P, Lunghi G, Bazzaco S, Iavarone M, Soffredini R, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Monitoring serum HBV-DNA during lamivudine therapy by
quantitative PCR assay may predict development of YMDD mutants. 50° Annual Meeting of
AASLD. Hepatology 1999; 30 (4); suppl 2, #1940
90.
Lampertico P, Bazzaco S, Iavarone M, Del Ninno E, Colombo M. A prospective study of
alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a predictor of hepatocellular
carcinoma (HCC). 50° Annual Meeting of AASLD. Hepatology 1999; 30 (4); Suppl 2, #472
28
91.
Iavarone M, Lampertico P, Bazzaco S, Del Ninno E, Colombo M. A prospective study of
alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a predictor of hepatocellular
carcinoma (HCC). Annual Meeting of AISF. Digestive and Liver Disease 2000; 32 (suppl 1):
89, #21
92.
Donato MF, Lampertico P, Arosio E, Del Ninno E, Ronchi G, Morabito A, Fasani P,
Colombo M. Reduction of liver cell proliferation in patients with anti-HBe chronic hepatitis
B treated with interferon (IFN). Annual Meeting of AISF. Digestive and Liver Disease 2000;
32 (suppl 1):89, #22
93.
Lampertico P, Iavarone M, Lunghi G, Orlandi A, De Filippi F, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Monitoring serum HBV-DNA during lamivudine therapy by
quantitative PCR assay may predict development of YMDD mutants. Annual Meeting of
AISF. Digest Liver Disease 2000; 32(suppl 1): 94, #10
94.
Lampertico P, Bazzaco S, Iavarone M, Del Ninno E, Colombo M. A prospective study of
alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a predictor of hepatocellular
carcinoma (HCC). 35th Annual Meeting of EASL. J Hepatol 2000;32 (suppl 2): 87, #12
95.
Lampertico P, Iavarone M, Lunghi G, Orlandi A, De Filippi F, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Monitoring serum HBV-DNA during lamivudine therapy by
quantitative PCR assay may predict development of YMDD mutants. 35th Annual Meeting of
EASL. J Hepatol 2000; 32 (suppl 2): 104, #32
96.
Lampertico P, Iavarone M, Bazzaco S, Del Ninno E, Colombo M. A prospective study of
alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a predictor of hepatocellular
carcinoma. 10th International Symposium on Viral Hepatitis and Liver Disease. Antiviral
Therapy 2000; 5 (Suppl. 1): 76
97.
Lampertico P, Iavarone M, Lunghi G, Orlandi A, De Filippi F, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Monitoring serum HBV-DNA during lamivudine therapy by
quantitative PCR assay may predict development of YMDD mutants. 10th International
Symposium on Viral Hepatitis and Liver Disease. Antiviral Therapy 2000; 5 (Suppl. 1):B65
98.
Iavarone M, Lampertico P, Romeo R, Del Ninno E, Colombo M. Long-term lamivudine
therapy improves Child-Pugh score in patients with hepatitis B-related cirrhosis. Annual
Meeting on Molecular Biology of hepatitis B viruses. Abstract Book 2000
99.
Lampertico P, Iavarone M, Lunghi G, Orlandi A, De Filippi F, Rumi MG, Colucci G, Del
Ninno E, Colombo M. Monitoring serum HBV-DNA during lamivudine therapy by
quantitative PCR assay may predict development of YMDD mutants. Annual Meeting of
AGA. Gastroenterology 2000;118(4):6621
100. Lampertico P, Iavarone M, Romeo R, Del Ninno E, Colombo M. Long-term lamivudine
therapy improves Child-Pugh score in patients with hepatitis B-related cirrhosis. 51th Annual
Meeting of AASLD. Hepatology 2000; 32(4):458A, #1195
101. Lampertico P, Vigano M, Romeo R, Iavarone M, Del Ninno E, Colombo M. Incidence of
YMDD mutants, hepatocellular carcinoma and hepatic decompensation in patients with
HBV-related cirrhosis treated long-term with lamivudine monotherapy. Annual Meeting of
AISF. DLD 2001;33(S1):104
29
102. Romeo R, Lampertico P, Zadra G, Colombo M. Lamivudine treatment of chronic hepatitis
B: evaluation of drug-resistance by the InnoLipa HBV DR. 36th Annual Meeting of EASL. J
Hepatol 2001;34(S1):125
103. Lampertico P, Vigano M, Romeo R, Iavarone M, Del Ninno E, Colombo M. Incidence of
YMDD mutants, hepatocellular carcinoma and hepatic decompensation in patients with
HBV-related cirrhosis treated long-term with lamivudine monotherapy. 36th Annual Meeting
of EASL. J Hepatol 2001;34(S1):149
104. Lampertico P, Vigano M, Iavarone M, Del Ninno E, Colombo M. Long-term outcome of
patients with HBeAg-negative chronic hepatitis B treated witha a 24-month course of
interferon alfa. 36th Annual Meeting of EASL. J Hepatol 2001;34(S1):149
105. Lunghi G, Lampertico P, Orlandi A, Vigano M, Mascheroni E, Galli C, Colombo M,
Pagano A. Comparison of different methods for the quantitative determination of HBV-DNA
in chronic hepatitis B. VII International Conference on Current Trends in Chronic Evolving
Viral Hepatitis. Abstract book 2001; pag 39
106. Sangiovanni A, Fasani P, Ronchi G, Lampertico P, De Fazio C, Del Ninno E, Colombo M.
The long-term course of hepatitis C – related cirrhosis. 7th Italian Meeting of Digestive
Disease. DLD 2001; 33(S1):A111
107. Lampertico P, Vigano M, Lunghi G, Orlandi A, Romeo R, Iavarone M, Colucci G, Del
Ninno E, Colombo M. Viral kinetics in HBeAg positive and negative patients with HBVRelated cirrhosis treated long-term with lamivudine. 7th Italian Meeting of Digestive
Disease. DLD 2001; 33(S1):A56
108. Lampertico P, Vigano' M, Iavarone M, Del Ninno E, Colombo M. Long-term outcome of
patients with HBeAg-negative chronic hepatitis B heated with a 24-month course of
interferon alfa. Annual Meeting of AGA. Gastroenterology 2001;120(5): 2905
109. Lampertico P, Vigano' M, Romeo R, Del Ninno E, Colombo M. Incidence of YMDD
mutants, hepatocellular carcinoma and hepatic decompensation in patients with HBV-related
cirrhosis treated long-term with lamivudine monotherapy. Annual Meeting of AGA.
Gastroenterology 2001;120(5):2909
110. Lampertico P, Vigano M, Lunghi G, Orlandi A, Romeo R, Iavarone M, Colucci G, Del
Ninno E, Colombo M. Viral kinetics in HBeAg positive and negative patients with HBVRelated cirrhosis treated long-term with lamivudine. 52th Meeting of AASLD. Hepatology
2001;34:1836
111. Romeo R, Lampertico P, Del Ninno E, Colombo M. High prevalence of YMDD mutants in
responders to long-term lamivudine treatment. 52th Meeting of AASLD. Hepatology
2001;34:1841
112. Sangiovanni A, Fasani A, Ronchi G, Donato MF, De Fazio C, Del Ninno E, Lampertico P,
Colombo M. The impact of surveillance of hepatocellular carcinoma. Detection and survival
of 417 patients with compensated cirrhosis: a 12-year prospective cohort study. Annual
Meeting of the Italian Association for the Study of Liver. DLD 2002;34:155
30
113. Sangiovanni A, Fasani A, Ronchi G, Donato MF, De Fazio C, Del Ninno E, Lampertico P,
de Franchis R, Colombo M. The impact of surveillance of hepatocellular carcinoma.
Detection and survival of 417 patients with compensated cirrhosis: a 12-year prospective
cohort study. 37th Annual Meeting of EASL. J Hepatol 2002;36(S1):20
114. Lampertico P, Vigano M, Romeo R, Iavarone M, Del Ninno E, Colombo M. Long-term
outcome of hepatitis B in lamivudine-resistant cirrhotic patients. 37th Annual Meeting of
EASL. J Hepatol 2002;36(S1):115
115. Lampertico P, Vigano M, Seletti C, Andreone P, Marzano A, Di Marco V, Iavarone M,
Lunghi G, Del Ninno E, Colombo M. Genotypic analysis of ymdd locus in hbv patients,
long-term responders to lamivudine monotherapy. 53th Meeting of AASLD. Hepatology
2002; 36(4):1885
116. Di Marco V, Lampertico P, Marzano A, Andreone P, Santantonio T, Almasio P, Rizzetto M,
Craxì A and the A.I.S.F. Lamivudine Study Group. Long-term lamivudine in patients with
anti-HBe/HBV-DNA positive liver disease. 53th Meeting of AASLD. Hepatology 2002;
36(4):835
117. Iavarone M, Lampertico P, Seletti C, Ronchi G, Romeo R, Colombo M. Low expression of
estrogen receptor beta RNA in hepatocellular carcinoma. 53th Meeting of AASLD.
Hepatology 2002;36(4):2127
118. Donato MF, Agnelli F, Rumi MG, Lampertico P, Arosio E, Monti V, Del Ninno E,
Colombo M. Outcome of antiviral treatment in patients with serological markers of both
HBV and HCV coinfection. 53th Meeting of AASLD. Hepatology 2002;36(4):1753
119. Iavarone M, Lampertico P, Seletti C, Ronchi G, E Del Ninno, Colombo M. The clinical and
pathogenetic significance of estrogen expression in chronic liver diseases and liver cancer.
XIV Simposio: Il fegato al femminile: fattori ormonali, genetici, metabolici e immunologici
nel danno epatico. Abstract book, gennaio 2003.
120. Di Marco V, Marzano A, Lampertico P, Androne P, Santantonio T, Almasio P, Rizzetto M,
Craxì A and the AISF Lamivudine Study Group. 36th Annual Meeting of AISF. DLD 2003;
35 (Supp 1); A4, #7
121. Lampertico P, Viganò M, Seletti C, Iavarone M, Del Ninno E, Lama N, Colombo M.
Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post-liver
transplantation. 36th AISF Annual Meeting. DLD 2003; 35 (Supp 1); A9, #27
122. Iavarone M, Lampertico P, Seletti C, Ronchi G, E Del Ninno, Colombo M. Liver expression
of estrogen receptors alpha and beta correlates with aetiology and presentation og
hepatocellular carcinoma.. 36th AISF Annual Meeting. DLD 2003; 35 (Supp 1); A19, #19
123. Lampertico P, Seletti C, Vigano M, Marzano A, Andreone P, Santantonio T, Di Marco V,
Iavarone M, Lunghi G, Del Ninno E, Colombo M. Genotypic analysis of YMDD locus of
HBV patients responding to lamivudine monotherapy. 38th Annual Meeting of EASL. J
Hepatol 2003:38(Suppl 2):620
31
124. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio P, Rizzetto M,
Craxi A The course of anti-Hbe/HBV-DNA positive chronic liver disease during long-term
lamivudine treatment. 38th Annual Meeting of EASL. J Hepatol 2003:38(Suppl 2):68
125. Lampertico P, Vigano M, Seletti C, Iavarone M, Del Ninno E, Lama N, Colombo M.
Genotypic analysis of YMDD locus of HBV patients responding to lamivudine monotherapy.
Annual Meeting of AGA. Gastroenterology 2003:124(4):A709-A710
126. Agnelli F, Donato MF, Arosio E, Monti V, Sangiovanni A, Lampertico P, Rumi MG,
Lunghi G, Del Ninno E, Colombo M. A five-year cohort study of patients with dual infection
with HBV and HCV. 54th Annual Meeting of AASLD. Hepatology 2003;38(4):1072, Suppl 1
127. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault C, Lampertico P, Tillmann H, Didier
S, Lama N, James C, Currie G, Brosgart CL. Adefovir dipivoxil 10 mg (ADV) for the
treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-resistant
patients. 54th Annual Meeting of AASLD. Hepatology 2003:38(4):11, Suppl 1
128. Viganò M, Lampertico P, Iavarone M, Lunghi G, Colucci G, Del Ninno E, Colombo M.
Rescue treatament with adefovir dipivoxil in lamivudine-resistant patients with chronic
hepatitis B. 10th Italian Congress of Digestive Disease. Digestive and Liver Disease 2004;
36(suppl 2):S139
129. Iavarone M, Lampertico P, Arosio E, Donato MF, Sangiovanni A, Del Ninno E, Colombo
M. Increased espressione of vascular endothelial growth factor and its receptor in
hepatocellular carcinoma and extra-tumoural cirrhotic tissues. 10th Italian Congress of
Digestive Disease. Digestive and Liver Disease 2004; 36(suppl 2):S133
130. Lampertico P, Viganò M, Iavarone M, Lunghi G, Romeo R, Colucci G, Morabito A, Del
Ninno E, Colombo M. The long-term outcome of HBeAg-negative patietns with cirrhosis
treated with lamivudine monotherapy: a 5 year prospective cohort study. 10th Italian Congress
of Digestive Disease. Digestive and Liver Disease 2004; 36(suppl 2):S161
131. Lampertico P, Viganò M, Iavarone M, Lunghi G, Romeo R, Colucci G, Morabito A, Del
Ninno E, Colombo M. The long-term outcome of HBeAg-negative patietns with cirrhosis
treated with lamivudine monotherapy: a 5 year prospective cohort study. 39th Annual Meeting
of EASL. J Hepatol 2004; 40(suppl 2):16
132. Viganò M, Lampertico P, Iavarone M, Lunghi G, Colucci G, Del Ninno E, Colombo M.
Rescue treatament with adefovir dipivoxil in lamivudine-resistant patients with chronic
hepatitis B. 39th Annual Meeting of EASL. J Hepatol 2004; 40(suppl 2):132
133. Iavarone M, Lampertico P, Arosio E, Donato MF, Sangiovanni A, Del Ninno E, Colombo
M. Increased espressione of vascular endothelial growth factor and its receptor in
hepatocellular carcinoma and extra-tumoural cirrhotic tissues. 39th Annual Meeting of EASL.
J Hepatol 2004; 40(suppl 2):79
134. Donato MF, Arosio E, Lampertico P, Treré D, Viganò M, Iavarone M, Derenzini M,
Colombo M. Low liver cell priliferation and high apoptosis rates in patients with HBeAgnegative chronic hepatitis B responding to interferon. 55th Annual Meeting of the American
Association for the Study of Liver Diseases Boston October 29 – November 2nd, 2004.
Hepatology 2004;40(S1):267A, Abs 233
32
135. Iavarone M, Lampertico P, Arosio E, Donato MF, Manenti E, Bertolini F, Sangiovanni A,
Colombo M. Tissue expression of vascular endothelial growth factors in the development of
hepatocellular carcinoma. 55th Annual Meeting of the American Association for the Study of
Liver Diseases Boston October 29 – November 2nd, 2004. Hepatology 2004;40S1:310A, Abs
339
136. Marzano A, Lampertico P, Gaia S, Viganò M, Romito R, Regalia E, Mazzaferro V,
Cololmbo M, Franchello A, Salizzoni M, Rizzetto M. Liver transplantation in lamivudineresistant YMDD-mutant carriers: role of adefovir-dipivoxil in prevention of hepatitis B virus
recurrence. 55th Annual Meeting of the American Association for the Study of Liver
Diseases Boston October 29 – November 2nd, 2004. Hepatology 2004;40S1:363A, Abs 458.
137. Lampertico P, Viganò M, Iavarone ; Manenti E, Romeo R, Lunghi G, Colucci G, Morabito
A, Del Ninno E, Colombo M. The long-term outcome of HBeAg-negative patients with
cirrhosis treated with Lamivudine monotherapy: A 5-year prospective cohort study. 55th
Annual Meeting of the American Association for the Study of Liver Diseases Boston October
29 – November 2nd, 2004. Hepatology 2004;40S1:674A, Abs 1171
138. Vigano` M, Aghemo A, Iavarone MA, Lampertico P, Rumi MG, Sangiovanni A, Del Ninno
E, Colombo M. Increased survival of patients with HCV-related cirrhosis with a long-term
response to interferon therapy. Proceedings of the AASLD Meeting San Francisco 11-15
November 2005 Hepatology 2005;42 S1: 432A (Abs 598)
139. Oliveti F, Puoti M, Santantonio T, Lampertico P, Colloredo G, Niro G, Fattovich G,
Morisco F, Marrone A, Costa P, Felder M, Cacciatore P, Smedile A, Brunetto MR. Impact of
IFN on progression of liver disease in hepatitis B “e” antigen (HBeAg) negative chronic
hepatitis B (CHB) patients: a long term italian multicenter AISF. study. Proceedings of the
AASLD Meeting San Francisco 11-15 November 2005 Hepatology 2005;42 S1: 577A (Abs
971)
140. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Five years of
sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAgnegative cirrhotics, preventing decompensation but not hepatocellular carcinoma.
Proceedings of the AASLD Meeting San Francisco 11-15 November 2005 Hepatology
2005;42 S1: 582A (Abs 983)
141. Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, Di Marco
V, Fagiuoli S, gazzella G, Raimondo G. A multicenter italian study of rescue adefovir
dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients.
Proceedings of the AASLD Meeting San Francisco 11-15 November 2005 Hepatology
2005;42 S1: 591A (Abs 1003)
142. Marzano A. Lampertico P, Mazzaferro V, Saia S, Viganò M, Romito R, Pulvirenti A,
Franchello A, Colombo M, Salizzoni M, Rizzetto M. Prophylaxis of hepatitis B virus
recurrence after liver transplantation. Proceedings of the EASL Meeting Paris 13-17 April
2005. J Hepatol 2005;42:55 (Abs 132).
143. Dunn C, Brunetto M, Flichman D, Lampertico P, Meier U, Borrow P, Gilson RJ, Bertoletti
A, Maini MK. Immunomodulatory effects of the large fluctuations in IFN-alpha and IL-8
33
accompanying hepatic flares in anti-HBe chronic HBV patients. Proceedings of the EASL
Meeting Paris 13-17 April 200. J Hepatol 2005;42:146 (Abs 397)
144. Lampertico P, Viganò M, Manenti E, Lunghi G, Iavarone M, Del Ninno E, Colombo M.
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in
lamivudine resistano patients with HBeAg-negative chronic hepatitis B. Proceedings of the
EASL Meeting Paris 13-17 April 2005. J Hepatol 2005;42:182 (Abs 504)
145. Oliveri F, Puoti M, Santantonio T, Lampertico P, Colloredo G, Niro G, Fattovich G,
Morisco F, Marrone A, Costa P, Felder M, Cacciatore P, Smedile A, Brunetto MR. IFN
impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long
term Italian Multicenter AISF study. Proceedings of the EASL Meeting Paris 13-17 April
2005. J Hepatol 2005;42:188 (Abs 520)
146. Lampertico P, Viganò M, Manenti E, Lunghi G, Iavarone M, Del Ninno E, Colombo M.
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in
lamivudine resistant patients with HBeAg-negative chronic hepatitis B. Proceedings of the
AGA Meeting Chicago 14-19 May 2005. Gastroenterology 2005;128:A741 (Abs M928)
147. Lampertico P, Viganò M, Manenti E, Lunghi G, Iavarone M, Colucci G, Colombo M.
Versant 3.0 and Cobas Taqman for monitorino serum HBV-DNA in HBeAg-negative
patients under lamivudine-adefovir combinant therapy. Proceedings of the AGA Meeting
Chicago 14-19 May 2005. Gastroenterology 2005;128:A741 (Abs M929)
148. Marzano A. Lampertico P, Mazzaferro V, Saia S, Viganò M, Romito R, Pulvirenti A,
Franchello A, Colombo M, Salizzoni M, Rizzetto M. Propjylaxis of hepatitis B virus
recurrence after liver transplantation in carriers of lavidudine-resistant mutants. Proceedings
of the AISF Meeting Roma 16-18 February 2005. Dig Liver Dis 2005;37:A36
149. Oliveri F, Puoti M, Santantonio T, Lampertico P, Colloredo G, Niro G, Fattovich G,
Morisco F, Marrone A, Costa P, Felder M, Cacciatore P, Smedile A, Brunetto MR. IFN
impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long
term Italian Multicenter AISF study. Proceedings of the AISF Meeting Roma 16-18 February
2005. Dig Liver Dis 2005;37:A40.
150. Lampertico P, Viganò M, Manenti E, Lunghi G, Iavarone M, Colucci G, Colombo M.
Versant 3.0 and Cobas Taqman for monitorino serum HBV-DNA in HBeAg-negative
patients under lamivudine-adefovir combinant therapy. Proceedings of the AISF Meeting
Roma 16-18 February 2005. Dig Liver Dis 2005;37:A49
151. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Five years of
sequential Lam to Lam+Adv therapy soppresse HBV replication in Most HBeAg negative
cirrhotics, preventing decompensation but not hepatocellular carcinoma. 41st Annual
Meeting of EASL April 26-30 2006 Vienna. J Hepatol 2006;44 S2:S38 Abs 85
152. Viganò M, Vener C, Soligo D, Lanfranchi F, Lambertenghi Deliliers G, Colombo M,
Lampertico P. High rates of hepatitis B virus riverse seroconversion in anti-HBc carriers
undergoing allogeneic bone marrow transplantation. 41st Annual Meeting of EASL April 2630 2006 Vienna. J Hepatol 2006;44 S2:S177 Abs 477
34
153. Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, Di Marco
V, Fagiuoli S, Mazzella G, Raimondo G. A multicenter Italian Study of rescue adefovir
dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 650 patients. 41st
Annual Meeting of EASL April 26-30 2006 Vienna. J Hepatol 2006;44 S2:S51 Abs 116
154. Lampertico P, Viganò M, Manenti E, Del Ninno E, Colombo M. No evidence for ADV
resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir
combination for 3 years. 41st Annual Meeting of EASL April 26-30 2006 Vienna. J Hepatol
2006;44 S2:S186 Abs 499.
155. Monti V, Aghemo A, Rumi MG, Donato MF, Arosio E, D’Ambrosio R, Lampertico P,
Soffredini R, Colombo M. The international autoimmune hepatitis group scoring system in
patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin
therapy: a prospective validation study. 37th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD) October 27-31 2006 Boston. Hepatology
2006;44(S1):330A (abs 373)
156. Lampertico P, Viganò M, Iavarone M, Manenti E, Lunghi G, Del Ninno E, Colombo M.
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with
adefovir-lamivudine combination therapy for 3 years. 37th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) October 27-31 2006 Boston.
Hepatology 2006;44(S1):556A (abs 989)
157. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunetto M, Andreone
P, Sagnelli E, Fagiuoli S, Mazzella G, Raimondo G, Gaeta G, Ascione A. Adefovir and
lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant
patients with HBeAg-negative chronic hepatitis B. 37th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) October 27-31 2006 Boston.
Hepatology 2006;44(S1):693A (abs LB5)
158. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Del Ninno E, Colombo M. 3
years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic
resistance to ADV in Lam resistant patients. Proceeding of the EASL Meeting Barcelona
April 11-15 2007. J Hepatol 2007;46 S1: S27 Abs 57
159. Iavarone M, Lampertico P, Viganò M, Del Ninno E, de Franchis R, Colombo M. Six years
of on demand Lam ± Adv combination therapy significantly reduces the development and
progression of esophageal varices in patients with HBeAg-negative cirrhosis. Proceeding of
the EASL Meeting Barcelona April 11-15 2007. J Hepatol 2007;46 S1: S189 Abs 496
160. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunetto M, Andreone
P, Sagnelli E, Fagiuoli S, Mazzella G. Adefovir and lamivudine combination therapy is
superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative
chronic hepatitis B. Proceeding of the EASL Meeting Barcelona April 11-15 2007. J Hepatol
2007;46 S1: S191 Abs 502
161. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunetto M, Andreone
P, Sagnelli E, Fagiuoli S, Mazzella G. Adefovir and lamivudine combination therapy is
superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative
chronic hepatitis B. Proceeding of the AISF Meeting Rome February 21-23 2007. Dig Liver
Dis 2007;39 (3): A7
35
162. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Del Ninno E, Colombo M. 3
years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic
resistance to ADV in Lam resistant patients. Proceeding of the AISF Meeting Rome February
21-23 2007. Dig Liver Dis 2007;39 (3): A18
163. Iavarone M, Lampertico P, Viganò M, Del Ninno E, de Franchis R, Colombo M. Six years
of on demand Lam ± Adv combination therapy significantly reduces the development and
progression of esophageal varices in patients with HBeAg-negative cirrhosis. Proceeding of
the AISF Meeting Rome February 21-23 2007. Dig Liver Dis 2007;39 (3): A20
164. Viganò M, Lampertico P, Iavarone M, Sangiovanni A, Del Ninno E, Colombo M. Natural
history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment
with nucleos(t)ide analogues. Proceeding of the AISF Meeting Rome February 21-23 2007.
Dig Liver Dis 2007;39 (3): A21
165. Iavarone M, Lampertico P, Viganò M, Primignani M, de Franchis R, Colombo M. Six-years
of “on demand” lam±adv combination therapy significantly reduces the development and
progression of esophageal varices in patients with HBeAg negative cirrhosis. 58th Annual
Meeting of the AASLD Boston, 2-6 November 2007. Hepatology 2007;46 (4) S1:581a Abs
775
166. Fraquelli M, Rigamonti C, Casazza G, Donato MF, Conte D, Rumi MG, Lampertico P,
Ronchi G, Colombo M. Low body mass index (BMI) predicts discordance between transient
elastography (TE) and liver biopsy (LB) assessment of liver fibrosis. 58th Annual Meeting of
the AASLD Boston, 2-6 November 2007. Hepatology 2007;46 (4) S1:650a Abs 929
167. Benhamou Y, Di Bisceglie AM, Goodman ZD, Lampertico P, Manss MP, Vig P, Qiao XJ,
Galil K. In-treatment virologic suppression at week 24 decreases the risk of histologic
progression at 1 year; data from the globe trial. 58th Annual Meeting of the AASLD Boston,
2-6 November 2007. Hepatology 2007;46 (4) S1:681a Abs 995
168. Donato MF, Arosio E, Agnelli F, Rigamonti C, Viganò M, Caccamo L, Lampertico P, Rossi
G, Colombo M. Graft dysfunction (GD) in HBV recurrence free recipience is associated with
serum autoantibodies reactivity. Proceedings of the 43rd Annual Meeting of the European
Association for the Study of the Liver Milan 23-27 April 2008. J Hepatol 2008;48 S2:S80
Abs 190.
169. Fraquelli M, Rigamonti C, Conte D, Casazza G, Donato MF, Rumi MG, Lampertico P,
Ronchi G, Colomnbo M. Independent predictors of discordance between transient
elastography (TE) and liver biopsy (LB). Proceedings of the 43rd Annual Meeting of the
European Association for the Study of the Liver Milan 23-27 April 2008. J Hepatol 2008;48
S2:S113 Abs 283
170. Lampertico P, Viganò M, Bhoori S, Agnelli F, Donato MF, Bongini M, Iavarone M.
Cotsoglou C, Russo A, Caccamo L, Rossi G, Colombo M. Low risk of hepatocellular
carcinoma recurrence after liver transplantation: a 3-year follow-up study in 78 patients with
chronic hepatitis B. Proceedings of the 43rd Annual Meeting of the European Association for
the Study of the Liver Milan 23-27 April 2008. J Hepatol 2008;48 S2:S151 Abs 389
36
171. Lampertico P, Viganò M. Manenti E, Iavarone M, Colombo M. Add on Adefovir prevents
the emergence of ADV resistance in Lamivudine-resistant patients: a 4-year study.
Proceedings of the 43rd Annual Meeting of the European Association for the Study of the
Liver Milan 23-27 April 2008. J Hepatol 2008;48 S2:S259 Abs 696
172. Aghemo A, Viganò M, Iavarone M, Rumi MG, Agnelli F, Lampertico P, Donato MF,
Colombo M. Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and
concurrent inactive hepatitis B infection treated with interferon and ribavirin. Proceedings of
the 43rd Annual Meeting of the European Association for the Study of the Liver Milan 23-27
April 2008. J Hepatol 2008;48 S2:S287 Abs 768
173. M. Fraquelli, C. Rigamonti, G. Casazza, M.F. Donato, D. Conte, S. Massironi, M.G. Rumi,
P. Lampertico, G. Ronchi, M. Colombo. INDEPENDENT PREDICTORS OF
DISCORDANCE BETWEEN TRANSIENT ELASTOGRAPHY (TE) AND LIVER
BIOPSY. Abstracts XIV National Congress of Digestive Diseases - Italian Federation of
Digestive Diseases – FIMAD Rimini, Italy 08-12 March 2008. Dig Liver Dis 2008;40 S1:S67
174. M. Viganò, M. Iavarone, M. Colombo, P. Lampertico. VERY EARLY ADD-ON
ADEFOVIR THERAPY IN PATIENTS WITH SUB-OPTIMAL VIROLOGICAL
RESPONSE TO LAMIVUDINE. Abstracts XIV National Congress of Digestive Diseases Italian Federation of Digestive Diseases – FIMAD Rimini, Italy 08-12 March 2008. Dig
Liver Dis 2008;40 S1:S112
175. M. Iavarone, A. Aghemo, M. Viganò, M.G. Rumi, F. Agnelli, P. Lampertico, M.F. Donato,
M. Colombo. LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH
CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION
TREATED WITH INTERFERON AND RIBAVIRIN. Abstracts XIV National Congress of
Digestive Diseases - Italian Federation of Digestive Diseases – FIMAD Rimini, Italy 08-12
March 2008. Dig Liver Dis 2008;40 S1:S112.
176. P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, M. Colombo. Maintained HBV
suppression in lamivudine-resistant patients treated with adefovir and lamivudine
combination: A 4- year cohort study in 63 patients. AISF Annual Meeting Roma 20-22
February 2008. Dig Liver Dis 2008;40(5):A26-27
177. Massimo Iavarone, Angelo Sangiovanni, Guido Ronchi, Laura Virginia Forzenigo, Alessio
Aghemo, Pietro Lampertico, Massimo Colombo. PROSPECTIVE STUDY OF
DYSPLASTIC NODES IN CIRRHOTIC PATIENTS: CORRELATION WITH CT
VASCULAR PATTERN. Hepatology 2008; 48:4 (suppl), 363A
178. Pietro Lampertico, Mauro Viganò, Sherrie Bhoori, et al. EXCELLENT 5-YEAR
OVERALL SURVIVAL IN PATIENTS WITH HBV-RELATED CIRRHOSIS
UNDERGOING
LIVER
TRANSPLANTATION
FOR
HEPATOCELLULAR
CARCINOMA. Hepatology 2008;48:4 (suppl), 584A
179. Roberta D’Ambrosio, Alessio Aghemo, Mariagrazia Rumi, Massimo Primignani, Alessandra
Dell’Era, Roberto deFranchis, Stella De Nicola, Pietro Lampertico, Massimo Colombo. THE
NATURAL HISTORY OF PORTAL HYPERTENSION IN PATIENTS WITH HCV
RELATED COMPENSATED CIRRHOSIS UNDERGOING INTERFERON RIBAVIRIN
THERAPY. Hepatology 2008;48:4 (suppl), 623A
37
180. Pietro Lampertico, Mauro Viganò, Floriana Facchetti, et al. EFFECTIVENESS OF
ENTECAVIR FOR THE TREATMENT OF NUC-NAïVE CHRONIC HEPATITIS B
PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE.
Hepatology 2008;48:4 (suppl), 707A
181. Mauro Viganò, Pietro Lampertico, Massimo Iavarone, et al. HIGH RISK OF RENAL
IMPAIRMENT AND ARTERIAL HYPERTENSION DURING LONG-TERM ADEFOVIR
AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINERESISTANT CHRONIC HEPATITIS B. Hepatology 2008;48:4 (suppl), 708A
182. Massimo Iavarone, Pietro Lampertico, Mauro Viganò, et al. PROGRESSIVE DECLINE
OF HBSAG TITERS IN LONGTERM VIROLOGICAL RESPONDERS TO
NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B. Hepatology
2008;48:4 (suppl), 709A
183. Pietro Lampertico, Mauro Viganò, Floriana Facchetti, et al. FOUR YEARS OF
ADEFOVIR ADD-ON IN 145 LAMIVUDINE RESISTANT PATIENTS WITH CHRONIC
HEPATITIS B: LOW RISK OF GENOTYPIC RESISTANCE TO ADV AND
PREVENTION OF VIROLOGIC BREAKTHROUGH. Hepatology 2008;48:4 (suppl), 712A
184. M. Iavarone, A. Sangiovanni, G. Ronchi, L.V. Forzenigo, A. Aghemo, P. Lampertico, M.
Colombo. PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS:
CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Dig Liver Dis 2009;41
(Supplement 1), Page S15
185. P. Lampertico, M. Viganò, F. Facchetti, E. Minola, et al. EFFECTIVENESS OF
ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B
PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE.
Dig Liver Dis 2009; 41 (Supplement 1), Page S50
186. M. Viganò, S. Massironi, P. Lampertico, M. Fraquelli, et al. CHANGES IN LIVER
STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC
HEPATITIS B. Dig Liver Dis 2009; 41 (Supplement 1), Page S50
187. M. Viganò, P. Lampertico, M. Iavarone, G.E. Tontini, et al. HIGH RISK OF RENAL
IMPAIRMENT
DURING
LONG-TERM
ADEFOVIR
AND
LAMIVUDINE
COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT
CHRONIC HEPATITIS. Dig Liver Dis 2009; 41 (Supplement 1), Page S7
188. M. Viganò, P. Lampertico, M. Iavarone, G.E. Tontini, et al. High risk of renal impairment
during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B. Dig Liver Dis 2009; 41:3, Pages A5-A6
189. P. Lampertico, M. Viganò, F. Facchetti, E. Minola, et al. Effectiveness of entecavir for the
treatment of NUC-naïve chronic hepatitis B patients: A large multicenter cohort study in
clinical practice. Dig Liver Dis 2009;41:3,Pages A6-A7
38
190. M. Viganò, S. Massironi, P. Lampertico, M. Fraquelli, et al. Transient elastography predicts
response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B.
Dig Liver Dis 2009; 41:3, Pages A29-A30
191. P. Lampertico, M. Viganó, F. Facchetti, F. Suter, et al. ENTECAVIR IS AN EFFECTIVE
TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL
PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY. J
Hepatol 2009; Vol. 50 (Supplement 1), Page S333
192. M. Viganó, P. Lampertico, M. Iavarone, G.E. Tontini, et al. HIGH RISK OF RENAL
IMPAIRMENT
DURING
LONG-TERM
ADEFOVIR
AND
LAMIVUDINE
COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT
CHRONIC HEPATITIS B. J Hepatol 2009; Vol. 50 (Supplement 1), Pages S338-S339
193. M. Iavarone, A. Sangiovanni, G. Ronchi, L.V. Forzenigo, A. Aghemo, P. Lampertico, M.
Colombo. PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS:
CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. J Hepatol 2009; Vol. 50
(Supplement 1), Pages S290-S291
194. M. Iavarone, P. Lampertico, M. Vigano, F. Facchetti, et al. PROGRESSIVE DECLINE OF
HBsAg TITERS IN LONG- TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE
ANALOGUE THERAPY FOR CHRONIC HEPATITIS. J Hepatol 2009; Vol. 50
(Supplement 1), Page S331
195. M. Viganò, S. Massironi, P. Lampertico, M. Fraquelli, et al. CHANGES IN LIVER
STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC
HEPATITIS B. J Hepatol 2009; Vol. 50 (Supplement 1), Page S145
196. M. Fraquelli, C. Rigamonti, G. Casazza, M.F. Donato, D. Conte, G. Ronchi, S. Massironi, M.
Rumi, P. Lampertico, M. Colombo. INDEPENDENT INFLUENCERS OF TRANSIENT
ELASTOGRAPHY ASSESSMENT OF LIVER FIBROSIS IN HEPATITIS B AND
HEPATITIS C PATIENTS. J Hepatol 2009; Vol. 50 (Supplement 1), Page S78
197. Pietro Lampertico, Mauro Viganò, Floriana Facchetti, et al. ENTECAVIR FOR NUCNAïVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM
EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376
PATIENTS. Hepatology 2009;Vol 50; 4 (suppl), 408A
198. Joerg Petersen, Marc Lutgehetmann, Fabien Zoulim, Martina Sterneck, Harry L. Janssen,
Thomas Berg, Peter Buggisch, Pietro Lampertico, Vlad Ratziu, Maria Buti, Christoph
Sarrazin. ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC
HEPATITIS B: RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND
MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN
INTERNATIONAL MULTICENTER COHORT STUDY. Hepatology 2009;Vol 50; 4
(suppl), 496A
199. Mauro Viganò, Barbara Olivero, Pietro Lampertico, et al. LAMIVUDINE PROPHYLAXIS
OF HEPATITIS B REACTIVATION IN ANTI-HBC SEROPOSITIVE PATIENTS
UNDERGOING CHEMOTHERAPY FOR ONCO-HEMATOLOGICAL DISEASES.
Hepatology 2009;Vol 50; 4 (suppl), 511A
39
200. Massimo Levrero, Letizia Cimino, Pietro Lampertico, et al. TENOFOVIR DF (TDF) FOR
CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADEFOVIR
(ADV) OR ADV/LAM TREATMENT: INTERIM ANALYSIS OF THE MULTICENTER
PROSPECTIVE OPEN LABEL STUDY OPTIB. Hepatology 2009;Vol 50; 4 (suppl), 537A
201. M. Viganò, F. Facchetti, P. Dongiovanni, L. Valenti, R. Soffredini, S. Fargion, M. Colombo,
P. Lampertico. DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL
TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONGTERM ADEFOVIR AND LAMIVUDINE COMBINATION. Dig Liver Dis 2010; 42
(Supplement 1), Page S8
202. D. Laccabue, C. Boni, A. Zerbini, D. Tola, A. Penna, T. Giuberti, V. Precone, G.B. Gaeta, M.
Viganò, P. Lampertico, G. Missale, C. Ferrari. THE HBV-SPECIFIC T CELL FUNCTION
CAN BE RECONSTITUTED IN CHRONIC HBV INFECTION: IMPLICATIONS FOR
IMMUNE THERAPIES. Dig Liver Dis 2010; 42 (Supplement 1), Page S21
203. P. Lampertico, M. Viganò, F. Facchetti, E. Minola, et al. EFFECTIVENESS OF
ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B
PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY
IN 311 PATIENTS. Dig Liver Dis 2010; 42 (Supplement 1), Page S39
204. P. Lampertico, M. Viganò, F. Facchetti, F. Suter, et al. ENTECAVIR FOR NUC-NAÏVE
CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM
EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376
PATIENTS. Dig Liver Dis 2010;42 (Supplement 2), Page S76
205. J. Petersen, M. Lütgehetmann, F. Zoulim, H. Janssen, M. Sterneck, A. Brown, T. Berg, P.
Buggisch, P. Lampertico, M. Buti, H. Wedemeyer, V. Ratziu, C. Sarrazin. SAFETY AND
EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN
HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN
INTERNATIONAL MULTICENTER COHORT STUDY. J Hepatol 2010; Vol. 52
(Supplement 1), Pages S394-S395
206. M. Levrero, L. Cimino, P. Lampertico, M. Vigano', et al. OPTIB – A MULTICENTER
PROSPECTIVE OPEN LABEL STUDY ON TENOFOVIR (TDF) FOR CHRONIC
HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADV OR ADV/LAM
TREATMENT. J Hepatol 2010; Vol. 52 (Supplement 1), Page S390
207. M. Viganò, P. Lampertico, P. Dongiovanni, F. Facchetti, et al. DRUG TRANSPORTER
GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS
WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE
COMBINATION. J Hepatol 2010; Vol. 52 (Supplement 1), Page S7
208. P. Lampertico, M. Viganò, F. Facchetti, E. Minola, et al. EFFECTIVENESS OF
ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B
PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY
IN 311 PATIENTS. J Hepatol 2010; Vol. 52 (Supplement 1), Pages S389-S390
209. P. Lampertico, M. Vigano, G. Di Costanzo, E. Sagnelli, et al. EXTENDED (2 YEARS)
TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED
40
RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE
CHRONIC HEPATITIS B. J Hepatol 2010; Vol. 52 (Supplement 1), Page S45
210. Pietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, et al. SAFETY AND
TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON
ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC
HEPATITIS B. Hepatology 2010;Vol 52:4 (suppl), 387A
211. Massimo Levrero, Letizia Cimino, Pietro Lampertico, et al. TENOFOVIR (TDF) FOR
CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADEFOVIR
(ADV) OR ADV/LAM TREATMENT: RESULTS OF THE OPTIB ITALIAN
MULTICENTER PROSPECTIVE OPEN LABEL STUDY. Hepatology 2010;Vol 52:4
(suppl), 389A
212. Pietro Lampertico, Mauro Viganò, Cristina Cheroni, et al. GENETIC VARIATION IN
IL28B POLYMORPHISM MAY PREDICT HBSAG CLEARANCE IN GENOTYPE D,
HBEAG NEGATIVE PATIENTS TREATED WITH INTERFERON ALFA. Hepatology
2010;Vol 52:4 (suppl), 442A
213. Pietro Lampertico, Mauro Viganò, Cihan Yurdaydin, et al. EFFECTIVENESS AND
SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A
MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC
HEPATITIS B. Hepatology 2010;Vol 52:4 (suppl), 503A
214. Pietro Lampertico, Mauro Viganò, Roberta Soffredini, et al. MAINTAINED LONG-TERM
SUPPRESSION OF HBV REPLICATION IN NUC-NAïVE PATIENTS WITH CHRONIC
HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE
ITALIAN MULTICENTER EXPERIENCE. Hepatology 2010;Vol 52:4 (suppl), 514A
215. Mauro Viganò, Pietro Lampertico, Cristina Eller-Vainicher, et al. HIGH PREVALENCE
OF REDUCED BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC
HEPATITIS B UNDER NUCLEOS(T)IDES ANALOGUES TREATMENT. Hepatology
2010;Vol 52:4 (suppl), 526A
216. Vincent Rijckborst, Bettina E. Hansen, Peter Ferenci, Maurizia R. Brunetto, Fehmi Tabak,
Yilmaz Cakaloglu, Alfonso G. Lanza, Vincenzo Messina, Claudio Iannacone, Benedetta
Massetto, Eduardo B. Martins, Massimo Colombo, Harry L. Janssen, Pietro Lampertico.
EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAGNEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF
PEGINTERFERON ALFA-2A THERAPY. Hepatology 2010;Vol 52:4 (suppl), 557A
217. P. Lampertico, M. Viganò, C. Cheroni, F. Facchetti, et al. Genetic variation in IL28B
polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated
with interferon alfa. Dig Liver Dis 2011; 43 (Supplement 2), Page S65
218. M. Viganò, P. Lampertico, C. Eller-Vainicher, R. Soffredini, et al. High prevalence of
reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides
analogues treatment. Dig Liver Disease 2011; 43 (Supplement 2), Page S102
219. P. Lampertico, M. Viganò, R. Soffredini, F. Facchetti, et al. Maintained long-term
suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with
41
ETV monotherapy in field practice: The Italian multicenter experience. Dig Liver Dis 2011;
43(Supplement 2), Pages S102-S103
220. E. Vezali, P. Lampertico, F. Invernizzi, M. Iavarone, et al. Nucleos(t)ide analogues can be
safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance. Dig Liver
Dis 2011; 43 (Supplement 2), Page S103
221. P. Lampertico, M. Viganò, C. Yurdaydin, R. Idilman, et al. Effectiveness and safety of
tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737
patients with chronic hepatitis B. Dig Liver Dis 2011; 43 (Supplement 2), Pages S103-S104
222. M. Levrero, L. Cimino, P. Lampertico, M. Vigano, et al. OptiB Italian multicenter
prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96
weeks results on efficacy and tolerance. Dig Liver Dis 2011;43 (Supplement 2), Pages S105S106
223. P. Lampertico, M. Viganò, F. Facchetti, V. Valveri, et al. GENETIC VARIATION IN
IL28B POLYMORPHISM MAY PREDICT HBSAG CLEARANCE IN GENOTYPE D,
HBEAG NEGATIVE PATIENTS TREATED WITH INTERFERON ALFA. Dig Liver Dis
2011;43 (Supplement 3), Page S139
224. P. Lampertico, M. Viganò, R. Soffredini, F. Facchetti, et al. MAINTAINED LONG-TERM
SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC
HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE
ITALIAN MULTICENTER EXPERIENCE. Dig Liver Dis 2011; 43 (Supplement 3), Pages
S137-S138
225. P. Lampertico, M. Viganò, C. Yurdaydin, R. Idilman, et al. EFFECTIVENESS AND
SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A
MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC
HEPATITIS B. Dig Liver Dis 2011; 43 (Supplement 3), Page S164.
226. J. Petersen, M. Lutgehetmann, M. Buti, H. Janssen, A. Brown, P. Lampertico, F. Zoulim, H.
Wedemeyer, M. Sterneck, T. Berg, C. Sarrazin, V. Ratziu, P. Buggisch. TREATMENT OF
MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2
YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL
MULTICENTER COHORT STUDY. J Hepatol 2011; Vol. 54 (Supplement 1), Page S299
227. M. Levrero, L. Cimino, P. Lampertico, M. Vigano, et al. EFFICACY AND TOLERANCE
OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM
TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER
PROSPECTIVE OPEN LABEL STUDY. J Hepatol 2011; Vol. 54 (Supplement 1), Page
S294
228. E. Vezali, P. Lampertico, F. Invernizzi, M. Iavarone, et al. NUCLEOS(T)IDE
ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B
PATIENTS ACHIEVING HBSAG SEROCLEARANCE. J Hepatol 2011; Vol. 54
(Supplement 1), Pages S302-S303
229. P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin,et al. EFFECTIVENESS AND
SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A
42
MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH
CHRONIC HEPATITIS B. J Hepatol 2011; Vol. 54 (Supplement 1), Pages S293-S294
230. P. Lampertico, M. Viganò, A. Galeota Lanza, E. Sagnelli, et al. PEGBELIVER STUDY:
HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEGIFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT
RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS. J Hepatol 2011; Vol. 54
(Supplement 1), Page S293
231. Mauro Viganò, Pietro Lampertico, Roberta Soffredini et al. THE COURSE OF BONE
MINERAL DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B LONG-TERM
TREATED WITH NUCLEOS(T)IDE ANALOGS: A LONGITUDINAL COHORT STUDY.
Hepatology 2011;54:4 (suppl),1016A
232. Pietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, et al. A RESPONSE
GUIDED APPROACH TO PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG
LEVELS AT WEEKS 12 AND 24 IMPROVES RESPONSE RATES IN HBEAGNEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS. Hepatology 2011;54:4
(suppl),1021A
233. Pietro Lampertico, Roberta Soffredini, Mauro Viganò, et al. 2-YEAR EFFECTIVENESS
AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC
HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE.
Hepatology 2011;54:4 (suppl),1041A
234. Pietro Lampertico, Mauro Viganò, Roberta Soffredini, et al. ENTECAVIR
MONOTHERAPY IN 418 NUC-NAïVE PATIENTS WITH CHRONIC HEPATITIS B
FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE
OVER 3 YEARS OF TREATMENT. Hepatology 2011;54:4 (suppl),1043A
235. Paul M. Trembling, Pietro Lampertico, Julie Parkes, et al. COMPARISON OF
ENHANCED LIVER FIBROSIS TEST AND TRANSIENT ELASTOGRAPHY FOR THE
NONINVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B.
Hepatology 2011;54:4 (suppl),1223A
236. M. Viganò, P. Lampertico, R. Soffredini, I. Chiodini, et al. The course of bone mineral
density in patients with chronic hepatitis B long term treated with nucleos(t)ide analogs: a
longitudinal cohort study. Dig Liver Dis 2012;44 (Supplement 1), Pages S15-S16
237. P. Lampertico, M. Viganò, R. Soffredini, F. Facchetti, et al. Entecavir monotherapy in 418
NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable
safety profile over 3 years of treatment. Dig Liver Dis 2012; 44 (Supplement 1), Page S16
238. P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin, et al. 2-year effectiveness and
safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter
European study in clinical practice. Dig Liver Dis 2012; 44 (Supplement 1), Pages S16-S17
239. P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin, et al. 2-YEAR EFFECTIVENESS
AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC
HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE. Dig
Liver Dis 2012; 44 (Supplement 2), Page S70
43
240. M. Viganò, P. Lampertico, R. Soffredini, I. Chiodini, et al. THE COURSE OF BONE
MINERAL DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B LONG TERM
TREATED WITH NUCLEOS(T)IDE ANALOGS: A LONGITUDINAL COHORT STUDY.
Dig Liver Dis 2012; 44 (Supplement 2), Page S106
241. P. Lampertico, M. Viganò, R. Soffredini, F. Facchetti, et al. ENTECAVIR
MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B
FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE
OVER 3 YEARS OF TREATMENT. Dig Liver Dis 2012; 44 (Supplement 2), Pages S184S185
242. M. Viganò, P. Lampertico, R. Soffredini, F. Invernizzi, et al. DECLINE OF BONE
MINERAL DENSITY DURING LONG-TERM NUCLEOS(T)IDE ANALOG THERAPY:
A LONGITUDINAL COHORT STUDY OF 135 PATIENTS WITH CHRONIC
HEPATITIS B. J Hepatol 2012; Vol. 56 (Supplement 2), Page S216
243. P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin, et al. TENOFOVIR
MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A
MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS
FOLLOWED FOR 30 MONTHS. J Hepatol 2012; Vol. 56 (Supplement 2), Page S208
244. P. Lampertico, M. Viganò, G.G. Di Costanzo, E. Sagnelli, et al. RESPONSE-GUIDED
PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12
AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE,
GENOTYPE D PATIENTS. J Hepatol 2012; Vol. 56 (Supplement 2), Pages S207-S208
245. P. Lampertico, F. Invernizzi, R. Soffredini, F. Facchetti, et al. ADD-ON PEG-IFN
IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY
NUCLEOS(T)IDE ANALOGS. J Hepatol 2012; Vol. 56 (Supplement 2), Page S207
246. P. Lampertico, F. Invernizzi, R. Soffredini, F. Facchetti, et al. MAINTAINED VIRAL
SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR
MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A
4-YEAR FIELD PRACTICE, MULTICENTER STUDY. J Hepatol 2012; Vol. 56
(Supplement 2), Pages S206-S207
247. Pietro Lampertico, Roberta Soffredini, Mauro Viganò, Eliseo Minola, et al. Entecavir
treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral
suppression and safety profile over 5 years of treatment. Hepatology 2012; vol 56, 4 (suppl),
page 370A
248. F. Invernizzi, P. Lampertico, A. Loglio, M. Iavarone, et al. Nucleos(t)ide analogues can be
safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance.
Hepatology 2012; Vol 56, 4 (suppl), page 368A
249. Patrizia Burra, Giacomo Germani, Renè Adam, Vincent Karam, Alfredo Marzano, Pietro
Lampertico, et al. Liver transplantation for HBV-related cirrhosis in Europe: a ELTR study
on 25.000 patients. Hepatology 2012; Vol 56, 4 (suppl), page 524A
44
250. Pietro Lampertico, Roberta Soffredini, Mauro Viganò, Cihan Yurdaydin, et al. Tenofovir
monotherapy suppressed viral suppression in most field practice, treatment-naïve patients
with chronic hepatitis B followed for 3 years in a multicenter European study. Hepatology
2012; Vol 56, 4 (suppl), page 389A
251. Mauro Viganò, Pietro Lampertico, Roberta Soffredini, Federica Invernizzi, et al.
SWITCHING TO TENOFOVIR IS SAFE IN MOST CHRONIC HEPATITIS B PATIENTS
WITH A REDUCED GLOMERULAR FILTRATION RATE DUE TO PREVIOUS
EXPOSURE TO ADEFOVIR DIPIVOXIL. Hepatology 2012; Vol 56, 4 (suppl), pages
391A-392A
252. P. Lampertico, R. Soffredini, M. Viganò, E. Minola, et al. 5-year entecavir in NUC-naïve,
field-practice patients with CHB showed excellent viral suppression and safety but no
prevention of HCC. Dig and Liv Dis 2013;45 (Suppl 1):S16
253. P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin, et al. Tenofovir suppressed viral
suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in
a multicenter European study. Digestive and Liver Disease 2013; 45 (Suppl 1):S16-S17
254. G. Mangia, P. Lampertico, F. Invernizzi, F. Facchetti, et al. Serum HBsAg decline is faster
than previously estimated in long-term NUC responders with low treatment-induced HBsAg
levels. Digestive and Liver Disease 2013;45 (Suppl 1):S36
255. M. Viganò, P. Lampertico, R. Soffredini, F. Invernizzi, et al. Switching to tenofovir is safe
in most CHB patients with a reduced glomerular filtration rate due to previous exposure to
adefovir dipivoxil. Digestive and Liver Disease 2013;45 (Suppl 1): S35
256. M. Viganò, P. Lampertico, G. Mangia, R. Soffredini, et al. Incidence and clinical
consequences of reduced tubular phosphate re-absorption in naïve CHB patients treated with
tenofovir: a two-year field study. Digestive and Liver Disease 2013; 45 (Suppl 1): S10-S11
257. F. Invernizzi, P. Lampertico, G. Mangia, R. Soffredini, et al. Add-on Peg-IFN improves
HBsAg kinetics in HBeAg-negative patients long-term fully suppressed by nucleos(t)ide
analogs. Digestive and Liver Disease 2013;45 (Suppl 1):S19
258. M. Vigano', L. Valenti, P. Lampertico, B.M. Motta, R. D'Ambrosio, F. Facchetti, P.
Dongiovanni, S. Fargion, et al. PNPLA3 I148M AFFECTS LIVER STEATOSIS IN
PATIENTS WITH CHRONIC HEPATITIS B. J Hepatol 2013;58:S164
259. G. Mangia, P. Lampertico, F. Invernizzi, F. Facchetti, R. Soffredini, G. Lunghi, M.
Colombo. SERUM HBsAg DECLINE IS FASTER THAN PREVIOUSLY ESTIMATED IN
LONG-TERM NUC RESPONDERS WITH LOW TREATMENT-INDUCED HBsAg
LEVELS. J Hepatol 2013;58:S307
260. H.L. Chan, M. Buti, P. Marcellin, L. Lin, B. Massetto, J. Flaherty, M. Subramanian, J.
McHutchison, G. Foster, S. Fung, A. Thompson, P. Lampertico. COMPARISON OF
SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF)
TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS. J
Hepatol 2013:58:S309–S310
45
261. M. Viganò, P. Lampertico, G. Mangia, R. Soffredini, F. Facchetti, F. Invernizzi, M.
Colombo. INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR
PHOSPHATE RE-ABSORPTION (TmPO4/GFR) IN NAÏVE CHRONIC HEPATITIS B
PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY. J Hepatol
2013;58:S316–S317
262. J. Petersen, S. Unger, M. Buti, M. Lutgehetmann, P. Lampertico, C. Sarrazin, P.
BuggischFROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT
EXPERIENCED CHB PATIENTS WITH VIRAL RESISTANCE OR PARTIAL
RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT
STUDY. J Hepatol 2013;58:S313
263. P. Lampertico, R. Soffredini, M. Viganò, E. Minola, G. Cologni, M. Rizzi, S. Zaltron, A.
Vavassori, and others5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELDPRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL
SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN
CIRRHOTICS J Hepatol 2013;58:S306–S307
264. Pietro Lampertico, Giampaolo Mangia, Mauro Viganò, Marta Borghi, Roberta Soffredini,
Floriana Facchetti, Federica Invernizzi, Massimo Colombo. Tenofovir monotherapy is
effective for Adefovir experienced patients but requires careful monitoring of glomerular and
tubular function and proactive dose reductions: a 4-year study in 320 patients.
HEPATOLOGY 2013;58,NUMBER 4 (SUPPL):649A
265. Pietro Lampertico, Roberta Soffredini, Cihan Yurdaydin, Ramazan Idilman, George V.
Papatheodoridis, et al. Four years of tenofovir monotherapy for NUC naïve field practice
European patients suppresses HBV replication in most patients with a favorable renal safety
profile but does not prevent HCC in patients with or without cirrhosis. HEPATOLOGY
2013;58,NUMBER 4 (SUPPL):653°
266. Joerg Petersen, Stefan Unger, Maria Buti, Marc Lutgehetmann, Pietro Lampertico,
Christoph Sarrazin, Peter Buggisch. From add-on dual therapy back to mono-therapy in
treatment experienced CHB patients with viral resistance or partial responses: results from an
international multicenter cohort study. HEPATOLOGY 2013;58,NUMBER 4 (SUPPL):659A
267. Mauro Viganò, Pietro Lampertico, Giampaolo Mangia, Roberta Soffredini, Floriana
Facchetti, Federica Invernizzi, Massimo Colombo. Incidence and clinical consequences of
reduced tubular phosphate reabsorption in naïve chronic hepatitis B patients either untreated
or treated with tenofovir for 2 years in a field practice study. HEPATOLOGY 2013:58,
NUMBER 4 (SUPPL):678A
268. Giampaolo Mangia, Pietro Lampertico, Mauro Viganò, Floriana Facchetti, Federica
Invernizzi, Roberta Soffredini, Massimo Colombo. ETV monotherapy improves renal
function in lamivudine resistant patients developing renal side effects during long-term TDF
exposure. HEPATOLOGY 2013;58,NUMBER 4 (SUPPL): 687A
269. P. Lampertico, G. Mangia, M. Viganò, M. Borghi, et al. High rates of tenofovir dose
adjustments are required in Adefovir experienced patients with chronic hepatitis B: A 4-year
prospective study in 320 patients. Digestive and Liver Disease 2014;46 (Suppl 1);e49
46
270. P. Lampertico, R. Soffredini, C. Yurdaydin, R. Idilman, et al. Four years of tenofovir
monotherapy for NUC naïve field practice European patients suppresses HBV replication in
most patients with a favorable renal safety profile but does not prevent HCC in patients with
or without cirrhosis. Digestive and Liver Disease 2014;46 (Suppl 1):e14
271. F. Invernizzi, P. Lampertico, G. Mangia, M. Iavarone, et al. Portal hypertension but not
HCC risk is attenuated in compensated cirrhotics following 10 years of treatment with
nucleos(t)ide analogs. Digestive and Liver Disease 2014;46 (Suppl 1):e50
272. G. Mangia, P. Lampertico, F. Invernizzi, F. Facchetti, et al. Chronic hepatitis B patients
developing tubular dysfunction during long-term tenofovir treatment can be successfully and
safely rescued by entecavir. Digestive and Liver Disease 2014;46 (Suppl 1):e24
273. M. Viganò, V. Varisco, P. Lampertico, A. Batticciotto, et al. Low risk of hepatitis B virus
reactivation in HBsAg negative, anti-HBc positive carriers undergoing rituximab for
rheumatoid arthritis. Digestive and Liver Disease 2014;46 (Suppl 1):e23
274. F. Invernizzi, P. Lampertico, G. Mangia, M. Iavarone, M. Viganò, M. Primignani, R. De
Franchis, M. Colombo. PORTAL HYPERTENSION BUT NOT HCC RISK IS
ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF
TREATMENT WITH NUCLEOS(T)IDE ANALOGS. J Hepatol 2014;60:S429–S430
275. J. Petersen, S. Unger, M. Buti, K. Wursthorn, M. Lutgehtemann, P. Lampertico, C. Sarrazin,
P. Buggisch. ADD-ON THERAPY WITH ENTECAVIR PLUS TENOFOVIR DUE TO
VIRAL RESISTANCE OR PARTIAL RESPONSES FOLLOWED BY MONOTHERAPY
IN CHB-PATIENTS: FINAL RESULTS FROM AN INTERNATIONAL MULTICENTRE
STUDY. J Hepatol 2014;60:S440
276. C. Boni, P. Lampertico, L. Talamona, T. Giuberti, F. Invernizzi, S. Schivazappa, A. Alfieri,
A. Cavalli, et al. INNATE ANTIVIRAL RESPONSES IN HBeAg NEGATIVE PATIENTS
WITH CHRONIC HEPATITIS B (CH-B) UNDER LONG-TERM NUCLEOS(T)IDE
ANALOGUE (NUC) TREATMENT: IMPLICATIONS FOR FUTURE IMMUNE
THERAPIES. J Hepatol 2014;60:S128
277. M. Viganò, V. Varisco, P. Lampertico, A. Batticciotto, A. Mascheroni, P. Gibertini, R.
Pellerito, G. Rovera, et al. LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN
HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB
FOR RHEUMATOID ARTHRITIS. J Hepatol 2014;60:S287–S288
278. G.V. Papatheodoridis, G. Dalekos, V. Sypsa, C. Yurdaydin, M. Buti, J. Goulis, P. Arends, S.
Manolakopoulos, G. Mangia, N. Gatselis, O. Keskın, S. Savvidou, B.E. Hansen, C.
Papaioannou, K. Galanis, R. Idılman, M. Colombo, R. Esteban, H.L.A. Janssen, P.
Lampertico. PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC)
DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS
RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF). J Hepatol 2014;60:S435
279. W.R. Kim, T. Berg, T. Asselah, R. Flisiak, S. Fung, S. Gordon, H.L.A. Janssen, P.
Lampertico, et al. APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN
TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS. J Hepatol
2014;60:S288–S289
47
LETTURE A CONGRESSI NAZIONALI ED INTERNAZIONALI
1.
Milano, 31 March–3 April 1992. II International Symposium on Therapy of Liver Diseases
"A multicenter, randomized, controlled study of the treatment with interferon of the acute
post–transfusion non–A, non–B hepatitis”
2.
San Francisco, 9–15 May 1992. 93rd Annual Meeting of the American Gastroenterological
Association (AGA), "A multicenter, randomized, controlled study of the treatment with
interferon of the acute post–transfusion non–A, non–B hepatitis."
3.
Roma, 18–19 June 1992. Spring Annual Meeting of the Italian Association for the Study of
the Liver (AISF). " A multicenter, randomized, controlled study of the treatment with
interferon of the acute post–transfusion non–A, non–B hepatitis ".
4.
Venezia, 6–9 July 1992. 1st Annual Meeting on Molecular Virology and Pathogenesis of
Hepatitis C virus and Related Viruses. "A multicenter, randomized, controlled study of the
treatment with interferon of the acute post–transfusion non–A, non–B hepatitis."
5.
Boston, 14–21 May 1993. 94th Annual Meeting of the American Gastroenterological
Association (AGA). "Changes of HBV pre–core gene in HBeAg positive patients treated with
interferon".
6.
Napoli, 28–29 May 1993. National Meeting on Interferon Therapy of Chronic Hepatitis.
"Treatment of acute post-transfusion hepatitis C”.
7.
Parma, 3–5 June 1993. International Meeting on Biology, Immunopathology and Clinic of
Hepatitis Viruses. "HBV pre–core mutations in HBeAg positive patients treated with
interferon".
8.
Roma, 15-16 June 1995. Spring Annual Meeting of the Italian Association for The Study of
the Liver (AISF). "Long-term treatment with recombinant interferon (IFN) alpha 2b of antiHBe positive chronic hepatitis B: a randomized controlled trial."
9.
Brisbane, 3 September 1995. 5th International Symposium on Hepatitis C Virus and Related
Viruses. "The natural history of hepatitis C virus in renal allograft recipients: a 5-year
prospective study".
10.
Milano, 2-4 October 1995. III International Symposium on Therapy of Liver Diseases.
"Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBe positive
chronic hepatitis B: a randomized controlled trial."
11.
Napoli, 23-28 November 1996. Annual Meeting of Digestive Disease. "High prevalence, low
pathogenecity of hepatitis G virus (HGV) in kidney transplant recipients"
12.
Bologna, 16-18 January 1997. I International Symposium. New perspectives in the treatment
of chronic viral hepatitis. "Long-term treatment with interferon of HBeAg-negative chronic
hepatitis B”
48
13.
Chicago, 4-10 November 1998. International Association for the Study of Liver (IASL)American Association for the Study of Liver Disease (AASLD). “The natural history of HCV
infection in kidney transplant recipients: a 8 year prospective cohort study of 443 patients”.
14.
Bari, 10-13 November 1998. Annual Meeting of Digestive Disease. “The natural history of
HCV infection in kidney transplant recipients: a 8 year prospective cohort study of 443
patients”.
15.
Milano, 14-16 November 1998. Annual Meeting of Internal Medicine. “The natural history of
HCV infection in kidney transplant recipients: a 8 year prospective cohort study of 443
patients”.
16.
Verona, 14-15 June 1999. Worshop: The prevention of viral hepatitis: from theory to
practice: “Hepatocellular carcinoma: epidemiology, diagnosis and treatment”.
17.
Atlanta, 9-13 April 2000. 10th International Symposium on Viral Hepatitis and Liver Disease.
“A prospective study of alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a
predictor of hepatocellular carcinoma”.
18.
Padova, 13 October 2000. International Symposium on Breaking the Resistance. Clinical
implications of geno-phenotyping in HIV and HBV/HCV infections. “Retreatment with
antivirals of patients with HBV-related chronic hepatitis resitant to interferon therapy”.
19.
Perugia, 18-22 November 2000. Annual Meeting of Digestive Diseases. “Long-term therapy
with lamivudine improves the Child-Pugh score in patients with decompensated HBV-related
cirrhosis”.
20.
Pisa, 11-12 December 2000. Annual Meeting of the Italian Association for The Study of the
Liver (AISF). The HBV carrier: virological, diagnostic and clinical aspects. “Treatment of
HBeAg-negative chronic hepatitis B”
21.
Sondrio, 31 March 2001. Workshop: from the virus to hepatocellular carcinoma. “Treatment
of chronic hepatitis B”.
22.
Milano, 13 June 2001, Workshop: Guidelines on treatment of viral hepatitis. “Advances in
the treatment of patients with chronic hepatitis B”
23.
Ferrara, 11 September 2001, International meeting: What’s there again in gastroenterology?.
“Cirrhosis by HBV”
24.
Milano, 6 December 2001, Workshop on Management of patients with hepatitis B.
“Treatment of chronic hepatitis B”
25.
Padova, Abano Terme, 1 March 2002. International workshop: New standards and strategies
for viral hepatitis B and C. “Antiviral resistance and future prospectives”
26.
Bari, Castellana Grotte, 7 June 2002, Workshop: Chronic viral hepatitis: the general
practitioner and the specialist. “Treatment of the HBeAg-negative chronic hepatitis B with
interferon”
49
27.
Sorrento, 5-7 December 2002. Workshop: Pathognesis, diagnosis, and therapy of viral
hepatitis”. “Interferon treatment of HBV-related chronic hepatitis”.
28.
Roma, 14 February 2003. Annual Meeting of the Italian Association for the Study of Liver
Disease (AISF), “Rescue treatment with adefovir dipivoxil for lamivudine resistant patients
pre- and post-liver transplantation”
29.
Milano, 9 May 2003. Workshop on Prevention and treatment of viral hepatitis in liver
transplantation. “Prevention of hepatitis B reinfection after liver transplantation”
30.
Orlando, 19 May 2003. Annual Meeting of the American Gastroenterological Association.
“Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post-liver
transplantation”
31.
Palermo, 20-21 Giugno 2003. G.R.E.C.A.S. Meeting. HBV: beyond the EALS Consensus
Conference: “Treatment of Chronic Hepatitis B: the past”
32.
Bologna 24-27 September 2003. 2nd SIMIT Annual Meeting. “Adefovir dipivoxil and new
antiretrovirals in the treatment of chronic hepatitis B”
33.
Milano, 1 Ottobre 2003. Hepatocellular Carcinoma: prevention and new therapeutic stategies.
“HBV infection”
34.
Venezia, 2-3 Ottobre 2003. AISF Meeting. Hepatitis C: Heterogeneity and disease cofactors.
“Hepatitis C virus and renal transplantation”
35.
Catania, 24 Ottobre 2003. Workshop on Molecular Biology. SIMTI meeting. “The burden of
Hepatitis B in Italy: morbidity, mortality and costs”
36.
Milano, 12-13 Novembre 2003. Update in Hepatology. Advancements in the treatment of
chronic viral hepatitis. “Chronic Hepatitis B and HCC”
37.
Bari, 14 November 2003. Update in Transfusion Medicine. HBV and residual risk of
transmission. “Molecular Epidemiology of HBV”
38.
Venezia, 20-22 Novembre 2003. HIV and Hepatitis B: from research to clinical management.
“HBV infection: a case report”
39.
Roma, 3 Dicembre 2003. Progetto Hep B free. “The AISF multicenter study on treatment of
chronic hepatitis B with lamivudine: preliminary results”.
40.
Milano, 5 dicembre 2003. Upadte in Liver Transplantation “HBV infection: recurrence of the
disease and new therapeutic strategies”
41.
Torino, 12-13 Dicembre 2003. Update on chronic Hepatitis B. “Therapy of HBV-related
cirrhosis”
42.
Roma, 16 Dicembre 2003. G.I.S.F Meeting. “Treatment of chronic hepatitis B”
43.
Monza, 30-31 January 2004. Workshop: “Virus and Liver”. “Treatment of HBV-related
chronic hepatitis”
50
44.
Roma 12-13 February 2004. Upadate on Chronic Hepatitis B. “Treatment of HBeAg-positive
chronic hepatitis B: standard of care and new strategies”
45.
Bari, 13-14 Febuary 2004. Update on chronic hepatitis B. “Treatment of HBeAg-positive
chronic hepatitis B”
46.
Roma, 18-20 February 2004. AISF Annual Meeting. “The long-term outcome of HBeAgnegative patients with cirrhosis treated with lamivudine monotherapy: a 5-yr psospective
cohort study”
47.
Milano, 12-13 March 2004. Update on Chronic Hepatitis B. “Treatment of chronic hepatitis
B”
48.
Pisa, 19 March 2004. Update on Chronic Hepatitis B. “Hepatocellular carcinoma in HBV
carriers”
49.
Genova, 26 March 2004. Update on Chronic Hepatitis B. “Treatment of HBV-Related
cirrhosis”
50.
Torino, 27-31 March 2004. 10th SIGE Annual Meeting. ”The long-term outcome of HBeAgnegative patients with cirrhosis treated with lamivudine monotherapy: a 5-yr psospective
cohort study”
51.
Brescia, 2 April 2004. Update on Chronic Hepatitis B. “Treatment of HBV-related cirrhosis”
52.
Berlin, 15 April 2004. 39th EASL Annual Meeting. Early morning workshop: “Hepatitis B”
53.
Berlin, 16 April 2004. 39th EASL Annual Meeting. “The long-term outcome of HBeAgnegative patients with cirrhosis treated with lamivudine monotherapy: a 5-yr prospective
cohort study”
54.
Berlin,16 April 2004. HBV Therapy Symposium: from today’s Principles to tomorrow’s
Practice. “Individualizing Therapy: The way forward ?”
55.
Palermo, 13 November 2004. Seminario in epatologia. “Epatite B: HBeAg(+) : risultati della
monoterapia con Peg IFN in comparazione con analoghi”.
56.
Milano, 19 Novembre 2004. Corso: Advances in the Treatment of Chronic Viral Hepatitis.
“Trattamento con IFN”
57.
Milano, 25 Novembre 2004. Corso di Formazione Diagnostica Molecolare e Pratica Clinica.
“L’infezione da HBV: scenari futuri”
58.
Torgiano, 30 Novembre 2004. 6° Corso di Evidence Based Gastroenterology & Hepatology.
“Epatite cronica da virus B: algoritmo diagnostico e terapeutico 2004”
59.
Brussels, 17 December 2004, IXTH WINTER MEETING, Belgian Association of the Study
of Liver. “Treatment of Hepatitis B virus”
51
60.
Lisbon, 10-12 December 2004, European Seminar on HBV Virology. “Clinical Management
of Immunocompromised patients”
61.
Napoli, 27 Gennaio 2005. Congresso IBAT’05. Le Infezioni Batteriche. Attualità
Terapeutiche. Le epatiti croniche virali: nuove acquisizioni, nuove prospettive terapeutiche.
“Terapia dell’epatite B: stato dell’arte”
62.
Zurich, 4 Febbruary 2005. Third Zurich Postgraduate Course in Hepatology “NucleosidAnalogues for chronic hepatitis B - What can we expect?”
63.
Praga, 11 Marzo 2005. Czech Hepsera Launch Symposium. “Hepatitis B: current treatment
options”
64.
Amsterdam, 10 Maggio 2005. Chronic hepatitis B infection: casuistry and consensus.
“Adefovir Dipivoxil, working mechanism and clinical research”
65.
Torino, 13 Maggio 2005. 1°AISF STC. Prophylaxis and therapy of hepatitis B in immunocompromised patients. “Storia Naturale ed Opzioni Terapeutiche”
66.
Milano, 18 Maggio 2005. Dalla cirrosi da Virus Epatitici al Trapianto. Terapia della cirrosi
da HBV “Presentazione dati letteratura Cirrosi da HBV”
67.
Milano, 21 Maggio 2005. Seminars in Viral Liver Diseases. “Individualized Management of
the Patient with Chronic Hepatitis B”
68.
Arona, 25 Maggio 2005. Tecnologie e soluzioni d’eccellenza per il moderno laboratorio di
Biologia molecolare. “CTM 48 HBV e Bdna HBV: il parere del clinico nella gestione del
dato di laboratorio”
69.
Instanbul, 6 June 2005. V National Turkish Hepatology Congress in Turkey. “Adefovir
Dipivoxil for the first line treatment”.
70.
Milano, 24 Giugno 2005. Corso “Nuovi sviluppi nella diagnosi e nel trattamento dell’epatite
virale B. “Terapia dell’epatite cronica B: paziente immunocompetente”
71.
Bergamo, 25 Giugno 2005. Novita’ terapeutiche nell’epatite cronica B e C: Aggiornamento
2005. “Terapia dell’ Epatite cronica B: update 2005”
72.
Verona, 9 Luglio 2005. FORUM UPGRADE IN HEPATITIS THERAPY. “Studi clinici a
confronto:qualità del dato e della raccomandazione d’uso. L’epate cronica da HBV”
73.
Pisa, 7 September 2005. The management of the patient with Hepatitis B Virus Infection and
Disease. “Therapy: Antivirals”
74.
Tel Aviv, 13 September 2005. National Congress of the Israeli Society of Liver Investigation.
“Interferon in the treatment of chronic hepatitis B”
75.
Napoli, 15 Settembre 2005. Dalla Scienza alla Pratica Clinica La terapia dell’epatite da virus
B. “Management of HBeAg pos and HBeAg negative CHB”
52
76.
Roma, 24 Settembre 2005. Advancements in the management of viral related liver diseases.
“Cirrhosis as a bridge between Hepatitis C and B”.
77.
Catania, 4-5 October 2005. Consensus Workshop on hepatitis B coinfection in HIV infected
patients: which role for combination therapies? “When to switch: How to manage
Lamivudine experienced patients?”
78.
Istanbul, 8 October 2005. EASL Monothematic Conference: From Viral Pathobiology to the
treatment of Hepatitis B Virus Infection. “Other nucleoside/nucleotide analogs” in the session
“Treatment Efficacy I, Round Table: HBeAg negative chronic hepatitis”
79.
Roma, 25 Ottobre 2005. GISF 2005 AGGIORNAMENTI IN EPATOLOGIA. “Linee guida
per il trattamento dell’epatite cronica HBV”
80.
Napoli, 26 Ottobre 2005. AISF Monothematic Conference: Terapia della Cirrosi Epatica:.
“Terapia della cirrosi da HBV: selezione del paziente da trattare”
81.
Napoli, 26 Ottobre 2005. Workshop: Strategie terapeutiche dell'Epatite Cronica B:
monoterapia o combinazione. “Terapia del paziente lamivudino resistente”
82.
Ancona, 19 Novembre 2005. Workshop “Dall’ epatite virale alle complicanze del posttrapianto di fegato”, “Terapia dell’ epatite cronica HBV-correlata”
83.
Padova, 21 Novembre 2005. 15° Convegno Internazionale. ATTUALITÀ E PROSPETTIVE
IN EPATOLOGIA. Il fegato, i virus e la terapia antivirale: nuove prospettive di trattamento.
“Insufficienza epatica in cirrosi HBV correlata”
84.
Milano, 26 Novembre 2005. Il Trattamento del Paziente con cirrosi epatica: dall’eziologia
alle complicanze. “Il Trattamento della Cirrosi HBV”
85.
Torgiano, 29 Novembre 2005. EVIDENCE BASED GASTROENTEROLOGY &
HEPATOLOGY. 7° Corso del laboratorio di epidemiologia. “Epatite Cronica da Virus B:
EASL Conference Istambul 2005”
86.
San Giovanni Rotondo, 1 dicembre 2005. 2nd AISF STC: TECNICHE DI BIOLOGIA
MOLECOLARE NELLE EPATITI VIRALI. “Determinazione della viremia e terapia
dell’HBV”
87.
Atene, 2-4 December 2005. 3rd European Clinical Review Forum on Chronic Hepatitis B
Treatment. “Tomorrow’s Treatment Guidelines: Looking into the Future and Anticipating
New Treatment Strategies”
88.
Roma, 7 Dicembre 2005. Progressi nella terapia dell’epatite B Focus sulla LamivudinaResistenza. “L’adefovir dipivoxil nella pratica clinica”
89.
Milan, 9-10 December 2005. EASL School of Hepatology, Course 5: Hepatitis C & B.
“Hepatitis B: Whom to treat and how”
90.
Bologna, 12 Dicembre 2005. Bookmarks in Epatologia 2005. “Terapia dell’epatite cronica B
HBeAg negativa”
53
91.
Atene, 28 January 2006. Two-Day Annual Meeting on Viral Hepatitis B and C. “Treatment
approach in HBeAg-negative patients”
92.
Rome, 4 February 2006. The HBV Seminar 2006. “Treatment of HBeAg negative chronic
hepatitis B”
93.
Milano, 11 febbraio 2006. Dalla scienza alla pratica clinica. Nuovi sviluppi nella gestione del
paziente con epatite cronica B. “Trattamento del paziente con epatite da HBV: indicatori di
efficacia”
94.
Roma, 16 Marzo 2006. Corso di Aggiornamento La Terapia delle Malattie Epatiche. “La
terapia antivirale per l’epatite B”
95.
Camogli, 24 Marzo 2006. Aggiornamenti in epatologia. Le epatiti virali e le epatiti
autoimmuni. “Epatite B: novita’ terapeutiche: trattamento con IFN peghilato”
96.
Roma, 28 Marzo 2006. Workshop: Topics on difficult to treat patients in hepatitis B&C. “La
terapia dell’epatite cronica B: NRTI o PEG-IFN”
97.
Milano, 31 March 2006. Therapeutic perspective of chronic hepatitis B and C in HIVcoinfected patients: from recent advances in immunopathogenesis to the patient. “Treatment
options in chronic hepatitis B”
98.
Napoli, 3 Aprile 2006. Il trattamento dell’epatite cronica B nell’era degli antivirali orali.
“Evoluzione delle strategie terapeutiche: ruolo della combinazione nella gestione della
farmaco – resistenza: paziente con cirrosi e lamivudina resistenza”
99.
Vienna, 28 Aprile 2006. 41st Annual Meeting of EASL. “Out with the old –
cutting-edge treatments for a versatile disease”
100. Vienna, 29 Aprile 2006. 41st Annual Meeting of EASL. “Five years of sequential LAM to
LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics,
preventing decompensation but not hepatocellular carcinoma”
101. Vienna, 30 Aprile 2006. 41st Annual Meeting of EASL. “A multicenter italian study of
rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 650
patients”
102. Verona, 9 Maggio 2006. IIª Edizione Convegno Nazionale Aggiornamenti in Epatologia.
“Storia naturale dell’epatite cronica da HBV”
103. Venezia, 11 Maggio 2006. Diagnostica Molecolare. “Determinazione dell’HBV DNA e
trattamento dell’epatite B”
104. Como, 20 Maggio 2006. Il virus dell’epatite B: dall’infezione occulta all’epatocarcinoma,
dalla profilassi alla terapia. “Terapia dell’epatite cronica B con IFNs”
105. Milano, 27 May 2006. Seminars in Viral Liver Diseases. Towards Individualized
Management of the Patients with Chronic Hepatitis. “Hepatitis B: whom to treat and how”
54
106. Castelsardo, 28 maggio 2006. Fegato e metabolismo. “Trattamento dell’epatite cronica da
HBV”
107. Rotterdam, 8 Giugno 2006. Erasmus Workshop on Hepatitis. “Prevention and treatment of
resistance in chronic HBV patients”
108. Genova, 28 Giugno 2006. Infezione da HBV Problematiche emergenti. “Come prevenire e
superare la resistenza farmacologia”
109. Barcelona, 7 September 2006. VIII Intenational Symposium on Viral Hepatitis. “Approach to
the therapy of HBeAg positive patients”
110. Cairo, 9 September 2006. Management challenges in chronic Hepatitis B. “Managing
resistance to oral antiviral drugs”
111. Bergamo, 13 settembre 2006. Corso di Aggiornamento E.C.M. Terapia delle Epatiti Virali
Croniche: attualità e prospettive. “terapia del paziente con Epatite B”
112. Sirmione, 19 Settembre 2006. Expert Meeting in HBV: nuove sfide per scenari
epidemiologici e clinici. “Individualizzazione del trattamento terapeutico: le popolazioni
speciali”
113. Interlaken, 22 September 2006. Annual Meeting of the Swiss Society of Gastroenterology.
“Hepatitis B: Management of viral resistance”
114. Torino, 30 Settembre 2006. Le epatiti virali: diversificare la gestione, migliorare i risultati.
“L’epatite cronica B: valutazione e gestione: Il problema della resistenza”
115. Torino, 7 Ottobre 2006. Corso Epatite B: profilassi e terapia nel paziente con epatite cronica
ed immunodepresso. “Pazienti immunocompetenti: Terapia del paziente naive”
116. Rome, 7 October 2006. HBV Resistance Forum 2006. “Management of Lamivudine resistant
patients: Switching or add-on therapy – which is more efficient?”
117. Milano, 9 Ottobre 2006. Corso di Aggiornamento ECM. Giornate multidisciplinari di
biologia molecolare. “HBV: Carica virale: applicazioni cliniche e tecnologie di laboratorio. Il
punto di vista del clinico”
118. Catania. 21 Ottobre 2006. Infezione cronica da HBV: problematiche emergenti. “Come
preventire e superare la resistenza farmacologia”
119. Boston, 30 October 2006. 57th Annual Meeting of the AASLD. “Adefovir and lamivudine
combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients
with HBeAg-negative chronic hepatitis B”
120. New York, 1 November 2006. Grand Rounds at Beth Israel Medical Center. “Managing of
viral resisatnce in Chronic Hepatitis B”
121. L’Aquila, 7 Novembre 2006. L’infezione da HBV e’ ancora un problema? “I ritrattamenti dei
pazienti con mutant”
55
122. Lisbon, 18 November 2006. New Frontiers, New Challenges for the Clinical Management of
HBV in Europe. “Use of combination therapy vs. monotherapy in patients with secondary
treatment failure”
123. Ferrara, 27 Novembre 2006. Simposio Internazionale. Le Neoformazioni Epatiche. Un
approccio multidisciplinare dalla diagnosi alla terapia. “Prevenzione dell’HCC HBV
correlato”
124. London, 30 November 2006. Advances in the treatment of chronic hepatitis B – 2006 end of
year review. “Advances in the understanding and treatment of disease resistance”
125. Bologna, 4 Dicembre 2006. Bookmarks in epatologia. “Trattamento dell’epatite cronica
HBeag negativa 2006”
126. Bologna, 11 Dicembre 2006. Corso di Aggiornamento Scelte Difficili in Epatologia
“Infezione da virus dell’epatite B: il paziente complesso”
127. Montreal, 11 January 2007. Canadian Chronic HBV Clinical Update Meeting. “Mangement
of patients with lamivudine resistance”
128. Hong Kong, 9 March 2007. Overcoming Challenges in Drug resistant Management.
“Management of CHB patients with viral resistance”
129. Sidney, 14 March 2007. Clinical Forum Update.“Drug resistance in chronic hepatitis B: from
management to prevention”
130. Auckland, 15 March 2007. Clinical Forum Update. “Drug resistance in chronic hepatitis B:
from management to prevention”
131. New York, 24 March 2007. Hepsera Antiviral Resistance Summit Agenda. “Future of HBV
therapy Add – on vs. de novo combination therapy.
132. Luso, 31 March 2007. The Annual Meeting of The Portuguese Association for the Study of
Liver APEF. “Combo therapies on CHB”
133. Barcelona, 11 April 2007. Second EASL-Virgil Joint Symposium: New Insights into
Antiviral Drug Resistance in Chronic Viral Hepatitis Treatment. “Management of lamivudine
resistance ; implications for novel antivirals”
134. Barcelona, 12 April 2007. Combination or Monotherapy for the Management of Chronic
Hepatitis B? “Combination or Monotherapy in Chronic Hepatitis B in Patients With Viral
Resistance?”
135. Barcelona, 13 april 2007. 42nd Annual Meeting of EASL. “3 years of adefovir and
lamivudine combination therapy minimizes the risk of genotypic resistance to ADV in LAM
resistant patients”
136. Montecatini, 20 April 2007. Montecatini Interactive Medicine International 2 - Clinical Cases
in Gastroenterology & Hepatology. “HBsAg positive on screening”
56
137. Padova, 27 April 2007. Corsi di Aggiornamento in Epatologia 2007. “HBV-DNA e mutanti
HBV nella gestione dell’epatite B”
138. Torino, 10 Maggio 2007. Prophylaxis and therapy of hepatitis B in immunocompromised
patients, update Turin 2007. “Prophylaxis and therapy of HBV in Nephrology”
139. Roma, 15 Maggio 2007. Problemi in epatologia: puntti di vistta a confronto - Il punto di vista
del medico e del laboratorista: la malattia HBV. “Algoritmi di trattamento dell’epatite cronica
da HBV”
140. Stresa, 22 Maggio 2007. Consensus Nazionale Epatite Cronica B. “Terapia dell’epatite
cronica HBeAg negativa”
141. Lyon, 23 May 2007. VIRGIL Annual International Symposium on Antiviral Drug
Resistance. “Management of HBV resistance to lamivudine, the Italian experience”
142. Piacenza, 25 Maggio 2007. Topics in gastroenterologia ed epatologia Alla ricerca
dell’evidenza scientifica in tematiche di grande impatto clinico. “Trattamento dell’epatite
cronica B 2007”
143. Istanbul, 8 June 2007. 6th National Hepatology Meeting of the Turkish Association for the
Study of the Liver (TASL). “The present and future of nucleoside and nucleotide analogs in
HBV management: A hope for cure or a supplice of Tantalos”
144. Milano, 11 Giugno 2007. HBV Seminar 2007. “Paziente LAM-Resistente: Quale strategia
adottare?”
145. Ancona, 13 Giugno 2007. Seminario “La gestione clinica del paziente con epatite cronica
HBV-correlata. “I percorsi terapeutici dell’epatite B cronica: come trattare”
146. Innsbruck, 15 June 2007. Hepatitis B Symposium: Nuove Prospettive nella terapia dell’epatie
B. “Management of viral esistance: switch vs add on”
147. Verona, 15 Giugno 2007. 3° Convegno Nazionale - Aggiornamenti in Epatologia e
Gastroenterologia. “Epatite cronica B: diagnosi e gestione delle resistenze alla terapia
antivirale”
148. New York, 19 June 2007. GI/Hepatology Rounds at Cornell University Hospital.
“Management of patients with lamivudine resistance”
149. Praha, 29 June 2007. Bridge to New Ways in HBV Care. ”Optimizing therapeutic outcomes
in secondary treatment failure-monotherapy of combination therapy?”
150. Shanghai, 23 September 2007. National Symposium on Hepsera Clinical Usage.
“Monotherapy or combination therapy in CHB patients: Resistance patients”
151. Lisbon, 29 September 2007. HepChallenge Meeting. “Combination therapy in HBV”
152. Palermo, 30 Settembre 2007. Il trattamento dell'epatite cronica B: Efficacia e durata di lungo
termine. “Ottimizzare la terapia oggi: chi, come e quando intervenire? Il trattamento dei
pazienti LAM-R”
57
153. Rimini, 2 Ottobre 2007. XXXVI Congresso Nazionale AMCLI. “La gestione del paziente
HBV-infetto con resistenza agli antivirali: dal trattamento alla prevenzione”
154. Roma, 5 Ottobre 2007. VIII Congresso Nazionale SIMSPe.“Terapia dell’epatite cronica B”
155. Bergamo, 12 Ottobre 2007. Epatite B: il trapianto epatico nell'era degli antivirali. “Gestione
pre-trapianto e profilassi in paziente multi-resistente”
156. Milano, 15 Ottobre 2007. Le Nuove Terapie in Medicina Interna. “Stato dell’arte e nuove
prospettive terapeutiche dell’epatite HBV”
157. Milano, 18 Ottobre 2007. Nuovi sviluppi nella gestione del paziente con epatite cronica B.
“La gestione della resistenza nella terapia soppressiva con NA”
158. Moltrasio, 27 Ottobre 2007. Aggiornamenti in Gastroenterologia. “Epatite cronica”
159. Riccione, 10 Novembre 2'007. La terapia delle infezioni da HIV e HCV. “Terapia dell’epatite
cronica B”
160. Pattaya, 22 November 2007. APASL Autumn Single Topic Conference 2007 - Innovation in
Chronic Hepatitis B Treatment. “Current optimal HBV Treatment in HBeAg-negative CHB”
161. Milano, 30 Novembre 2007. Infezione da HBV nel paziente monoinfetto e nel paziente
confetto HIV +. “Terapia dell’epatite cronica B”
162. Napoli, 1 Dicembre 2007. Malattie del fegato: percorsi diagnostici e terapeutici Dai trials
clinici alle “raccomandazioni”. “Terapia con antivirali: efficacia a breve e lungo termine”
163. Bologna, 3 Dicembre 2007. Boomarks in Epatologia. “trattamento dell’epatite cronica HBeag
negativa 2007”
164. Rottedam, 6 December 2007. 22nd Erasmus Liver Day. “Viral Hepatitis: Resistance in
hepatitis B treatment”
165. Roma, 13 December 2007. 2nd Annual Liver Meeting at Villa Mondragone - Burning issues
in clinical Hepatology: What should we expect in 2008? “Management of hepatitis B in
2008: Management of antiviral resistance in clinical practice”
166. Amalfi, 14 Dicembre 2007. X° Corso Avanzato Patogenesi, Diagnosi Terapia delle epatiti
virali e dell'infezione malattia da HIV. “Trattamento dell’epatite cronica HbeAg-positiva ed
HBeAg-negativa”
167. Modena, 26 Gennaio 2008. 4° Workshop - Hot Topics in Hepatology: L’epatite B. “La
terapia: il ruolo dell’HBsAg”
168. Cairo, 31 January 2008. 3rd APASL STC - Challenges and Solutions in the Management of
Chronic Hepatitis B. “Management of resistance and other challenging clinical settings in
chronic hepatitis B”
58
169. Paris, 14 February 2008. EASL Special Conference: Hepatitis B & C Virus Resistance to
Antiviral Therapies. “Definition of treatment endpoints, treatment failure and resistance”
170. Milan, 7 March 2008. International Meeting of Infections, Rheumatism and Autoimmunity.
“Update in HBV Treatment”
171. Rimini, 9 Marzo 2008. XVI Congresso Nazionale Congiunto Malattie Digestive – FIMAD “Efficacia e sicurezza di Entecavir nel paziente naive agli analoghi nucleos(t)idici.”
172. Rimini, 10 Marzo 2008. XVI Congresso Nazionale Congiunto Malattie Digestive – FIMAD –
“Terapia antivirale e prevenzione: il controllo a lungo termine della resistenza”
173. Padova, 3 Aprile 2008. Expert Meeting HBV - Quali strategie per i diversi stadi di malattia.
“Nodi clinici sulle problematiche di più comune riscontro nella pratica clinica corrente”
174. Brescia, 5 Aprile 2008. Top Seminar in HBV. “L’approccio terapeutico al paziente naive”
175. Atlanta, 8 April 2008. Hepatitis B Update. “Use of Hepsera: Special Populations”
176. Seattle, 10 April 2008. Clinical Update Forum. “Treatment of Hepatitis B: Update on the Use
of Hepsera
177. Milan, 24 April 2008. 43rd Annual Meeting of EASL. Satellite Symposium: shaping the
future together. “Switch or add? Determining the best approach for patients with treatment
failure”
178. Milan, 25 April 2008. 43rd Annual Meeting of EASL. EASL Clinical Symposium - HBV
Therapy: Mono or Combo? “The current results of nucleos(t)ide analogue: monotherapy,
add-on therapy and de novo combination therapy”
179. Milano, 6 Maggio 2008. Meet the Expert HBV. “Epatite B: Strategie Terapeutiche”
180. Milano, 15 Maggio 2008, Top Seminar in HBV. “L’approccio terapeutico al paziente mai
trattati”
181. Chicago, 27 May 2008. Hepatitis Clinical Update. “Treatment of Hepatitis B: Update on the
Use of Hepsera”
182. New York, 30 May 2008. Mount Sinai Medical School. Hepatitis Clinical Update. “The Use
of Hepsera: Special Population”
183. Verona, 3 Giugno 2008. Aggiornamenti in Epatologia. “La gestione del paziente HBV
positivo”
184. Milano, 4 Giugno 2008. Expert Meeting HBV: quali strategie per i diversi stadi di malattia.
“Scenari clinici e terapeutici per il paziente con epatite cronica B. Quali prospettive sono
disponibili per il paziente HBV+? Linee guida, dati da letteratura, clinical practice”
185. Salvador de Bahia, 11 July 2008. XI International Symposium on Viral Hepatitis. “Hepatitis
B. Can we already combine Nucleosíde/Nucleotíde Análogues for treating naive patients”
59
186. Shanghai, 25 July 2008. 6th Asia-Pacific Hepatitis B Academy. “CHB: the disease and its
treatment: Oral antiviral therapy: management of resistance”
187. Shanghai, 26 July 2008. 6th Asia-Pacific Hepatitis B Academy. “Advanced CHB and its
management: Management of HBV-related cirrhosis”
188. Hong Kong, 6 September 2008. 10th Join annual scientific Meeting. “Managment and
prevention of NUC resistance”
189. Taipei, 7 September 2008. Lamivudine 10th Anniversary Meeting. “Oral antiviral therapy:
Management of resistance”
190. Singapore, 8 September 2008. “Oral Antiviral Therapy: management of NUC resistance”
191. Kuala Lumpur, 9 September 2008. Malaysian Medical Association Meeting. “Chronic
Hepatitis B: theory meets practice“
192. Shanghai, 11 September 2008: Symposium on long-term antiviral treatment for CHB. “Long
term Adefovri dipivoxil for naïve and lamiduine resistant CHB patients.”
193. Milano, 18 Settembre 2008. MEET THE EXPERT HBV. “Il trattamento del paziente già
trattato o con resistenza”
194. Udine, 20 Settembre 2008. IV° Update in Gastroenterologia. “Linee guida nel trattamento
dell’epatite cronica HBV-relata”
195. Firenze, 2 Ottobre 2008. RIUNIONE MONOTEMATICA A.I.S.F. Simposio BMS.
“Entecavir for the treatment of nucleos(t)ide naive patients with CHB”
196. Roma, 9 Ottobre 2008.GISF meeting: Dalle linee guida di Stresa alla terapia individualizzata
del paziente con infezione HBV. “Gestione della farmacoresistenza in HBV”
197. Milano, 17 Ottobre 2008. Le Giornate Mediche dell’Ospedale Fatebenefratelli. “Epatite B –
Storia naturale e terapia con analoghi nucleosi/tidici”
198. Vienna, 20 October 2008. 16th United European Gastroenterology Week. Symposium:
evolution in the treatment of chronic Hepatitis B “Hepatitis B: Combination of antiviral
therapies
199. Roma, 27 Ottobre 2008. Il Trapianto Epatico Nel Paziente HBV Positivo. “Il trattamento del
paziente cirrotico avanzato”
200. Verona, 13 Novembre 2008. Corso Nazionale AIGO-AISF di Epatologia. “Nuove linee guide
nel trattamento del paziente con infezione da HBV”
201. Barcelona, 17 November 2008. Hepatology Perspectives Programme: The HBV Journey When to Start, Switch & Stop Treatment? International Expert Forum Meeting.
“Management of partial response to NUC (naïve patients)”
202. Istanbul, 22 November 2008. CHB Treatment: right from the beginning. “Oral antivirals in
first line. The latest evidence”
60
203. Bologna, 1 Dicembre 2008. Boomarks in Epatologia 2008. “Epatite virale B: update 20082
204. Milano, 9 Dicembre 2008. ANTARES: Aggiornamento Teorico-pratico allargato: la gestione
del paziente HBV. Presentazione e discussione casi clinici emblematici
205. Istanbul, 12 December 2008. Holding Back Resistance: Improving Long-term outcomes in
Chronic Hepatitis B. “Baraclude long-term use in nucleoside-naïve HBeAg(-) patients”
206. Orvieto, 17 Dicembre 2008. Patogenesi, Diagnosi, Terapia delle epatiti virali e dell'infezione
malattia da HIV. “Gestione delle resistenze agli analoghi nucleosidici-nucleotidici anti-HBV”
207. Paris, 20 January 2009. 3rd Paris Hepatitis Conference. “Why do I treat my patients with
nucleos(t)ide analogs ?”
208. Roma, 29 Gennaio 2009. Gli Incontri della Verità – Meeting on Evolving concepts and new
therapies in Gastroenterology and Hepatology. “New antiviral drugs for hepatitis B”
209. Frankfurt, 30 January 2009. Distinguished Histology Faculty Meeting. “Histology in CHB
treatment initiation and therapy assessment”
210. Frankfurt, 4 February 2009. European Perspective Meeting. “Emerging concepts in the
treatment of chronic hepatitis B”
211. Roma, 20 Febbraio 2009. 42nd Annual Meeting AISF “Effectiveness of entecavir for the
treatment of nuc-naïve chronic hepatitis b patients: a large multicenter cohort study in clinical
practice”
212. Milano, 27 Febbraio 2009. Agorà: Forum in epatologia. “NA: trattamento soppressivo di
lunga durata”
213. Milano, 3 Marzo 2009. Scuola Superiore di Epatologia. “Presentazione e discussione di casi
clinici paradigmatici selezionati tra quelli osservati durante l’attività ambulatoriale per HCV
e HBV: Processi decisionali, definizione e gestione del progetto terapeutico personalizzato”
214. Istanbul, 6 March 2009. Holding Back Resistance: Improving Long-term outcomes in
Chronic Hepatitis B. “Entecavir: Long-term Use in Nucleoside-naïve HBeAg(-) Patients”
215. Roma, 11 Marzo 2009. B Event: La nuova risposta per la terapia dell’Epatite B cronica. “Il
paziente pre-trattato e la prevenzione della resistenza:perché, quando e come cambiare?
216. Roma, 13 Marzo 2009. Top seminar in HBV. “La gestione clinica del paziente naive: quando
e come iniziare, come trattare”
217. Athens, 14 March 2009. Chronic Hepatitis B Treatment: Present and Future. “EASL Clinical
Practice Guidelines on HBV”
218. Ferrara, 18 Marzo 2009. Chronic Hepatitis and Peg-Interferon alpha 2a: a bridge to the
future. “Therapeutics strategies by single centres”
61
219. Sydney, 22 March 2009. Hepatitis B symposium “Chronic Hepatitis B: Virology,
Pathogenesis and Natural History in the Context of Treatment Goals”
220. Milano, 24 Marzo 2009. PATH 2009: Program for the Advancement of Therapy in
Hepatocellular Carcinoma. “Role and management of HepB and HepC while on waiting list /
post-transplantation and in the resection/ablation scenario.”
221. Milano, 30 Marzo 2009. XV Congresso Nazionale delle Malattie Digestive – Minicorso
Terapia dell'HBV: gestione delle resistenze. “Management and prevention of NUC
resistance”
222. Milano, 31 Marzo 2009. XV Congresso Nazionale delle Malattie Digestive. Tavola Rotonda
Epatite Cronica B: Le nuove strategie terapeutiche. “Nuovo algoritmo di trattamento del
paziente Naive”
223. Palermo, 18 Aprile 2009. Top Seminr in HBV. “La gestione clinica del paziente naïve:
quando e come iniziare, come trattare”
224. Copenhagen, 22 April 2009. 44th Annual Meeting of EASL. ELITA EASL Joint Meeting.
“New antiviral drugs for HBV liver disease: do we stil need liver transplantation ?”
225. Copenhagen, 23 April 2009. 44th Annual Meeting of EASL. Clinical Management of Chronic
Hepatitis: Impact of HCV and HBV Viral Load Dynamics. “Viral Load as a Sensitive Marker
of HBV Infection and Its Related Liver Disease States and Treatment”
226. Copenhagen, 24 April 2009. 44th Annual Meeting of EASL. Early Morning Workshop.
“EASL Clinical Practice Guidelines on HBV: everything solved?”
227. Copenhagen, 24 April 2009. 44th Annual Meeting of EASL: Gilead Symposium. “An HBV
patient naïve to therapy: What is the clinical evidence for the best first choice treatment?”
228. Monza, 29 Aprile 2009. Workshop: il paziente al centro: soluzioni innovative per la salute.
“Viral load as a sensitive marker of HBV infection and its related liver disease states and
treatment”
229. Milano, 30 Aprile 2009. Top Seminar in HBV. “La gestione clinica del paziente mai trattato:
quando e come iniziare, come trattare”
230. Taormina, 7 Maggio 2009. Riunione Monotematica AISF. Simposio: Malattia da HBV e
terapie a lungo termine. “Il trattamento a lungo termine con analoghi può modificare la storia
naturale dell’infezione HBV?”
231. Corfu, 9 May 2009. 11th Greek National Hepatology Congress. “Managing cHBV in the
Clinical Setting: Case Studies”
232. Milano, 25 Maggio 2009. Progetto Antares: kick-off meeting. “Strategie Terapeutiche e
Gestione delle Farmaco Resistenze nell’Epatite Cronica B”
233. Parigi, 29 May 2009. Faculty Masterclass Meeting. “Entecavir: real-life clinical data2
62
234. Seoul, 9 June 2009. Hepatitis B meeting. “Oral Antiviral Therapy: Management of NUC
resistance”
235. Ferrara, 14 June 2009. New therapeutic frontiers in Hepato-Gastroenterology. ““What
therapy for the Naive HBV patient?”
236. Padova, 22 June 2009. Top seminar in HBV “La terapia antivirale a lungo termine: strategie
ed effetti sulla istologia epatica e l'outcome clinic”
237. Bangkok, 26 June 2009. 7th Asia-Pacific Hepatitis B Academy. “Management of resistance
to oral antiviral therapies and of HBV-related cirrhosis”
238. Amsterdam, 6 July 2009. Hepatology Perspectives: Expert Forum 2 – HBV Resistance:
Current Questions and Future Strategies. “Managing resistance in a highly treatment
experienced patient”
239. Kuala Lumpur, 17 July 2009. 8th Liver Update: Malysian Liver Foundation. “Emerging
concepts in the treatment of chronic hepatitis B”
240. London, 9 September 2009. British Association for the Study of the Liver (BASL) annual
meeting. Complex Patients and Evolving Treatment Strategies: Time for Change in the UK.
“What is the clinical evidence for optimal first line treatment in a patient naïve to therapy?”
241. Beijing, 14 September 2009. The 4th B-FOCUS FORUM. “Strategies for long-term success
in naïve patients: Making rational choice in first-line therapy”
242. Monza, 17 Settembre 2009. Master Universitario di II livello in Medicina dei Trapianti:
Gestione Pre-Trapianto delle Malattie Epatiche Croniche. “Infezione da HBV”
243. Barcelona, 24 September 2009. 8th International Meeting on Therapy in Liver Diseases.
“How to manage patients with antiviral resistant HBV ?”
244. Parigi, 28 September 2009. Hepatitis Expert Forum 2009. “Long-term Patient Management:
Future management and data needs: expert perspectives on long-term patient management”
245. Parma, 2 Ottobre 2009. Hepatogy Perspectives Meeting. “Trattamento dei non-responders e
dei sub-optimal responders”
246. Stockholm, 5 Ocotber 2009. Regional HBV Treatment Meeting. “NUC treatment in the
management of hepatitis B”
247. Santander, 17 October 2009. II Aula Abierta Multidisciplinar en Hepatología. “An HBV
patient naive to therapy: what is the clinical evidence for the best first choice treatment”
248. Boston, 2 November 2009. 60th annual meeting of AASLD. “Entecavir for NUC-naïve
chronic hepatitis B patients in clinical practice: long-term effectiveness from a large
multicenter cohort study in 376 patients”
249. Madrid, 28 Novembre 2009. Post-AASLD meeting. “Entecavir new data overview”
63
250. Bologna, 30 Novembre 2009. Bookmarks in Epatologia 2009. “Chronic Hepatitis B antiviral
treatment: 2009 update”
251. Milano, 3 Dicembre 2009. Progetto Antares: Wrap-up meeting. “Presentazione, discussione e
approfondimenti dei dati provenienti dagli ultimi congressi in ambito Epatite Cronica B”
252. Roma, 4 Dicembre 2009. Congresso Monotematico SIGE - Malattia da virus dell’epatite B:
clinica e terapia. “La storia naturale dei pazienti trattati ed i rischi residui alla terapia
efficace”
253. London, 11 December 2009. Long-term CHB patient management – current and future
perspectives. “Entecavir long-term use in nucleoside-naïve HBeAg(-) patients
254. Melegnano, 18 Dicembre 2009. Attualita’ In Epatologia e Pneumologia. “Terapia dell’
epatite virale cronica B: le ultime novità in tema di trattamento”
255. Pisa, 23 Gennaio 2010. 1st Hepatitis B virus Heterogeneity Meeting – A means to
personalized care. “Combination therapies in managing difficult-to-treat patients”
256. Bangkok, 30 January 2010. International Conference on Gastroenterology and Hepatology
2010.” Prediction and Optimization with Immune Control in CHB Management”
257. Athens, 31 January 2010. XVII Viral Hepatitis B and C Meeting of Athens. “Tenovor versus
entecavir : a debate”
258. Napoli, 5 Febbraio 2010. First Forum Progress in Hepatology - Recenti acquisizioni in tema
di clinica e terapia delle epatiti croniche. “l paziente naive: evidenze cliniche per la scelta
della terapia di prima linea”
259. Chianciano, 13 Febbraio 2010. Corso Educazionale AISF- SIGE
dell'epatite B. “Terapia soppressiva”
"Malattia da Virus
260. Milano. 15 Febbraio 2010. Antares – Kick off meeting. “Therapeutical Strategies and
management of Pharmacoresistance in Chronic Hepatitis B
261. Sorrento, 16 Febbraio 2010. Meeting Progetto Epa-NET. “Anti-HBV therapy: safety and
tolerability”
262. Verona, 6 Marzo 2010. XVI Congresso Nazionale Malattie Digestive. “Entecavir for nucnaïve chronic hepatitis B patients in clinical practice: long-term effectiveness from a large
multicenter cohort study in 376 patients”
263. Stresa, 12 Marzo 2010. Meeting Progetto Epa-NET. “Anti-HBV therapy: safety and
tolerability
264. Brisbane, 16 March 2010. Brisbane Liver Group Meeting. “A new era in the management of
CHB: new patient treatments, endpoints & decisions”
265. Sydney, 17 March 2010. Sydney Liver Group Meeting. “Managing CHB with the end in
mind – minimising the risk of HCC (in high & low risk patients). When to start treatment?”
64
266. Adelaide, 18 March 2010. Adelaide Liver Research Group. “A new era in the management of
chronic hepatitis B: New patient treatments, endpoints and decisions”
267. Melbourne, 20 March 2010. 21st Melbourne Liver Group Meeting. “A new era in the
management of chronic hepatitis B: New patient treatments, endpoints and decisions”
268. London, 7 April 2010. Invited lecture at Kings hospital. “Treatment of NUC-nave patients
with CHB: Effectiveness of ETV in real life practice”
269. Vienna, 14 April 2010. EASL-Virgil Joint Workshop. “Utility of interferon alpha in the
treatment of chronic hepatitis B: Cons”
270. Vienna, 15 April 2010. 45th Annual Meeting of EASL. Symposium: Individualized care for
patients with CHB – meeting challenges head-on. “How? – the opportunity for a treatmentfree future for CHB patients”
271. Vienna, 16 April 2010. 45th Annual Meeting of EASL. Symposium: Refocusing On The
Future: Optimising Long-Term Management Of Patients With Chronic Hepatitis B. “Future
prognosis: Guiding today’s clinical decisions with the latest real world data”
272. Vienna, 17 April 2010. 45th Annual Meeting of EASL. “Extended (2 years) treatment with
peginterferon alfa-2a [40KD] improves sustained response rates in genotype D patients with
HBeAg negative chronic hepatitis B”
273. Barcelona, 20 May 2010. Long-term Patient Management Workshop. “anti-HBV therapy:
Considerations in the aging population”
274. Barcelona, 21 May 2010. BC)VH- X Interntional Symposium on Viral Hepatitis. “Long-term
treatment with oral antiviral for HBeAg negative patients”
275. Bergamo, 26 Maggio 2010. Epatiti Croniche Virali - L’ottimizzazione nella cura del paziente.
“Come ottimizzare il trattamento con interferone”
276. Londra, 28 May 2020. International HBV meeting: Looking towards the future of CHB
patients. “Can clinical trial experiences transfer into clinical practice?”
277. Athens, 5 June 2010. Hepatology Perspectives meeting: Expert Forum 4 – Managing
Complexities of Advancing Chronic Hepatitis B. “Managing the older CHB patient: impact
of long-term CHB etiology and treatment“
278. Seoul, 18 June 2010. 8th Asia-Pacific Hepatitis B Academy. ”Management of resistance to
oral antiviral therapies”
279. Milano, 29 Giugno 2010. Meeting ECM - Riattivazione dell’Epatite B nel Paziente
Immunodepresso: la profilassi. “Marcatori virali e meccanismi di riattivazione dell’HBV”
280. Milano, 30 Giugno 2010. Hepatology Pespectives Meeting. “Anti-HBV therapy for naïve
patients”
65
281. Milano, 7 Luglio 2010. Corso ECM “Training Live - Gestione del paziente con Epatite
Cronica HBV correlata. “Processo decisionale nella scelta della strategia terapeutica: chi,
come, quando trattare”
282. Nice, 11 September 2010. 4ème Seminaire Hépatite B. “Traitement par analogues :
Données de la pratique Clinique”
283. Monza, 16 Settembre 2010. VBMH Focus Group. “Anti-HBV therapy: from clincal trials to
clinical practice”
284. Padova, 17 Settembre 2010. The Hepatologist in a Liver Tranplant Program. “Antiviral
treatment of HBV-related cirrhosis”
285. Milano, 21 settembre 2010. Antares – Wrap-up meeting. “Presentation and discussion of data
coming from last Major International Congresses”
286. Oporto, 24 September 2010. Hepatitis B in 2010 meeting. “Where are we?”
287. Roma, 8 Ottobre 2010. Riunione Monotematica AISF 2010 – Simposio: Terapia in Epatite B
cronica: efficacia nel breve con orizzonte di lungo periodo. “Trattamento longlife del
paziente HBV”
288. Erba, 9 Ottobre 2010. Cirrhosis and its complications: am international Hepatology update
course. “Nucleos(t)ide analogues in compensated and decompensated HBV cirrhosis”
289. Roma, 11 Ottobre 2020. Ominia – La comunicazione scientifica oggi. “Analisi di lavori
presentati dai partecipanti, scelte vincenti e strategie efficaci”
290. Milano, 22 Ottobre 2010. Academy in HBV. “Ottimizzazione della terapia con interferone
peghilato”
291. Boston, 1 November 2010. 61th Annual Meeting of AASLD. “Safety and tolerability of
extended (96 weeks) treatment with peginterferon alfa-2a [40KD] in genotype D patients
with HBeAg-negative chronic hepatitis B”
292. Boston, 2 November 2010. 61th Annual Meeting of AASLD “Genetic variation in IL28B
polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated
with interferon alfa”
293. Milano, 18 Novembre 2010. Epa-Net: Nework Italiano peril trattamento dell’epatite cronica
B. “Il trattamento dell’epatite cronica B: dagli studi randomizzati alla pratica clinica”
294. Roma, 26 Novembre 2010. 9° Congresso Nazionale SIMIT. Simposio: Epatite cronica B e
Peg-IFN alfa-2a: la terapia a misura di paziente. “Come ottimizzare l’impiego
dell’interferone peghilato in HBV”
295. Bari, 2 Dicembre 2010. III Corso AIGO-AISF di Epatologia: Terapia delle Malattie Epatiche.
“Trattamento antivirale del paziente con cirrosi scompensata”
296. Athens, 29 January 2011. XVIII Viral Hepatitis B and C Meeting. “Treatment of Viral
Hepatitis B : State of the Art, Unmet Needs and Perspectives: Tenofovir”
66
297. Bangkok, 18 February 2011. The 21st Conference of the Asian Pacific Association for the
Study of the Liver - Enlightening the future. “Drug resistant HBV management – oral
nucleoside / nucleotide analogues modification is better than immunomodulatory drugs”
298. Roma, 25 Febbraio 2011. 44° Congresso Annuale AISF. “Genetic variation in IL28B
polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated
with interferon alfa”
299. Berlin, 30 March 2011. EASL-VIRGIL Joint Workshop. “Adherence and tolerance of
nucleos(t)ide analogs: impact on treatment failure”
300. Berlin, 2 April 2011. 46th Annual Meeting of EASL. Symposium: Therapy and Monitoring:
Working towards personalized Healthcare in CHB. “‘How can HBsAg levels help develop a
response-guided therapy approach?”
301. Berlin, 3 April 2011. 46th Annual Meeting of EASL. Symposium: Masterminds in CHB:
debating practical solutions to everyday challenges. “A future without lifelong therapy?”
302. Barcelona, 21 May 2011. 1st World Congress on Controversies in the Management of Viral
Hepatitis (C-Hep). “HBV therapy”
303. Sydney, 28 May 2011. Case by Case 2011 Meeting. “Third generation nucleos(t)ide
analogues for the treatment of chronic hepatitis B: from clinical trials to field practice”
304. Berna, 16 June 2011. Hepatitis: past, present and future. “Hepatitis B therapy: un update”
305. Riyadh, 7 October 2011. Invited lecure. “Management of NUC resistance: 2011 update”
306. Dammam, 9 October 2011. Invited lecure. “Current treatment paradigms for hepatitis B
therapy”
307. Madina, 10 October 2011. Invited lecure. “Management of NUC resistance: 2011 update”
308. Jeddah, 11 October 2011. Invited lecure. “Current treatment paradigms for hepatitis B
therapy”
309. Istambul, 29 October 2011. Bridging The Way To Treatment Success. “Making the right
connections: predictors of treatment response”
310. Taipei, 25 November 2011. Invited Lecture. “Treatment of Chronic Hepatitis B: From
Clinical Trials to Daily Practice”
311. Hong Kong, 27 November 2011. Asia Hepatology Perspectives Forum - Long‐Term
Treatment in Disease Outcomes in Chronic Hepatitis B. " What are the long-term data for
CHB antiviral therapy?”
312. Singapore, 29 November 2011. Invited Lecture. “Treatment of Chronic Hepatitis B: From
Clinical Trials to Daily Practice”
67
313. Bruxelles, 9 December 2011. BASL Winter Meeting - Symposium. “Tenofovir: 5 year’s data
in CHB, focus on histological improvement”
314. Brescia, 13 Gennaio 2012. IV Edizione Grandangolo Malattie Infettive. “Year in review:
epatiti HBV”
315. Kolkata, 20 January 2012. Liver Foundation West Bengal Meeting. “Hepatitis B - Towards a
Personalized Management”
316. Delhi, 22 January 2012. Delhi Liver Foundation Meeting. “Hepatitis B - Towards a
Personalized Management”
317. Roma, 2 Febbraio 2012. II Workshop Nazionale Di Economia E Farmaci In Epatologia WEF-E 2012. “La gestione attuale dell’epatite da HBV”
318. Milano, 28 Febbraio 2012. Question Time HBV. “epatite cronica B: Trattamento precoce o
“vigile attesa”?
319. Milano, 8 Marzo 2012. HIV, HBV e HCV: clinici e virologi a confronto. “L’HBsAg
quantitativo nella gestione del paziente con Epatite B Cronica”
320. Oslo, 9 March 2012. 2 International Hepatitis Meeting. “How can HBsAg levels help develop
a response-guided therapy approach”
321. Napoli, 28 Marzo 2012. 18° Congresso Nazinale Malattie Digestive. Minicorso su HBV.
“Approccio terapeutico attuale”
322. Barcelona, 30 March 2012. X European Meeting on HIV & Hepatitis. “Role of Interferon in
CHB: pros”
323. Barcelona, 21 April 2012. 47° Annual Meeting of EASL. Early Morning Workshop: Longterm management issues in chronic hepatitis B”
324. Lisbon, 4 May 2012. International Meeting on Viral Hepatitis. “Treatment of Chronic
Hepatitis B – state of the art”
325. Munich, 11 May 2012. International Standalone Meeting: “Start strong: The key attributes of
an effective treatment”
326. Padova, 14 Maggio 2012. Extra HBV Meeting. “Presentazione e discussione di casi clinici
paradigmatici”
327. Parma, 28 Maggio 2012. Corso HIV & Epatiti. “Luci e ombre della terapia anti-HBV”
328. Barcellona, 1 June 2012. BC)VH. XI International Symposium on Viral Hepatitis. “Longterm treatment with oral antivirals for HBeAg negative patients with CHB”
329. Padova, 4 Giugno 2012. Extra HBV Meeting. “Presentazione e discussione di casi clinici
paradigmatici”
68
330. Milano, 23 Giugno 2012. V Congresso Nazionale Liver-Pool: Nuove Frontiere nella Cura
delle Malattie del Fegato:. “Terapia dell’Epatite B”
331. Singapore, 29 July 2012. 9th Asia Pacific Hepatitis B Academy. “Management of advanced
CHB and Pre- and post-transplant”
332. Frankfurt, 9 September 2012. The Viral Hepatitis Congress. “Practical management of
hepatitis B in 2012: Starting with Nucs”
333. Marseille, 14 September 2012. XI Seminaire Hepatite B. “Efficacité à long terme des
analogues nucléos(t)idiques”
334. Beirut, 15 September 2012. Hepatitis Regional Forum Meeting. “How to optimize interferon
treatment in patients with chronic hepatitis B”
335. Montreal, 21 September 2012. André Viallet Annual Symposium “Recent developments of
the treatment of chronic B hepatitis2.
336. Vienna, 22 September 2012. International Standalone Meeting. “Entecavir for the treatment
of CHB: real life experience”
337. Padova, 26 Settembre 2012. Extra HBV Meeting. “Presentazione e discussione di casi clinici
paradigmatici”
338. Roma, 3 Ottobre 2012, UOC Gastroenterologia dell'Umberto I Policlinico, Università La
Sapienza. Lettura: “Treatment of chronic hepatitis B: 2012 update”
339. Bologna, 11 Ottobre 2012, Divisione di Malattie Infettive, Policlinico – S. Orsola-Malpighi.
Lettura: “Treatment and prophylaxis of chronic hepatitis B”
340. Seoul, 16-18 Ottobre 2012, Severance Hospital, Yonsei Univerity. Lettura: “Real Life
Experiences with tenofovir in NUC naïve and experienced patients”
341. Taipei, 19 Ottobre 2012, International meeting: New treatment Era of Chronic Hepatitis B.
Lettura” Chronic Hepatitis B treatment update: from clinical trials to real world data”
342. Amsterdam, 23 Ottobre 2012, UEG Week. Management of chronic hepatitis B in 2012.
Lettura: “Can treatment with interferons be improved?”
343. Milano, 22 Novembre 2012. Progetto Matrix HBV – Progettare la cura dell’epatite cronica B.
Lettura “Strategie terapeutiche nel paziente naive”
344. Pisa, 29 Novembre 2012. V Corso Di Epatologia Congiunto Aigo-Aisf. Lettura “Nuove
prospettive terapeutiche nella terapia dell’HBV”
345. Milano, 5 Dicembre 2012. Progetto Viral 2012. Lettura “Terapia anti-HBV: Novità dai
congressi internazionali”
346. Padova, 13 Dicembre 2012. Xxii International Congress ‘Trends And Perspectives In
Hepatology. Lettura “Long-term management of patients with hepatitis B - 2012 update”
69
347. Milano, 14 Dicembre 2012. Management of Hepatitis B in the Chinese community in Italy.
Lettura “Natural History and Management of Hepatitis B: the Italian experience”
348. Parigi, 15 Gennaio 2013. 6th Paris Hepatitis Conference. Lettura: “HBeAg-negative chronic
hepatitis B: Why do I treat my patients with PEG-IFN ?
349. Milano, 18 Gennaio 2013. New Insights In Gastrointestinal And Liver Diseases .Lettura
“Treatment of chronic hepatitis B: HBsAg, an old test for a new treatment?”
350. Modena, 25 Gennaio 2013. 9° Workshop “Hot Topics In Hepatology”. Lettura “Management
del paziente con epatite cronica B : significato clinico dell’HBsAg”
351. Shanghai, 27 Gennaio 2013. HBV Expert Meeting. Lettura “HBeAg-negative chronic
hepatitis B: Why do I treat my patients with PEG-IFN ?”
352. Lisbona, 2 Febbraio 2013. VII Hepatology Perspectives Meeting. Lettura: “Is there a role for
combination therapy for HBV in 2013”
353. Francoforte, 8 Febbario 2013. International HBV Expert Meeting. Lettura: “Can successful
treatment of CHB prevent HCC?”
354. Kolkata, 16 Febbario 2013. 16th Annual Conference Indian Society of Gastroenterology,
West Bengal. Lettura: “Chronic Hepatitis B – Current Perspective on role of Peg Interferon &
HBsAg Kinetics”
355. Roma, 22 Febbraio 2013. 46th AISF Annual Meeting - Symposium 2013 update on viral
hepatitis. Lettura “Clinical management of HBV chronic hepatitis patients”
356. Palermo, 28 Febbario 2014. Convegno Nazionale - From research to bedside: new challenges
in viral Hepatitis. Lettura “Linee guida EASL HBV 2012: Le sfide da raccogliere”
357. Kuwait, 6 Aprile 2013. III Liver Disease Update Conference. Lettur2: “Clinical applications
of HBsAg quantification”, “Impact of therapy on the outcome of Chronic Hepatitis B” and
“Antiviral treatment of decompensated cirrhosis”
358. Trieste, 20 Aprile 2013. BF1RST Meeting. Lettura: “Early treatment in HBV: opportunità e
vantaggi”
359. Amsterdam, 24-25 Aprile 2013. 48th EASL Annaul Meeting Letture: “HBV in non-liver
transplant organ recipients”, “Starting with the outcome in mind: can successful treatment of
CHB prevent HCC”
360. Torino, 14 Maggio 2013. Question Time in HBV - Nuove strategie per antichi problemi:
intercettare il sommerso. Lettura “La terapia ad personam”
361. Teheran, 16 Maggio 2013. 5th International Tehran Hepatitis Congress. Lettura: “Chronic
Hepatitis B – Current Perspective on role of Peg Interferon & HBsAg Kinetics”
362. Milano, 20 Maggio 2013. Euromedlab 2013 Congress. Lettura: “Clinical implications of
HBsAg quantification in patients with chronic hepatitis B”
70
363. Milano, 24 Maggio 2013. Progetto Target In HBV - Optimize Treatment with Response
Guided Therapy. Lettura “A ponte tra occidente ed oriente: le novità dai congressi EASL e
APASL 2013”
364. Singapore, 6-9 Giugno 2013. 23rd Conference of the APASL. Letture: “Usefulness of risk
calculators in the clinical management of chronic hepatitis B patients”, “Suboptimal response
to NUC – what’s next ?”
365. Brisbane, 11 Giugno 2013. Hepatitis Epert Meeting. Lettura “Tenofovir and the kidney.
Monitoring and managing kidney function in CHB”
366. Sydney, 12 Giugno 2013. Hepatitis Epert Meeting. Lettura “Tenofovir and the kidney.
Monitoring and managing kidney function in CHB”
367. Melbourne, 13 Giugno 2013. Hepatitis Epert Meeting. Lettura “Tenofovir and the kidney.
Monitoring and managing kidney function in CHB”
368. Milano, 20 Giugno 2013. 9th A.I.S.F. Single Topic Conference - Clinical outcomes and value
of care in Hepatology. Lettura: Indicatori di outcomes nell’ epatite cronica da virus B:
Prospects for treatment”
369. Shanghai, 20 Luglio 2013. Hepatitis B Expert Meeting. Lettura “Why do I treat my HBeAgnegative CHB patients with PEG-IFN ?”
370. Guanzhou, 21 Luglio 2013. Hepatitis B Expert Meeting. Lettura “Why do I treat my HBeAgnegative CHB patients with PEG-IFN ?”
371. Uppsala, 5 Settembre 2013. Swedish Hepatitis Meeting. Lettura: “The long-lasting immune
control over hepatitis B; NUC or pegylated interferon or both; new strategies in sight?”
372. Pechino, 6 Settembre 2013. EASL-CSH School of Hepatology. Letture: Update on HBV
therapy: NUCs, IFNs and beyond”, “Clinical interactive case on HBV: HBV and pregnancy”,
“Clinical interactive case on HBV (II): HCC risk”
373. Guangzhou, 9 Settembre 2013. EASL-CSH School of Hepatology. Letture: Update on HBV
therapy: NUCs, IFNs and beyond”, “Clinical interactive case on HBV: HBV and pregnancy”,
“Clinical interactive case on HBV (II): HCC risk”
374. Barcellona, 18 settembre 2013. 10th International Meeting on Therapy in Liver Diseases.
Lettura “Hepatitis B treatment strategies 2013: NUCs only, PEG-IFN, or both?”
375. Verona, 3 Ottobre 2013. IX° Convegno Nazionale - Aggiornamenti In Epatologia E
Gastroenterologia. Lettura: “Epatite B: Valutazioni cliniche del trattamento a lungo termine”
376. Stoccolma, 8 Ottobre 2013. Swedish educational event (R.U.N) - Expert Hepatitis Meeting.
Lettura: “Treatment strategies against HBV in 2013 NUC or PEG or both?
377. Pisa, 18 Ottobre 2013. Monotematica AISF 2013- Personalizzazione della Cura in
Epatologia. Lettura” terapia anti-HBV: paziente con cirrosi avanzata ( HBeAg pos e HBeAg
neg)”
71
378. Trapani, 20 Ottobre 2013. The 2013 Italy-Japan Liver Workshop - Hepatitis, Steatosis and
Hepatocellular Carcinoma: molecular basis and clinical links. Lettura: “Long term
suppression of HBV by NUCs: still not enough to prevent HCC”
379. Bucarest, 25 Ottobre 2013. Romanian National Conference of Infectious Disease. Lettura
“ETV real-life data confirm Phase III registrational data in NA-naïve patients with CHB”
380. Losanna, 13 Novembre 2013. HBV Expert Meeting - State of the Art in Hepatitis B & D.
Lettura: “State of the Art in Hepatitis B”
381. Ginevra, 14 Novembre 2013. HBV Expert Meeting - State of the Art in Hepatitis B & D.
Lettura: “State of the Art in Hepatitis B”
382. Riyadh, 22 Novembre 2013. Chronic Hepatitis B Exchange Program Meeting. Letture: “De
Novo Combo and Extension of therapy”, “RGT based on HBsAg quantification” and
“Hepatitis B treatment, finite or long term duration?”
383. Milano, 25 Novembre 2013. Hepatitis Journey after AASLD - Breaking News in Hepatitis.
Lettura “Nuove strategie nel management dell’epatite B”
384. Ahmedabad, 29 Novembre 2013. 54 Annual conference of Indian Society of
Gastroenterology. Lettura “Long-term treatment of HBV is associated with cirrhosis
regression and HCC risk reduction”
385. Bologna, 10 Dicembre 2013. IX Edizione Bookmarks in Epatologia 2013. Lettura: NUC
therapy for chronc hepatitis B: Update 2013”
386. Milano, 13 Dicembre 2013. Progetto VIRAL – per una diffusione delle esperienze in HBV e
HCV. Lettura “Early treatment in HBV: quali gli endpoint?”
387. Parigi,14 Gennaio 2014. 7th Paris Hepatitis Conference. Lettura: “Why do I treat my HBeAg
negative patients with NUC ?
388. Roma, 17 Gennaio 2014. Corso SIGE/AISF 2014 - L’Epatite Virale Cronica: dalle
conoscenze scientifiche alla pratica clinica”. Lettura: “Indicazioni al trattamento dell’Epatite
da HBV: quando trattare e come”
389. Modena, 24 Gennaio 2014. 10th Workshop Hot Topics in Hepatology - La gestione dei
pazienti con epatite cronica virale: novità e prospettive. Lettura: “Does long-term HBV
therapy prevent or reduce HCC ?
390. Riyadh, 31 Gennaio 2014. HBV Expert Meeting. Lettura “Optimizing long term outcomes in
patients with CHB”
391. Jeddah, 1 Febbraio 2014. HBV Expert Meeting. Lettura “Long Term Treatment success start
today in CHB Patients”
392. Dammam, 2 Febbraio 2014. HBV Expert Meeting. Lettura: “Stary Strong – Long term
benefits for the life time of patients”
72
393. Mestre, 6-7 Marzo 2014. Convegno Nazionale - Strategies and challenges for viral hepatitis
treatments. Lettura: “Quando la terapia è a lungo termine: problematiche cliniche extraepatologiche nel paziente con HBV”
394. Brisbane, 14 Marzo 2014. 23rd Conference of the Asian Pacific Association for the Study of
the Liver (APASL). Lettura: “Applying response-guided therapy in clinical practice”
395. Mosca, 24 Marzo 2014. XIX Congress Hepatology Today - HBV: cure or long-term disease
management? Lettura: “Long-term suppression of HBV replication halts disease progression
in CHB: from clinical trials to real life”
396. Berna, 27 Marzo 2014. HBV Expert Meeting. Lettura: “State of the Art in Hepatitis B –
2014”
397. Lucerna, 28 Marzo 2014. HBV Expert Meeting. Lettura: “State of the Art in Hepatitis B –
2014”
398. Londra, 30 Aprile 2014. UK Infectious Disease Symposium. Lettura: “Hepatitis B –
Improving patient management HBsAg quantification”
399. Berlino, 3 Maggio 2014. The 3rd World Congress on Controversies in the Management of
Viral Hepatitis (C-Hep). Lettura: “Prevention of HCC by anti-HBV therapy”
400. Copenhagen, 8 Maggio 2014. Regional HBV Meeting. Lettura: “Hepatitis B – Guidelines
regarding surveillance/ treatment”
401. Milano, 9 Maggio 2014. Prima Conferenza internazionale ICE - Insieme Contro l'Epatite Epatiti Virali tra presente e future. Lettura: “Terapia per HBV con analoghi nucleosidi e
oltre”
402. Milano, 14 Maggio 2014. International Meeting Breakthroughs in Viral Hepatitis. Lettura:
“Long term benefits of antiviral therapy of hepatitis B”
403. Milano, 20 Maggio 2014. Progetto HBsAg Day 2014 - New Approach in Chronic Hepatitis
B. Personalized Treatment with RgT (Response Guided Therapy). Lettura. “Quantification of
HBsAg – EASL 2014 and beyond”
404. Lodi, 21 Maggio 2014. HBV 2014 - Meet the Expert. Lettura: “Anti-HBV therapy – 2014
update, safety of therapy and new approaches”
405. Asti, 22 Maggio 2014. Tutoring in HIV e HBV. Lettura “ Challenges and achievements in
HBV therapy in 2014”
406. Bologna, 26 Maggio 2014. I Meeting della Gastroenterologia di Bologna - L’Epatite B.
Lettura: “Anti-HBV therapy and HCC”
407. Barcellona, 30 Maggio 2014. XII International Symposium On Viral Hepatitis. Lettura:
“Optimal therapy for HBeAg negative patients”
73
408. Singapore, 6-7 Giugno 2014. 1st Singapore Hepatitis Conference. Letture: “Long term NUC
therapy for HBV”, “HBsAg quantification (qHBsAg): ready for clinical use ?”, “Response
guided therapy in HBV: dead or alive ?”
409. Vicenza, 10 Giugno 2014. Aspetti Clinici, Gestionali e Legali nel Management del Paziente
con Epatite B. Lettura: “Early treatment e strategie di prevenzione degli eventi”
410. Modena, 11 Giugno 2014. Aspetti Clinici, Gestionali e Legali nel Management del Paziente
con Epatite B. Lettura: “Early treatment e strategie di prevenzione degli eventi”
411. Milano, 13 Giugno 2014. “2nd New Insights in Gastrointestinal and Liver Diseases: The
Future around the corner in HCV/HBV Infections. Lettura: “Long-term benefits of HBV
therapy and new therapeutic approaches”
412. Coimbra, 18 Giugno 2014. Hepatitis Expert Meeting. Lettura: “HBV in 2014 - Early
treatment and prevention of complications”
413. Varsavia, 21 Giugno 2014. Hepatology Perspectives - Expert Forum 10. Lettura: “Is finite
therapy with oral antiviral agents an achievable goal in chronic hepatitis B? The case FOR
finite therapy “
414. Milano, 25 Giugno 2014. Hepatitis Journey post EASL Meeting. Lettura: “New therapeutic
strategies and HBV cure”
Le dichiarazioni rese nel presente curriculum sono da ritenersi rilasciate ai sensi degli artt. 46 e 47 del DPR
n. 445/2000.
Il presente curriculum, non contiene dati sensibili e dati giudiziari di cui all’art. 4, comma 1, lettere d) ed
e) del D.Lgs. 30.6.2003 n. 196.
Il sottoscritto dichiara di essere consapevole che nel rispetto delle regole di trasparenza previste dalla
legge e come stabilito dal bando di concorso, i curricula di tutti candidati saranno pubblicati sul sito Web
dell’Università degli Studi di Milano www.unimi.it/valcomp entro 30 giorni dalla scadenza del termine di
presentazione delle domande.
Data
27 Agosto 2014
Luogo
Milano
Firma
74